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ABSTRACT 
Hypertrophic cardiomyopathy (HCM) is a common, inherited heart disease in which no 
pharmacological therapies have been shown to prevent, delay onset, or cause 
regression in humans.  This disease is caused by mutations in sarcomere-encoding 
genes, and up to 5% of HCM patients have been found to harbour multiple disease-
causing mutations, correlating with a more severe clinical phenotype, including 
increased hypertrophy, early disease onset and elevated incidence of sudden cardiac 
death events.  Recent studies in animal models have shown that the angiotensin II type 
1 receptor inhibitor, losartan, is effective in preventing disease in HCM caused by 
single-mutations, in which disease develops gradually and presents in adulthood.  
However, studies are lacking that investigate this treatment in multiple-mutation HCM. 
 
This thesis investigated losartan as a preventative therapy in a mouse model of severe 
HCM (Chapter 3).  The TnI-203/MHC-403 mouse model was used, which expresses 
two HCM-causing mutations resulting in a severe disease phenotype and 100% 
mortality by 21 days.  This model recapitulates a subgroup of HCM patients who 
progress to a dilated phenotype and heart failure.  TnI-203/MHC-403 and non-
transgenic mice were treated with losartan or water from a pre-disease time point and 
features of disease were investigated.  Losartan treatment significantly increased 
survival, improved cardiac function as analysed by echocardiography, restored heart 
morphology and heart-weight:body-weight ratios, decreased cardiac fibrosis, and 
reduced the expression of pro-fibrotic and pro-hypertrophic molecules in the TnI-
203/MHC-403 mice. 
 
After analysing the beneficial effects of losartan therapy in the TnI-203/MHC-403 model, 
changes in miRNA expression with this treatment were evaluated (Chapter 4) in an 
attempt to identify microRNA targets for potential therapeutic intervention.  MiRNA 
	   xxiii 
profiling employed TaqMan® Low Density Arrays and candidate miRNAs were 
validated by individual RT-qPCR analysis, which showed six miRNAs were 
differentially expressed between treatment groups.  Of these, two were up-regulated 
with losartan treatment (miR-203 and miR-30c) and four miRNAs were down-regulated 
(miR-21, -214, -31 and -199a-3p).  According to the available literature, miRNA 
therapies that restore the aforementioned miRNAs (toward non-transgenic expression 
levels) are likely to be beneficial in this disease model, with the exception of  
miR-199a-3p. 
 
While the TnI-203/MHC-403 mouse model was valuable for evaluating losartan therapy 
in severe HCM and for investigating miRNAs altered with treatment in the target organ, 
studies in animal models tend to be time-consuming and expensive.  In contrast, cell 
culture models that genetically- and phenotypically- recapitulate disease, allow for the 
screening of pharmacological agents and investigation of miRNAs or miRNA therapies, 
in a simple setting.  The final aim of this thesis was to engineer lentiviral particles for 
delivering the HCM-causing mutations, TNNI3-G203S and MYH7-R403Q, into cells.  
Chapter 5 describes the methodology used for successful construction of lentiviral 
transfer vectors, packaging lentiviral particles, and transduction of the cardiomyocyte 
cell line, HL-1.  Lentiviral vectors were designed so that each of the sarcomere-
encoding genes were linked to different fluorescent reporters, which will allow for the 
development of a cell culture model that expresses both HCM-causing mutations, and 
genetically recapitulate the TnI-203/MHC-403 mouse model.  While this study is a work 
in progress, preliminary characterisation of HL-1 cells expressing the TNNI3-G203S 
mutation, showed an enlargement of cells by microscopic visualisation.  This is a 
promising preliminary result, as cardiomyocyte hypertrophy is a feature of HCM and 
mimics the single-mutant TnI-203 mouse model. 
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In summary, the studies within this thesis work toward evaluating, and identifying novel 
targets for, therapies in severe HCM.  This work has shown losartan to be an effective 
therapy in a mouse model of severe HCM.  This investigation has also identified 
miRNAs altered with losartan treatment, thereby providing novel targets for therapeutic 
intervention.  Finally, lentiviral-mediated gene transfer tools have been developed for 
creating a cell line where pharmacological or miRNA therapies could be easily 
screened. 
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ABSTRACT 
Hypertrophic cardiomyopathy (HCM) is a common, inherited heart disease in which no 
pharmacological therapies have been shown to prevent, delay onset, or cause 
regression in humans.  This disease is caused by mutations in sarcomere-encoding 
genes, and up to 5% of HCM patients have been found to harbour multiple disease-
causing mutations, correlating with a more severe clinical phenotype, including 
increased hypertrophy, early disease onset and elevated incidence of sudden cardiac 
death events.  Recent studies in animal models have shown that the angiotensin II type 
1 receptor inhibitor, losartan, is effective in preventing disease in HCM caused by 
single-mutations, in which disease develops gradually and presents in adulthood.  
However, studies are lacking that investigate this treatment in multiple-mutation HCM. 
 
This thesis investigated losartan as a preventative therapy in a mouse model of severe 
HCM (Chapter 3).  The TnI-203/MHC-403 mouse model was used, which expresses 
two HCM-causing mutations resulting in a severe disease phenotype and 100% 
mortality by 21 days.  This model recapitulates a subgroup of HCM patients who 
progress to a dilated phenotype and heart failure.  TnI-203/MHC-403 and non-
transgenic mice were treated with losartan or water from a pre-disease time point and 
features of disease were investigated.  Losartan treatment significantly increased 
survival, improved cardiac function as analysed by echocardiography, restored heart 
morphology and heart-weight:body-weight ratios, decreased cardiac fibrosis, and 
reduced the expression of pro-fibrotic and pro-hypertrophic molecules in the TnI-
203/MHC-403 mice. 
 
After analysing the beneficial effects of losartan therapy in the TnI-203/MHC-403 model, 
changes in miRNA expression with this treatment were evaluated (Chapter 4) in an 
attempt to identify microRNA targets for potential therapeutic intervention.  MiRNA 
	   xxiii 
profiling employed TaqMan® Low Density Arrays and candidate miRNAs were 
validated by individual RT-qPCR analysis, which showed six miRNAs were 
differentially expressed between treatment groups.  Of these, two were up-regulated 
with losartan treatment (miR-203 and miR-30c) and four miRNAs were down-regulated 
(miR-21, -214, -31 and -199a-3p).  According to the available literature, miRNA 
therapies that restore the aforementioned miRNAs (toward non-transgenic expression 
levels) are likely to be beneficial in this disease model, with the exception of  
miR-199a-3p. 
 
While the TnI-203/MHC-403 mouse model was valuable for evaluating losartan therapy 
in severe HCM and for investigating miRNAs altered with treatment in the target organ, 
studies in animal models tend to be time-consuming and expensive.  In contrast, cell 
culture models that genetically- and phenotypically- recapitulate disease, allow for the 
screening of pharmacological agents and investigation of miRNAs or miRNA therapies, 
in a simple setting.  The final aim of this thesis was to engineer lentiviral particles for 
delivering the HCM-causing mutations, TNNI3-G203S and MYH7-R403Q, into cells.  
Chapter 5 describes the methodology used for successful construction of lentiviral 
transfer vectors, packaging lentiviral particles, and transduction of the cardiomyocyte 
cell line, HL-1.  Lentiviral vectors were designed so that each of the sarcomere-
encoding genes were linked to different fluorescent reporters, which will allow for the 
development of a cell culture model that expresses both HCM-causing mutations, and 
genetically recapitulate the TnI-203/MHC-403 mouse model.  While this study is a work 
in progress, preliminary characterisation of HL-1 cells expressing the TNNI3-G203S 
mutation, showed an enlargement of cells by microscopic visualisation.  This is a 
promising preliminary result, as cardiomyocyte hypertrophy is a feature of HCM and 
mimics the single-mutant TnI-203 mouse model. 
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In summary, the studies within this thesis work toward evaluating, and identifying novel 
targets for, therapies in severe HCM.  This work has shown losartan to be an effective 
therapy in a mouse model of severe HCM.  This investigation has also identified 
miRNAs altered with losartan treatment, thereby providing novel targets for therapeutic 
intervention.  Finally, lentiviral-mediated gene transfer tools have been developed for 
creating a cell line where pharmacological or miRNA therapies could be easily 
screened. 
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1 GENERAL INTRODUCTION 
Identifying the causal mutations of inherited disease and elucidating the underlying 
mechanisms that link mutations to disease phenotype, is of central importance when 
identifying new targets for novel therapies.  Over the past few decades, significant 
advances have been made in our understanding of inherited cardiovascular diseases.  
Hypertrophic cardiomyopathy (HCM) was the first cardiovascular disorder in which a 
genetic basis was identified (Geisterfer-Lowrance et al., 1990), and has acted as a 
paradigm for the investigation of inherited heart disease.  While major advances have 
been made in the clinical characterisation of patients with HCM and in the identification 
of pathogenic mutations, little is known about how these mutations lead to disease.  
Studies in genetically engineered cell and animal models are instrumental in confirming 
gene causation, determining mechanisms of pathogenesis and for investigating novel 
therapeutic approaches in HCM. 
 
1.1 HYPERTROPHIC CARDIOMYOPATHY 
1.1.1 Pathophysiology and diagnosis 
HCM is the most prevalent cardiovascular genetic disorder known, affecting 1 in 500 in 
the general population (Maron et al., 1995), and is a complex, primary disorder of the 
myocardium in which cardiac muscle is markedly thickened in the absence of other 
hypertrophy-causing diseases (e.g. Friedrich ataxia, glycogen storage disease), 
loading conditions (such as hypertension, aortic stenosis or thyroid disease) or dilated 
cardiac chambers (i.e. dilated cardiomyopathy).  While the distribution and severity of 
hypertrophy in HCM varies, it typically occurs in the left ventricle (Figure 1.1) and a 
ventricular wall thickness of ≥15mm in adults, by echocardiography, is diagnostic of 
disease (Gersh et al., 2011).  Left ventricular hypertrophy is characteristically 
asymmetric, primarily affecting the anterior septum, however no single pattern of 
hypertrophy is universal, with HCM patients observed to exhibit hypertrophy diffusely, 
symmetrically and localised to single segments (Maron, 2002). 
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Figure 1.1.  Pathology of hypertrophic cardiomyopathy.  (Seidman and Seidman, 
2001)  Postmortem human hearts demonstrating (A) normal heart wall thickness and 
chamber dimensions in a healthy heart, in comparison to (B) HCM heart showing 
marked asymmetrical left ventricle hypertrophy and reduced cavity size. 	  
At the cellular level, HCM is characterised by a triad of histopathological features 
including cardiomyocyte hypertrophy, myofibre disarray and interstitial fibrosis (Figure 
1.2).  While HCM patients can display varying degrees of these features (Kuusisto et 
al., 2012), the presence and severity of fibrosis has been associated with an elevated 
risk of major adverse events such as sudden cardiac death (SCD) and non-sustained 
ventricular tachycardia (O'Hanlon et al., 2010).  Increased myocardial disarray has also 
been associated with SCD in HCM individuals under the age of 21 years (Varnava et 
al., 2001b). 	  	  	  
 
A       B 
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Figure 1.2.  Histopathological features of HCM:  myocardial disarray, 
cardiomyocyte hypertrophy and interstitial fibrosis.  (A) Haematoxylin and eosin 
staining of heart sections, show normal myocyte arrangement in a healthy heart and 
disarray in HCM (Ho, 2009).  (B) Heart sections probed with cell membrane specific, 
Texan-red conjugated antibody showed larger cardiomyocytes in HCM compared to 
normal hearts (Lombardi et al., 2009).  (C) Masson’s trichrome staining shows 
interstitial fibrosis (blue) in HCM but not normal heart sections (Chung et al., 2003). 	  
A 
B           
C           
Normal            HCM 
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HCM is clinically heterogeneous, with affected individuals exhibiting a wide range of 
symptoms.  These can vary from asymptomatic, to mild symptoms including chest pain, 
dyspnoea, heart palpitations and syncope, through to end-stage heart failure and SCD 
(Maron, 2002).  In some cases, the more benign symptoms are absent prior to severe 
HCM sequelae, with heart failure or SCD being the first symptom of disease.  Although 
the incidence of SCD in HCM is relatively rare, occurring in <1% of cases annually 
(Maron et al., 1999, Cecchi et al., 1995), it is an important and tragic complication of 
this disease, with HCM being the most common structural cause of SCD in individuals 
aged under 35 years (Maron et al., 1996).  The explanation for highly variable 
symptoms and severity of disease remains unclear.  Genetic variation, including the 
specific gene involved, and the type and location of the mutation, are thought to 
contribute to phenotype heterogeneity. 
 
1.1.2 Genetics of hypertrophic cardiomyopathy 
Since the discovery of the first HCM-causing mutation in 1990 (Geisterfer-Lowrance et 
al., 1990), over 1000 mutations have been identified in 24 genes (Alcalai et al., 2008, 
Morita et al., 2010, Ho, 2010, Maron et al., 2012a) (Table 1.1).  Most of these genes 
encode proteins of the sarcomere (Figure 1.3), or are associated with sarcomere 
structure (Z-disc proteins) or function (calcium-handling proteins).  The majority of 
these mutations have been identified in two genes, β-myosin heavy chain (MYH7) and 
myosin-binding protein C (MYBPC) (Richard et al., 2003).  HCM mutations are 
commonly missense, encoding for a single incorrect amino acid into the translated 
protein.  As such, these mutations may not considerably alter protein stability and thus 
are thought to be incorporated into the sarcomere (Rust et al., 1999, Watkins et al., 
1996), potentially impacting on sarcomere function.   
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Table 1.1:  Mutations identified in HCM patients. 
Protein location Gene symbol Encoded protein % of disease* 
Sarcomere Thick 
Filament 
MYH7 β-myosin heavy chain 30-44 
MYBPC3 Myosin-binding protein C 20-41 
MYL2 Regulatory myosin light chain <2 
MYL3 Essential myosin light chain <1 
MYH6 α-myosin heavy chain <1 
Sarcomere Thin 
Filament 
TNNT2 Cardiac troponin T 7-15 
TPM1 α-tropomyosin 5-15 
TNNI3 Cardiac troponin I <5 
TNNC1 Cardiac troponin C <1 
ACTC1 Cardiac actin <1 
Z-disc 
ACTN2 α-actinin 2 <2 
CSRP3 Cardiac muscle LIM protein <2 
TCAP Telethonin <1 
MYOZ2 Myozenin 2 <1 
ANKRD1 
Cardiac ankyrin repeat 
protein 
<1 
VCL Vinculin <1 
LDB3 LIM domain binding 3 <1 
NEXN Nexilin <1 
Calcium handling 
JPH2 Junctophilin <1 
PLN Phospholamban <1 
CASQ2 Calsequestrin <1 
CALR3 Calreticulin <1 
RYR2 Ryanodine receptor 2 <1 
Sarcomere 
Structural support 
TTN Titin <1 
 
* ‘% of disease’ represents the incidence at which mutations are found in HCM patients.  This 
data is given as a range, which encompasses the results reported in various HCM cohorts.  
(Alcalai et al., 2008, Lind et al., 2006, Doolan et al., 2004b, Richard et al., 2003, Chiu et al., 
2007, Chiu et al., 2010, Carniel et al., 2005, Arimura et al., 2009, Geier et al., 2003, Hayashi et 
al., 2004, Theis et al., 2006, Landstrom et al., 2007, Landstrom et al., 2011, Osio et al., 2007, 
Vasile et al., 2006, Fujino et al., 2006, Wang et al., 2010) 	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Figure 1.3.  Schematic of the sarcomere.  (Morita et al., 2005)  The  sarcomere is a 
complex arrangement of proteins which together function as the basic contractile unit of 
muscle cells, including cardiomyocytes.  The sarcomere is composed of thick and thin 
filaments, and is flanked by Z-discs.  HCM-causing mutations are found in sarcomere 
proteins, or associated proteins.  As such, HCM is known as the ‘disease of the 
sarcomere’.	  
 
HCM-causal mutations are principally inherited in an autosomal dominant pattern 
(Maron et al., 1984), however penetrance is incomplete, with at least 30% of mutation 
carriers failing to develop the disease phenotype (Richard et al., 2003, Mogensen et 
al., 2004, Charron et al., 1997).  This subset of patients is classified as ‘genotype 
positive, phenotype negative’ (G+/P-) and is an expanding population on account of 
improved knowledge of causal mutations and increasingly available genetic testing 
(Maron and Semsarian, 2010).  As HCM is age-dependent (Charron et al., 1997), 
genetic testing is helpful for early diagnosis and has had an important impact on the 
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clinical management of G+/P- patients, including periodic screening for phenotype 
development (Maron et al., 2011).  Early identification of G+/P- patients may allow for 
pre-emptive therapeutic intervention, however no pharmacological strategies are 
currently available. 
 
Variable penetrance and diverse clinical presentations, even within families where 
individuals have the same causal mutation, suggest that other factors can influence 
phenotype, including polymorphisms, epigenetic features such as DNA methylation 
(Meurs and Kuan, 2011), post-translational modifications (Predmore et al., 2010), 
microRNA modifiers and polymorphisms in their 3’UTR binding sites (Kelly et al., 
2011), environmental factors (such as diet, lifestyle and exercise), and the presence of 
additional HCM-causing mutations, all of which may interplay with the primary gene 
defect. 
 
1.1.3 Multiple mutations in HCM 
Genetic studies suggest that up to 5% of HCM patients have multiple pathogenic-
mutations, including homozygous (identical mutation, both alleles), double 
heterozygous (mutations in two genes) and compound heterozygous (different 
mutations in the same gene) mutational patterns (Ingles et al., 2005, Richard et al., 
2003, Van Driest et al., 2004).  Affected individuals exhibit a more severe clinical 
phenotype, including earlier presentation of disease, increased left ventricle 
hypertrophy and an elevated incidence of SCD events (Ingles et al., 2005, Richard et 
al., 2003).  Furthermore, a recent study has identified triple sarcomere gene mutations 
in 0.8% of HCM-affected individuals, with this genotype associated with a markedly 
increased risk of progression to end-stage disease and elevated incidence of 
ventricular arrhythmias (Girolami et al., 2010).  These results support the notion of a 
correlation between the number of sarcomere mutations with disease severity and 
progression.  Consequently, thorough genetic testing may provide valuable insight in 
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terms of risk stratification and lead to adjusted clinical management including 
aggressive treatment (Maron et al., 2012b). 
 
1.2 ANIMAL MODELS OF HCM 
While human studies have been valuable in both the clinical aspects of disease, as well 
as the identification of HCM-causing mutations, little is known about the mechanisms 
leading from gene defect to clinical phenotype.  This is due to the limitations associated 
with human studies, which include variation in genetic background and environmental 
influences, as well as the lack of tissue availability from living patients.  To overcome 
some of these limitations, a number of animal models have been established that 
express HCM mutations and reproduce the disease phenotype (summarised in Table 
1.2).   
 
Like the human disease, these models exhibit heterogeneity from histopathology to 
survival, between animals harbouring different mutations and within the same model.  
In humans, MYH7 mutations are associated with significant cardiac hypertrophy and a 
high incidence of SCD events (Richard et al., 2003, Solomon et al., 1993), with animal 
models also exhibiting these features (Teekakirikul et al., 2010, Marian et al., 1999).  
Similarly, MYBPC3 mutations are associated with late disease onset and lesser 
incidence of hypertrophy in both human and animals (Richard et al., 2003, McConnell 
et al., 2001).  TNNI3 mutations cause a variable phenotype with patient symptoms 
ranging from asymptomatic to severe heart failure and SCD (Mogensen et al., 1999, 
Kimura et al., 1997), as is also seen between animal models with different troponin I 
mutations (James et al., 2000, Tsoutsman et al., 2006, Sanbe et al., 2005).  Models 
that are relevant to this thesis are discussed in detail in Sections 1.2.1 to 1.2.3, and are 
shown to mimic the phenotype of humans harbouring these mutations. 
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These models have been instrumental in confirming mutation causation, and have 
facilitated the study of disease pathogenesis without the limitations of human studies.  
Inbred animal strains eliminate genetic variability and allow for effective identification of 
gender differences in phenotype.  Environmental influences such as diet and exercise 
can be regulated to investigate effect on disease (Nguyen et al., 2007) and animal 
models provide tissue samples that can be used for a range of molecular investigations 
including histopathology, cellular, RNA and protein studies.  The high degree of 
homology between humans and the common animal models of HCM, including mice 
and rabbits, allows for disease-causing mutations to be investigated in a relevant 
model of cardiac physiology and disease.  This enables novel treatment and prevention 
studies to be performed. 
 
While mouse models are a valuable resource for HCM therapy studies, there are 
several differences in cardiovascular physiology that need to be considered.  
Sarcomere composition varies between species, in particular, the predominant isoform 
for myosin heavy chain (MHC) differs, with the α isoform most prevalent in adult mouse 
ventricles, compared to human ventricles in which the β isoform predominates (Ng et 
al., 1991, Reiser et al., 2001).  Not only does the α isoform have a faster velocity of 
shortening, but also higher ATPase activity and thus uses more ATP than the β isoform 
to perform the same workload (Marian, 2005).  It is possible that these differences, as 
well as the kinetics of actomyosin crossbridge cycling between the two isoforms, could 
affect the phenotype of animal models.  Other differences between species includes 
heart rate, which is 10-fold higher in mice than humans (Stull et al., 2002), a shorter 
action potential duration in mice (Baker et al., 2000), and differences in Ca2+ flux (Bers, 
2000).  While these differences do not negate data gathered from HCM mouse models, 
there is the need for caution when applying findings from mouse studies to human 
disease.
  11 
Table 1.2.  Selected rodent models of HCM. 
Protein Mutation Species 
Histology Cardiac 
hypertrophy Survival References Myocyte 
hypertrophy Disarray 
Interstitial 
fibrosis 
α-MHC Missense R403Q Mouse + + + Yes 
1 year (sedentary) 
SCD associated with 
exercise 
(Geisterfer-Lowrance et 
al., 1996, Teekakirikul et 
al., 2010) 
β-MHC Missense R403Q Rabbit + + + 
Yes  
(IVS) 
Reduced.  2-year 
survival was 53%. (Marian et al., 1999) 
α-MHC 
Missense 
R403Q and  
Truncated 
Δaa468-527 
Mouse + + + Yes  (LV) > 8 months (Vikstrom et al., 1996) 
α-MHC Missense R719W Mouse + + + Yes > 35 weeks 
(Teekakirikul et al., 
2010) 
α-MHC Knockout  (α-MHC+/-) Mouse + + + 
Yes 
(LV, IVS, RV) 
Normal, 
30-36 months (Jones et al., 1996) 
MyBP-C Truncated at exon 30 Mouse + + + 
Yes  
(LV) 
Normal 
>125 weeks 
(McConnell et al., 1999, 
McConnell et al., 2001) 
MyBP-C Knockout (MyBP-C-/-) Mouse + + + 
YES  
(LV, IVS, PW) >11 months (Carrier et al., 2004) 
MyLC-2 Missense E22K Mouse N/A - - 
Yes 
(IVS, papillary) > 13months 
(Szczesna-Cordary et 
al., 2005) 
MyLC-2 Missense D166V Mouse N/A N/A + No >17 months (Kerrick et al., 2009) 
MyLC-2 Missense A13T Mouse N/A - + 
Yes  
(IVS) > 6 months 
(Kazmierczak et al., 
2012) 
MyLC-3 
Truncated 
Δ43aa at 
N-terminal 
Mouse N/A - - Yes (IVS) >12 months 
(Kazmierczak et al., 
2009, Muthu et al., 2011) 
MyLC-3 Missense A57G Mouse N/A + + No >12 months (Muthu et al., 2011) 
 
MHC, myosin heavy chain; MyBP-C, myosin binding protein-C; MyLC-2, myosin light chain 2 (myosin regulatory light chain); MyLC-3, myosin light chain 3 
(myosin essential light chain); LV, left ventricle; RV, right ventricle; IVS, interventricular septum; PW, posterior wall. 
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Table 1.2 (continued).  Selected rodent models of HCM. 
	  
Protein Mutation Species 
Histology Cardiac 
hypertrophy Survival References Myocyte 
hypertrophy Disarray 
Interstitial 
fibrosis 
cTnT Truncated (exons 15, 16) Mouse - + + No Normal (Tardiff et al., 1998) 
cTnT Missense R92Q Mouse - + + 
Yes 
(Atrial) > 8 months (Tardiff et al., 1999) 
cTnT Truncated (exon 16) Rat - 
+ 
with exercise - No 
Reduced with 
exercise at 6 
months 
(Frey et al., 2000) 
cTnI Missense R146G Mouse N/A + + No 
Higher expression 
of mutant protein:  
Age 13-17 days 
Lower expressing:  
Normal 
(James et al., 2000) 
cTnI Missense R146G Rabbit N/A + + 
Yes  
(LV and IVS) Normal (Sanbe et al., 2005) 
cTnI Missense G203S Mouse + + + 
Yes  
(LV) Normal (Tsoutsman et al., 2006) 
α -TM Missense D175N Mouse + + + No N/A (Muthuchamy et al., 1999) 
α -TM Missense E180G Mouse N/A + + Yes 
100% mortality in 6 
months 
(Prabhakar et al., 2001, 
Prabhakar et al., 2003) 
α-TM Missense D175N Rat - + - No 
Normal 
>12 months (Wernicke et al., 2004) 
α -TM Missense E180G Rat - + - No 
Normal 
>12 months (Wernicke et al., 2004) 
Actin Missense E99K Mouse N/A + + 
Yes  
(Apical) 
High death rate at 
age 28-45 days (Song et al., 2011) 
 
cTnT, cardiac troponin T; cTnI, cardiac troponin I, TM, tropomyosin; LV, left ventricle; RV, right ventricle; IVS, interventricular septum; PW, posterior wall.
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1.2.1 MHC-403 mouse model 
Mutations in MYH7 account for approximately 30-35% of all HCM-causal mutations 
(Richard et al., 2003, Watkins et al., 1992).  MHC is the major contractile protein of the 
thick filament of the sarcomere, and is a critical component required for normal cardiac 
muscle contraction.  There are two isoforms of MHC in the heart, α and β.  The 
predominant MHC isoform in the ventricles varies between species, with the α isoform 
predominating in adult mice (Ng et al., 1991) and the β isoform being most prevalent in 
humans (Reiser et al., 2001) and rabbits (Everett et al., 1984).  The first mutation 
identified to cause HCM in humans was a missense mutation, Arg403Gln (R403Q), in 
MYH7 (Geisterfer-Lowrance et al., 1990).  This mutation is associated with high 
penetrance (>90% express HCM phenotype by age 20 years), early disease onset, and 
SCD, with approximately 50% of individuals dying by age 45 years (Seidman and 
Seidman, 1995).  The first genetically engineered animal model of HCM reproduces the 
R403Q mutation in mice and provided definitive evidence that a mutation in a 
sarcomere gene leads to HCM (Geisterfer-Lowrance et al., 1996).  This knock-
out/knock-in model was generated by introduction of the R403Q missense mutation 
into one allele of the endogenous mouse Myh6 gene, which encodes cardiac α-MHC.  
The mutation was introduced into α-MHC instead of β-MHC, due to isoform differences 
between species.  The heterozygous model (α-MHC403/+, referred to as MHC-403 in 
this thesis) genetically imitates the human situation:  the mutation is present in a single 
allele, protein expression is under endogenous regulatory mechanisms, and is 
expressed at physiologically relevant levels.  This model recapitulates the phenotype of 
the human disease in several ways, with mice developing diastolic dysfunction 
(Georgakopoulos et al., 1999), myocyte hypertrophy, disarray and interstitial fibrosis 
(Geisterfer-Lowrance et al., 1996), and LV hypertrophy (McConnell et al., 2001) (Figure 
1.4, Table 1.3).  Onset of disease was early, with LV hypertrophy evident by 30 weeks; 
however, severity of disease was age-dependent, with cardiac systolic dysfunction and 
histopathology worsening as they aged.  Survival of MHC-403 mice was not affected. 
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Figure 1.4.  Pathology of the MHC-403 mouse model.  (A) Gross morphology of 
hearts from non-transgenic (NTG) and MHC-403 mice.  Myocardial hypertrophy and 
left atrial enlargement (indicated by arrow) is evident in the MHC-403 heart.   
(B) Histopathology of mouse heart sections with Masson’s trichrome showing fibrosis 
(blue) and disarray in MHC-403 heart sections, but not in the NTG control.  (Geisterfer-
Lowrance et al., 1996) 
 
Table 1.3:  Comparison of R403Q mutation in mice and humans. 
HCM Feature α-MHC R403Q mutation in mouse 
β-MHC R403Q mutation in 
human 
Cardiac hypertrophy Present by 30 weeks Present in 90% by age 20 years 
Histopathology Myocyte hypertrophy, disarray, fibrosis 
Myocyte hypertrophy, 
disarray, fibrosis 
Cardiac function Systolic function reduced, diastolic function impaired 
Systolic function 
supernormal, diastolic 
function impaired 
Ventricular arrhythmias Common (~60%) Common (>50%) 
Sudden death Rare in sedentary mice, associated with exercise 
Common (survival at age 40 
years is ~50%) 
	  
NTG       MHC-403 
A 
B 
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1.2.2 TnI-203 mouse model 
Cardiac troponin I (cTnI) is the inhibitory component of the troponin complex, restricting 
actin-myosin interaction and thus preventing sarcomere contraction.  TNNI3 mutations 
account for up to 5% of cases of HCM (Richard et al., 2003, Mogensen et al., 2004, 
Doolan et al., 2005).  The clinical presentation of patients with TNNI3 mutations range 
from no symptoms and a normal life span, to severe heart failure and SCD.  Several 
mutations in the TNNI3 gene have been reported in HCM patients, including the 
missense mutation Gly203Ser (G203S), which is located in the carboxyl terminal end of 
the gene.  Individuals harbouring this mutation have a tendency for cardiac hypertrophy 
to be located at the apex (Kimura et al., 1997). 
 
Tsoutsman et al developed a transgenic mouse model (TnI-203) in which the human 
TNNI3 gene with a G203S mutation is expressed in a cardiac specific manner, 
replacing the endogenous mouse troponin (Tsoutsman et al., 2006).  Control 
transgenic mice were also generated in which the wild-type human TNNI3 was 
expressed (TnI-wt).  Western blot analysis showed that the expression of human cTnI 
protein replaced the endogenous mouse protein by 80% in both models (Figure 1.5A).  
TnI-203 mice develop all the characteristic features of HCM by 21 weeks, including LV 
hypertrophy, up-regulation of RNA markers of hypertrophy, and histopathological 
features including myocyte hypertrophy, disarray and interstitial fibrosis (Figure 1.5B).  
However, unlike humans with this mutation, the TnI-203 mice did not display apical 
hypertrophy.  Studies in isolated cardiomyocytes show the G203S mutation results in a 
significant increase in myocyte volume, disrupts interactions with partner proteins 
(troponins T and C), and causes intracellular Ca2+ dysregulation. 
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Figure 1.5. Characterisation of the TnI-203 mouse model. Adapted from 
(Tsoutsman et al., 2006)  (A) Western blot analysis of endogenous mouse cTnI and 
human cTnI (wild-type or mutant G203S) in ventricular protein extracts from NTG,  
TnI-wt control and TnI-203 mice.  *, indicates mice of interest with 80% endogenous 
protein replaced by human cTnI.  (Only mice with 80% replaced protein are discussed 
and used in this thesis.)  (B) Histopathological analysis of transgenic mouse ventricle 
sections, stained with Masson’s trichrome, showing myocyte disarray and marked 
interstitial fibrosis (shown in blue) occurs in TnI-203 hearts, but not in TnI-wt or NTG 
control hearts. 
 
1.2.3 Mouse model of multiple HCM mutations 
The presence of multiple mutations in HCM, and the association of multiple mutations 
with a more severe clinical phenotype, suggest that additional mutations have a 
cumulative effect in terms of molecular pathogenesis (Kelly and Semsarian, 2009).  To 
understand how mutations interact to cause more severe disease, Tsoutsman and 
colleagues developed the first double heterozygous mutant model of HCM (Tsoutsman 
et al., 2008b).  This was achieved by crossing the TnI-203 and MHC-403 models, to 
obtain offspring with the double-mutant genotype, designated TnI-203/MHC-403 
	  B  
NTG                               TnI-wt                            TnI-203 
 
Human  NTG        TnI-wt                 TnI-203            Human 
Mouse 
Human 
A 
 
*                           * 
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(Figure 1.6).  The TnI-203/MHC-403 mouse has a severe phenotype, characterised by 
marked cardiac hypertrophy at age 14 days, followed by subsequent rapid disease 
progression at 16-18 days including four-chamber cardiac dilation, severe myocyte 
disarray, excessive interstitial fibrosis, inducible ventricular tachycardia on 
electrocardiogram, and severe heart failure resulting in 100% mortality by age 21 days.  
The TnI-203/MHC-403 mouse model mimics a subgroup of human patients who 
progress to a burnt-out phase, including dilation of the left ventricle chamber, thinning 
of the heart walls, impaired systolic function and categorically exhibiting severe heart 
failure that requires aggressive treatment, such as heart transplantation.  Similarities 
between the phenotype of humans with multiple HCM mutations and the TnI-203/MHC-
403 model are summarised in Table 1.4. 
 
Table 1.4. Phenotype comparison of multiple-mutation HCM. 
Clinical Feature TnI-203/MHC-403 mice 
Human HCM patients with 
multiple mutations 
Survival Decreased (<21 days) Decreased (often <50 years) 
Early onset Yes Yes 
Ventricular tachycardia Present Present 
Progression to dilation Yes Yes 
Increased incidence of  
SCD events 
Yes Yes 
More severe phenotype than 
single mutant carriers 
Yes Yes 
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Figure 1.6.  Double-mutant mouse model of HCM.  Adapted from (Tsoutsman et al., 
2008b). (A) Offspring produced from cross breeding of single mutant models, TnI-203 
and MHC-403.  (B) Kaplan-Meier survival curve showing 100% mortality by age 21 
days in TnI-203/MHC-403 mice.  (C) Gross morphology and longitudinal sections of 
hearts from 14 day old mice.  (D) Masson’s trichrome staining, showing marked 
interstitial fibrosis in TnI-203/MHC-403 hearts compared to NTG and single-mutant 
mice of the same age (14 days). 
  
A 
B 
C 
D 
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1.3 CELL MODELS FOR INVESTIGATING HCM-RELATED PATHWAYS 
Animal models have proven valuable in the understanding of disease pathogenesis 
and for pharmacological testing, however, cell culture models can also be useful.  Cells 
grown in vitro are less complex to study than cells situated within the body, can be 
obtained in large quantities and allow for molecular mechanisms to be explored and 
pathways to be stimulated or attenuated in a simple setting without systemic influence.  
Indeed, in vitro studies have become an essential tool of cell and molecular biologists. 
 
Cardiac muscle consists of cardiomyocytes, fibroblasts, endothelial cells and vascular 
smooth muscle cells.  Cardiomyocytes are cardiac-specific, elongated, multi-nucleated, 
striated and involuntarily contractile muscle cells, and are the principle cell population 
in the heart.  These cells consist of sarcomeres that contract and relax, and are 
ultimately responsible for allowing the heart to beat.  Primary neonatal cardiomyocytes 
have been a valuable tool in a wide range of experimental settings, from voltage-clamp 
experiments allowing for electrophysiological examination of cells, to investigation into 
Ca2+ homeostasis.  These cells are able to be transfected or transduced for the 
purpose of gene over-expression or knockdown studies, and have been valuable for 
investigating cell signalling processes, including those involved in cardiac hypertrophy.  
One study introduced, by adenoviral transduction, the HCM-causal mutation TnI-
G203S into neonatal cardiomyocytes (Tsoutsman et al., 2006) and resulted in 
increased cell volume, confirming that the presence of this disease-causing mutation 
alone can elicit cardiomyocyte hypertrophy, and that this is not a result of other factors 
from different, neighbouring cell types or due to systemic influence.  Such conclusions 
can only be drawn in the presence of a single cell type, indicating the importance of in 
vitro cell studies.  There are disadvantages to using primary cultures in that they are 
time-consuming, involve animal sacrifice, the availability of cells is limited, and cell 
viability is generally short which restricts the number of experimental procedures that 
can be performed.  
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Compared to primary tissue culture, secondary cell lines are advantageous in that cells 
are easily retrieved from frozen stocks, do not require sacrifice of animals, and cells are 
immortalised with boundless availability of cells derived from the same source allowing 
for less variation between replicates.  The myoblast cell line, H9c2, is a subclone of a 
cell line derived from embryonic BD1X rat heart tissue (Kimes and Brandt, 1976).  
H9c2 cells are often used to study molecular processes in a ‘cardiac’ model, and have 
been verified to have a similar response to hypertrophic stimuli compared to primary 
cardiomyocytes (Watkins et al., 2011).  This cell line has been used to investigate the 
effect of pro-fibrotic molecule connective tissue growth factor (CTGF), and found H9c2 
cells increased in cell size, had elevated expression of hypertrophy markers, and the 
level of apoptosis was increased (Wang et al., 2009b).  This was an interesting finding, 
as CTGF is known to be a pro-fibrotic molecule, and its effect on hypertrophy of muscle 
cells has not been well established.  However, the use of H9c2 cells as a ‘cardiac’ cell 
model has been questioned, as H9c2 cells have been shown to possess features of 
skeletal muscle differentiation, including myotube formation, which is in contrast to 
cardiomyocytes in vivo that connect by intercalated discs (Kimes and Brandt, 1976, van 
den Eijnde et al., 2001).  To date, the HL-1 cell line is the only cardiomyocyte cell line 
that has the ability to continuously divide while maintaining a differentiated cardiac 
phenotype, providing a viable alternative to H9c2 cells. 
 
1.3.1 HL-1 cardiomyocyte cell line 
Adult mammalian cardiac muscle, unlike skeletal muscle, does not contain 
undifferentiated satellite cells and thus cannot regenerate in the event of injury or 
disease.  The irreversible differentiation of cardiomyocytes and their inability to re-enter 
the mitotic cycle has been problematic for the development of an accurate secondary 
cell culture model, which both possesses the phenotype of adult cardiac muscle cells 
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and also has essential properties of secondary cell lines, including the ability to 
proliferate and be serially passaged in vitro. 
 
To reinitiate proliferation in non-dividing cells, the large T oncogene of simian 
vacuolating virus 40 (SV40) can be employed as a potent inducer of proliferation.  The 
ANF-SV40 mouse model does this, in that it expresses the SV40 large T oncogene 
under the control of the tissue-specific human atrial natriuretic factor (ANF) (Field, 
1988).  The expression of this gene in an atrial specific-manner resulted in atrial 
hyperplasia.  Cardiomyocytes isolated from the primary tumour did not proliferate in 
culture, however, these hyperplastic cardiac muscle cells were able to be passaged 
serially as subcutaneous ectopic grafts in syngeneic animals, for over 6 years 
(Steinhelper et al., 1990).  This transplantable tumour line (designated AT-1) 
possessed a highly differentiated adult cardiac muscle cell phenotype.  These cells 
exhibit all morphological characteristics typical of normal adult atrial cardiomyocytes, 
including rhythmic contractile activity (Borisov and Claycomb, 1995). 
 
While AT-1 cells retain the ability to proliferate in culture and maintain the cardiac 
phenotype, they lack the ability to be serially passaged in vitro or recovered from frozen 
stocks, and consequently must be treated as a primary cell line (Borisov and 
Claycomb, 1995).  To overcome this, Claycomb and colleagues undertook the process 
of controlling the cell culture environment of isolated AT-1 cells to deduce favourable 
culturing conditions in vitro (Claycomb et al., 1998).  Over 100 separate preparations to 
passage cells in vitro were attempted before suitable culturing conditions were 
identified.  The resulting secondary cardiac muscle cell line was derived, and 
designated HL-1.  Like AT-1 cells, HL-1 cells maintain the ability to contract and retain 
differentiated cardiac morphological, biochemical and electrophysiological properties of 
adult atrial cardiomyocytes.  The HL-1 cell line, however, also has the ability to be 
serially passaged in vitro and can be recovered from frozen stocks, making it an 
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invaluable tool for in vitro studies of cardiac myocytes, and for investigation of diseases 
affecting cardiomyocytes, including HCM. 
 
In vitro cardiomyocyte models that express HCM mutations could be useful in 
investigating pathogenic signalling pathways, manipulating specific molecules to 
identify novel targets in disease, and for high-throughput screening of pharmacological 
or RNA-based therapies, which may modulate cellular features of the HCM phenotype 
such as cardiomyocyte enlargement. 
 
1.4 TREATMENTS IN HYPERTROPHIC CARDIOMYOPATHY 
To date, there are no pharmacological therapies that have definitively been shown to 
prevent, delay onset of, or cause regression of HCM in humans.  Instead, treatment is 
primarily aimed at relieving symptoms and avoiding complications of disease.  Due to 
the clinically heterogeneous nature of HCM, there is no single treatment strategy and 
treatment is often guided based on the presenting symptoms (Figure 1.7). 
 
Patients can be categorised based on their likelihood of having a SCD event.  Major 
risk factors of SCD include left ventricular wall thickness of 30mm or greater, family 
history of SCD, previous resuscitated cardiac arrest, unexplained syncope, and non-
sustained ventricular tachycardia (Semsarian and Group, 2011).  Fortunately, this 
tragic complication of disease can be prevented in at-risk individuals, by implantation of 
an implantable cardioverter defibrillator (ICD) (Figure 1.7) (Jayatilleke et al., 2004, 
Maron et al., 2007).  Furthermore, as up to 70% of SCD have been reported to occur 
during or immediately after exercise, HCM patients are advised to avoid high-impact, 
competitive sports (Maron et al., 1996, Doolan et al., 2004a, Gersh et al., 2011). 
 
Patients who are asymptomatic and categorically ‘low-risk’ for SCD generally do not 
receive treatment, as no improvement in disease outcome has been shown with any 
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pharmacological therapy.  Symptomatic patients are treated based on their presenting 
symptoms.  In cases of palpitations, angina or dyspnoea, beta-blockers or verapamil-
type calcium antagonists are the first drugs administered (Gilligan et al., 1993).  Beta-
blockers and verapamil are effective in slowing the heart rate and prolonging diastole, 
allowing for increased ventricular filling thus improving cardiac efficiency and controlling 
heart palpitations (Spirito et al., 1997).  Further, beta-blockers decrease myocardial 
oxygen demand (Harrison et al., 1964, Cohen and Braunwald, 1967) and verapamil 
improves microvascular functions and myocardial perfusion (Bonow et al., 1985, 
Udelson et al., 1989, Gistri et al., 1994), with the resulting consequence being the relief 
of angina.  If symptoms persist, disopyramide in combination with a beta-blocker is 
often administered.  Disopyramide is an anti-arrhythmic agent, however due to its 
ability to increase atrioventricular nodal conduction, low-dose beta-blockers are 
recommended in order to maintain a normal heart rate (Maron et al., 2003).  In patients 
where drug therapy is ineffective, non-pharmacologic therapies including surgical 
myectomy, alcohol septal ablation or dual chamber pacing may also be considered. 
 
Approximately 10% of HCM patients progress to a ‘burnt out’, end-stage heart failure 
phenotype, characterised by ventricle dilation and decreased systolic function.  
Treatment of these patients includes ACE inhibitors and angiotensin II receptor 
blockers, which dilate arteries to decrease afterload; beta-blockers; diuretics if 
congestive symptoms persist such as spironolactone; and digoxin which is an anti-
arrhythmic drug that is sometimes administered, however it has not been shown to 
improve mortality in heart failure patients (The Digitalis Investigation Group, 1997). 
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Figure 1.7.  Treatment strategies for HCM patients based on clinical presentation 
and presence of SCD risk factors.  SCD, sudden cardiac death; ICD, implantable 
cardioverter defibrillator; ACE, angiotensin converting enzyme; A2RB, angiotensin II 
receptor blocker. 
 
Atrial fibrillation (AF) is the most common sustained arrhythmia in HCM, with chronic 
AF occurring in 25% of HCM patients.  AF is suspected to trigger life-threatening 
ventricular arrhythmias (Varnava et al., 2001a, Ohe, 2009), and is associated with 
heart failure related death and the occurrence of stroke.  As such, patients should be 
treated with heart rate lowering medications such as beta-blockers, and anti-coagulants 
should be employed to prevent thromboembolism and stroke (Gersh et al., 2011). 
 
While the aforementioned therapies have been beneficial in relieving patient 
symptoms, no treatments to date have been definitively shown to improve prognosis.  
Consequently, studies in animal models are important for investigating novel 
therapeutic approaches to HCM, in an attempt to improve disease outcome. 
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1.4.1 Treatment studies in animal models of HCM 
In a disease where no pharmacological treatment currently exists that improves patient 
survival, processes to identify novel therapies are the crucial next steps.  The high 
degree of homology between humans and animal models of HCM, allows for potential 
new therapies to be investigated in relevant models of disease.  A number of treatment 
studies in HCM animal models have shown beneficial effects in terms of prevention or 
regression of disease.  These pharmacological therapies include the L-type calcium 
channel inhibitor, diltiazem (Semsarian et al., 2002); HMG-CoA reductase inhibitors 
(Patel et al., 2001, Senthil et al., 2005); N-acetylcysteine (NAC), a prodrug against 
oxidation (Lombardi et al., 2009); and angiotensin II type 1 receptor (AT1) blocker, 
losartan (Lim et al., 2001, Teekakirikul et al., 2010). 
 
Calcium dysregulation has been a feature identified early in pathogenesis in a number 
of animal models of HCM (Fatkin et al., 2000, Semsarian et al., 2002, Tsoutsman et al., 
2006).  In the MHC-403 mouse model described previously, treatment with diltiazem, 
from a pre-disease timepoint, resulted in the prevention of hypertrophy and fibrosis in 
approximately half of the treated HCM mice as well as reduced myocyte disarray and 
RNA markers of hypertrophy (Semsarian et al., 2002).  Diltiazem therapy was also 
found to be beneficial in a HCM mouse model harbouring a cTnT mutation, I79N, 
supporting the potential beneficial role of diltiazem as an early therapy in patients 
predisposed to developing HCM (Westermann et al., 2006).  These findings have 
translated to a clinical study of G+/P- HCM patients, which is currently in progress 
(ClinicalTrials.gov identifier: NCT00319982). 
 
Another target for therapeutic intervention has been the use of HMG-CoA reductase 
inhibitors (‘statins’).  In addition to their cholesterol-lowering properties, statins have 
been shown to inhibit intracellular signalling molecules involved in cardiac hypertrophy.  
Administration of simvastatin in established disease resulted in the regression of 
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hypertrophy and interstitial fibrosis, and improved cardiac function in the MHC-R403Q 
rabbit model of HCM (Patel et al., 2001).  Furthermore, a study in the same model 
showed treatment with atorvastatin from a preventative time-point, stopped the 
development of cardiac hypertrophy, reduced interstitial fibrosis, and decreased 
hypertrophy marker expression (Senthil et al., 2005).  A subsequent pilot study of 
atorvastatin treatment in humans with HCM (Bauersachs et al., 2007) did not show 
improvement in LV mass or dimensions, function or fibrosis.  The lack of improvement 
may be due to the disease-stage at which therapy was initiated (established 
hypertrophy) and the short follow-up period (9 months).  To better replicate the 
atorvastatin study in rabbits, long-term studies need to be conducted at a pre-clinical 
time point on G+/P-. 
 
Most recently, the long-term effect of N-acetylcysteine (NAC), a prodrug against 
oxidation, was studied in MHC-R403Q rabbits exhibiting established cardiac 
hypertrophy (Lombardi et al., 2009).  NAC administration reversed cardiac and 
myocyte hypertrophy and interstitial fibrosis, prevented LV systolic dysfunction, and 
improved arrhythmogenic propensity.  This novel finding, derived from the use of 
animal models, suggests the potential use of NAC in causing regression of the HCM 
phenotype in humans.   
 
Another drug with antioxidant properties that may reduce oxidative stress in the heart is 
losartan.  This angiotensin II type 1 receptor antagonist is commonly used to treat 
hypertension and heart failure in humans.  Losartan has been shown to decrease 
fibrosis in various diseased organs, including the heart (Günther et al., 2010, 
Teekakirikul et al., 2010), lungs (Molina-Molina et al., 2006) and kidneys (Yang et al., 
2009).  The effect of losartan in HCM has been previously investigated in three mouse 
models (Lim et al., 2001, Teekakirikul et al., 2010).  Losartan treatment in the cTnT-
Q92 model has been shown to be effective in reversing and normalising cardiac 
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interstitial fibrosis, however as these mice do not develop significant hypertrophy the 
effect of losartan on cardiac hypertrophy was not able to be studied (Lim et al., 2001). 
Losartan therapy has also been trialled in two HCM mouse models harbouring MYH7 
mutations (missense R403Q and R719W).  These mice develop all HCM features, 
including cardiac hypertrophy and histopathological characteristics.  Chronic 
administration of losartan initiated prior to phenotype development in these models, 
was shown to prevent the emergence of hypertrophy, non-myocyte proliferation and 
fibrosis (Teekakirikul et al., 2010).  However, treatment was only found to be beneficial 
when initiated prior to disease onset, with losartan failing to reverse hypertrophy or 
fibrosis in established HCM.  In addition to these animal studies, losartan treatment has 
been previously investigated in two small human HCM cohorts (Yamazaki et al., 2007, 
Araujo et al., 2005).  These small human studies demonstrated slight, but not clinically 
significant, improvements with losartan treatment, and it is likely that the absence of 
benefit may have been related to the timing of treatment, short follow-up period, and 
the considerable clinical heterogeneity of HCM.  To better replicate the beneficial 
findings of losartan therapy in HCM found in animals, human studies need to be carried 
out with treatment initiated prior to phenotype development and over a more lengthy 
follow up. 
 
These examples of treatment studies illustrate the value of physiologically relevant 
animal models in the investigation of novel therapeutic agents.  To date, treatment 
studies have only employed animal models with single HCM-causing mutations that 
gradually develop disease with the phenotype presenting in adulthood.  In contrast, the 
TnI-203/MHC-403 mouse model is an acute, rapidly progressing model of disease, and 
mimics a subgroup of human patients with multiple mutations who have severe disease 
phenotype including progression to heart failure and requiring aggressive treatment 
such as heart transplantation.  Treatment studies into multiple-mutation HCM are 
lacking, with no studies focusing on this subpopulation.  The TnI-203/MHC-403 model 
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is an ideal candidate for screening of pharmacological therapies, as it is a 
physiologically relevant and phenotypically accurate model of the human disease. 
 
1.5 THE ROLE OF MICRORNAS IN DISEASE AND TREATMENT 
MicroRNAs (miRNAs) are small, non-coding RNAs that negatively regulate gene 
expression through binding to the 3’UTR of specific mRNA transcripts, acting to 
repress translation or induce the degradation of target mRNA.  Single miRNAs often 
regulate the expression of many target genes with related functions.  Consequently, 
altering the expression or inhibiting the action of one miRNA can theoretically impact 
on entire gene networks and change disease phenotypes.  MiRNAs that are aberrantly 
expressed in disease, may potentially be manipulated or restored in order to correct 
disease phenotype.  For pharmacological treatments that are beneficial in disease, 
investigation of miRNA expression that is altered with treatment is an important step to 
better understand the mechanisms involved in drug therapy and to gain greater insight 
into how treatment can be modified and improved, including the identification of novel 
miRNA targets. 
 
1.5.1 MiRNA biogenesis and function 
To date, over 1500 miRNAs have been identified in the human genome (miRBase, 
Release 18).  In humans, miRNAs predominantly arise from precursors called ‘primary 
transcripts’ (pri-miRNA), and this canonical biogenesis pathway is summarised in 
Figure 1.8.  In the nucleus, pri-miRNAs are transcribed by RNA polymerase II and are 
variable in length, from hundreds to thousands of nucleotides long (Lee et al., 2004).  
Pri-miRNAs are then capped, polyadenylated and can be regulated by transcription 
factors, similar to protein-coding mRNAs (Cai et al., 2004).  Due to the imperfect 
complementarity of pri-miRNA sequence, these molecules form complex stem loop 
structures.  The double-stranded RNA regions of pri-miRNAs are recognised and 
cleaved, releasing a hairpin-loop structure of 60- to 80- base pairs, called precursor-
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miRNA (pre-miRNA).  A single pri-miRNA may be cleaved into several pre-miRNAs.  
This cleavage occurs near the base of the hairpin stem and is carried out by the RNase 
III-containing ‘microprocessor’ complex, which consists of DGCR8 (DiGeorge 
Syndrome Critical Region 8) and Drosha (Han et al., 2006, Lee et al., 2003, Denli et al., 
2004, Gregory et al., 2004).  DGCR8 recognises the double-stranded RNA structure of 
the hairpin, allowing for cleavage by the Drosha component of the microprocessor 
complex (Lee et al., 2003).  Cleavage by RNase III enzymes leaves a two-nucleotide 3’ 
overhang, a feature of pre-miRNAs recognised by the export factor, Exportin-5.  
Following cleavage, Exportin-5 transports pre-miRNAs to the cytoplasm (Yi et al., 
2003). 
 
Once in the cytoplasm, another RNase III enzyme, ‘Dicer’, and its associated proteins, 
form a complex that cleaves pre-miRNA, removing the loop joining the 3’ and 5’ arms 
and resulting in a 19- to 25- nucleotide miRNA/miRNA* duplex (Vermeulen et al., 
2005).  Bound to Dicer, the miRNA/miRNA* duplex, associates with the RNA induced 
silencing complex (RISC), which consists of TAR RNA binding protein 2 (TRBP), an 
argonaute protein (AGO) and other proteins.  Interaction with RISC involves the 
double-stranded RNA duplex being unwound, with one RNA strand binding to AGO.  
The thermodynamic properties of this unwound RNA determine which strand will 
become the mature miRNA and which will be degraded (Khvorova et al., 2003, 
Schwarz et al., 2003). 
 
Once the miRNA is associated with RISC, gene silencing can be carried out.  This 
occurs due to RISC binding the target mRNA 3’UTR at sites complementary to the 
miRNA sequence.  Target specificity is principally dependent on pairing specificity of 
the highly conserved seed region (nucleotides 2 to 8) of the miRNA to the 3’UTR of 
target mRNA (Lewis et al., 2003).  When miRNA–target complementarity is high, 
degradation of the mRNA occurs, however when there is only partial complementarity 
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between miRNA and the mRNA target, translational repression occurs (Valencia-
Sanchez et al., 2006, Pillai et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Biogenesis and function of miRNA.  (Lynn, 2009) 
(a) Pri-miRNAs are transcribed in the nucleus and (b) subsequently cleaved by the 
microprocessor complex, consisting of Drosha (purple star) and DGCR8 (blue oval), 
releasing the hairpin structure, pre-miRNA.  (c) Pre-miRNA is exported to the 
cytoplasm by Exportin-5 where it is (d) cleaved by Dicer complex, resulting in double-
stranded RNA duplex (miRNA/miRNA*).  (e) The dicer-bound RNA associates with the 
RISC complex, consisting of a number of proteins including AGO and TRBP.  
Interaction with RISC leads to the dissociation of the RNA duplex, with one miRNA 
strand (red strand) remaining bound to AGO.  The miRNA-loaded-RISC can then carry 
out gene silencing, through selective binding to 3’UTR mRNA sequence 
complementary to the miRNA sequence.  (f) mRNA degradation results when miRNA–
target complementarity is high, and (g) translational repression when miRNA–target are 
only partially complementary. 
 
Mature miRNAs are primarily generated by the aforementioned mechanism however 
recent studies have discovered alternative miRNA biogenesis pathways (Westholm 
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and Lai, 2011, Miyoshi et al., 2010).  An alternative method for generation of miRNAs 
involves substitution of Drosha cleavage with intron splicing (Ruby et al., 2007, 
Okamura et al., 2007).  Mirtrons are the result of this process.  Introns are spliced and 
exons debranched by lariat debranching enzyme, after which step they fold into pre-
miRNA hairpins.  Subsequent mechanisms, including exportation to cytoplasm, Dicer 
cleavage and incorporation into the RISC complex are the same as in the canonical 
miRNA biogenesis pathway.  
 
1.5.2 MiRNAs in cardiac hypertrophy 
MiRNAs are involved in a wide range of biological processes, including cardiac 
development and disease.  miRNAs that are aberrantly expressed in cardiac disease 
represent novel therapeutic targets for modulation.  To date, the anomalous expression 
of many miRNAs has been observed in cardiac diseases, most notably by means of 
expression profiling.  In contrast, far fewer functional studies have been carried out to 
confirm the pathogenic consequence of this altered miRNA expression. 
 
In cardiac hypertrophy, a number of miRNAs are differentially expressed, with miRNAs 
identified that regulate the expression of genes involved in cardiomyocyte hypertrophy, 
fibrosis and electrical remodelling as well as ‘switching’ to the gene expression of fetal 
MHC isoform.  Some of the miRNAs involved in cardiac hypertrophy, and their 
respective, validated mRNA targets are summarised in Table 1.5 (Abdellatif, 2012). 
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Table 1.5.  MiRNAs in cardiac hypertrophy and their validated targets. 
Feature in 
cardiac 
hypertrophy 
miRNA Expression of miRNA 
Negatively regulates 
expression of 
mRNA 
expression 
Cellular 
hypertrophy 
miR-208b Up-regulated Myostatin Decreased 
miR-23a Up-regulated MuRF1 Decreased 
miR-199b Up-regulated Dyrk1a Decreased 
miR-27a Up-regulated PPARγ Decreased 
miR-1 Down-regulated Calmodulin, Mef2a, IGF1 Increased 
miR-26b Down-regulated GATA4, PLCβ1 Increased 
Fibrosis 
miR-21 Up-regulated SPRY1 Decreased 
miR-30c Down-regulated CTGF Increased 
miR-133 Down-regulated CTGF, Col1a1 Increased 
miR-29b Down-regulated Col 1a1 Increased 
Myosin switch, 
from α isoform 
to β isoform 
miR-208b Up-regulated Thrap1 Decreased 
miR-499 Up-regulated Sox6 Decreased 
miR-27 Up-regulated Thrb Decreased 
Electrical 
remodelling 
miR-1 Up-regulated Ppp2r5a Decreased 
miR-133 Up-regulated PP2Ac Decreased 
miR-208b Up-regulated   
 
MiRNAs that are dysregulated in disease are potential targets for therapeutic 
intervention.  While miRNA expression can be influenced by pharmacological 
therapies, there are no current drugs that inhibit specific miRNAs.  Instead, miRNAs 
can be targeted by RNA interference based technologies, including anti-miRs, which 
bind to and interfere with miRNA function (Krützfeldt et al., 2005).  Conversely, when 
miRNA expression is down-regulated in disease, miRNA mimics can be used in a 
technology called ‘miRNA replacement therapy’.  MiRNA mimics are synthetic double-
stranded precursor-miRNA molecules in which one strand is identical to the native 
miRNA.  As miRNA-mimics have the same sequence as the depleted, naturally 
occurring miRNA and are expected to inhibit the same mRNA targets (Bader et al., 
2010). 
 
While miRNA-based therapies are not studied within the scope of this thesis, drug 
therapies can inadvertently affect miRNA expression, and as such, investigation of 
miRNA changes by expression profiling in treatment verse control therapy, would help 
elucidate any beneficial involvement of miRNAs in drug therapy, and provide new 
therapeutic options for future gene therapy studies.  
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1.6  HYPOTHESES AND AIMS 
  
There are two hypotheses being addressed in this study. 
 
Hypothesis 1.  Losartan therapy initiated prior to development of a severe HCM 
phenotype will improve disease outcome and will affect both messenger RNA and 
microRNA expression in the hearts of the TnI-203/MHC-403 double-mutant model. 
 
The specific aims are: 
- To determine the effect of losartan on survival, cardiac function, heart 
morphology, cardiac fibrosis, and the expression of pro-fibrotic and pro-
hypertrophic molecules. 
- To identify the changes in miRNA and mRNA expression in TnI-203/MHC-403 
mouse ventricles, that occurs with losartan treatment. 
 
Hypothesis 2.  HCM-causing mutations can be introduced into the secondary 
cardiomyocyte cell line, HL-1, by lentiviral transduction. 
 
The specific aims are: -­‐ To engineer lentiviral particles for the delivery of TNNI3-G203S and  
MYH7-R403Q mutated genes into cells. -­‐ To determine if HL-1 cells can be transduced using the lentivirus. 
 
An overview of the thesis structure is outlined in Figure 1.9. 
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Figure 1.9.  Thesis overview. 
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2 MATERIALS AND METHODS 
This chapter describes the methodology for breeding and genotyping mice, media and 
reagent preparation, plasmid amplification and extraction, and maintaining cell culture 
lines, used within this thesis. 
 
2.1 MOUSE MODELS 
Single-mutant mouse models, MHC-403 and TnI-203, were generated and have been 
characterised previously (Geisterfer-Lowrance et al., 1996, McConnell et al., 2001, 
Tsoutsman et al., 2006).  These models have been briefly described in Section 1.2.1 
and 1.2.2 of this thesis.  TnI-203 female and MHC-403 male mice, on C57BL6 
background, were crossed to obtain offspring of the following genotypes:  non-
transgenic (NTG), single-mutants TnI-203 and MHC-403, and the double-mutant model 
TnI-203/MHC-403 (Figure 1.6).  The TnI-203/MHC-403 offspring have been described 
in Section 1.2.3 of this thesis (Tsoutsman et al., 2008b).  Breeding and experimental 
procedures were approved by the Animal Ethics Committee of the University of 
Sydney, under protocol numbers K75/12-2005/4/4247, K75/12-2009/3/5185 and  
K75/7-2006/5/4419. 
 
2.2 METHODS FOR GENOTYPING ANALYSIS 
2.2.1 Materials 
All media, solutions and buffers were made with triple distilled water, unless otherwise 
indicated.  Reagents and their suppliers are named in Table 2.1.  Thermocyclers used 
for polymerase chain reaction (PCR) and small volume incubations, were either the 
PTC-100 or the PTC-200 Peltier Thermal Cycler (both from MJ Research Inc., MA, 
USA). 
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Table 2.1.  Reagents used for genotyping analysis 
 
Reagent Source / Supplier 
DNA extraction Procedure  
Extraction Solution Sigma Aldrich (St. Louis, MO, USA) 
Tissue Preparation Solution Sigma Aldrich (St. Louis, MO, USA) 
Neutralization Solution B Sigma Aldrich (St. Louis, MO, USA)  
PCR reagents  
Green GoTaq® Flexi Buffer Promega (Maddison, WI, USA) 
MgCl2 Promega (Maddison, WI, USA) 
GoTaq® Flexi DNA polymerase Promega (Maddison, WI, USA) 
Primers Geneworks (Hindmarsh, SA, Australia) 
Restriction enzyme digestion  
AvaI restriction enzyme New England Biolabs (Beverly, MA, USA) 
Buffer 4 New England Biolabs (Beverly, MA, USA) 
Agarose gel electrophoresis  
Agarose Amresco (Solon, OH, USA) 
Tris base Sigma Aldrich (St. Louis, MO, USA) 
Glacial acetic acid Crown Scientific (Moorebank, NSW, Australia) 
EDTA Sigma Aldrich (St. Louis, MO, USA) 
Gel Red Biotium (Hayward, CA, USA) 
5x Loading Buffer Bioline (Alexandria, NSW, Australia) 
Hyperladder I Bioline (Alexandria, NSW, Australia) 
DNA Molecular Weight Marker IX Roche Diagnostics GmbH (Mannheim, Germany) 
 
Table 2.2.  Primers used for genotyping analysis 
Primer Name Primer Sequence Amplicon Size 
Mus Myh6 I13F 
Mus Myh6 I14R 
5’-GCTGGGACAAAGAAATGGAGGTA-3’ 
5’-CTGATGGTCTGAGTGGGTAGGTGAG-3’ 386 bp 
Mus TnI F 
Mus TnI R 
5’-CTGACTTTCCACTTGCAGGA-3’ 
5’-GGTTTGGAGAGGTTTATTCTGC-3’ 161 bp 
h TnI TgF 
h TnI TgR 
5’-AGAAGGAGGACACCGAGAAG-3’ 
5’-CAGGAGAATCGCTTGAACC-3’ 429 bp 
SMCX1F 
SMC41R 
5’-CCGCTGCCAAATTCTTTGG-3’ 
5’-TGAAGCTTTTGGCTTTGAG-3’ 
X chromosome = 330 bp 
Y chromosome = 301 bp 
 
PCR products, DNA and RNA were separated by agarose gel electrophoresis.  
Samples were mixed with 5x Loading Buffer prior to loading onto agarose gel.  Agarose 
gel contained the appropriate percentage of agarose (w/v), made to the correct volume 
with TAE buffer and 1:10 000 parts of Gel Red.  TAE buffer consists of 100 mM Tris 
base, 50 mM glacial acetic acid, 3 mM EDTA, pH 8.0.  Gels were visualised by UV 
radiation using Syngene Image Analyser G:Box.  DNA molecular weight markers 
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(Marker IX or Hyperladder I) were run simultaneously next to samples, to determine 
approximate size of nucleic acids. 
 
2.2.2 DNA extraction 
Mice were ear clipped between ages 5 to 10 days, and tail clips (~2 mm) were 
collected post-mortem.  DNA was extracted from ear and tail clips, and genotyping was 
conducted in duplicate for each mouse.  Tail samples were added to 100 µL of 
Extraction Solution and 25 µL of Tissue Preparation Solution, vortexed and incubated 
at room temperature for 10 minutes.  Samples were heated for 3 minutes at 95˚C, and 
100 µL of Neutralization Solution B was added.  For ear clipped tissue samples, the 
same procedure was followed as for tail DNA extraction, with the exception that half the 
solution volumes were used.  DNA was diluted 1:100 in triple distilled water, prior to 
use for PCR. 
 
2.2.3 Identification of mice with the MHC-403 mutation 
To identify mice that carry the α-MHC-R403Q mutation, PCR was conducted to amplify 
a section of this gene, followed by an AvaI restriction enzyme digest, and visualisation 
by agarose gel electrophoresis.  Primers, Mus Myh6 I13F and Mus Myh6 I14R, were 
designed to flank exon 14 of the α-myosin heavy chain gene (Myh6) (Table 2.2).  PCR 
mixture contained 2 µL of diluted (1:100) DNA template, 1X Green GoTaq® Flexi 
Buffer, 1.5 mM MgCl2 125 µM dNTPs, 0.4 µM forward primer, 0.4 µM reverse primer 
and 0.25 units (U) GoTaq® Flexi DNA Polymerase, made up to a final volume of 10 µL 
with triple distilled water.  The PCR cycling conditions were as follows: 95˚C for 5 
minutes; followed by 35 cycles of 95˚C for 30 seconds, 58˚C for 30 seconds and 72˚C 
for 30 seconds.  The resulting amplicon was 386 bp and contained part of introns 13 
and 14, and the entire exon 13, in which the missense mutation at codon R403Q is 
located. 
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PCR products were digested using AvaI restriction endonuclease.  AvaI digest reaction 
mixture contained 10 µL PCR product, 10 U AvaI restriction enzyme, 1X Buffer 4 and 
was made up to a total volume of 20 µL with triple distilled water.  Sample reactions 
were incubated for 5 hours at 37˚C in a Peltier Programmable Thermal Controller. 
AvaI-digested samples were separated on a 2% agarose, electrophoresed at 90V for 
30-60 minutes and visualised. 
 
The AvaI recognition site is present within the MHC-wt allele, but not in the MHC-403 
mutant allele (Table 2.3).  The missense mutation in the MHC-403 allele remains 
undigested, yielding only one product.  Therefore, wild-type MHC mice will display 2 
bands on an agarose gel, compared to MHC-403 heterogeneous mice, which will 
display 3 bands (2 bands for digested wild-type allele, 1 band for undigested mutant 
allele) (Figure 2.1). 
 
Table 2.3.  AvaI recognition site and corresponding sequence for MHC-wt and 
MHC-R403Q alleles. 
 Sequence 
AvaI recognition site * 5’-C^(C/T)CG(A/G)G-3’ 
MHC-wt allele 5’-CTCGGG-3’ 
MHC-R403Q allele 5’-CTCAGG-3’ 
* Cleavage site denoted by ^.  Missense mutation denoted by red font. 
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Figure 2.1.  Identification of mice carrying the MHC-R403Q mutation.  Lane 1, 
DNA Molecular Weight Marker IX (Roche).  The presence of two bands indicates a 
wild-type genotype (lane 2).  Three bands indicate heterozygous genotype for the 
αMHC-R403Q mutation (lane 3). 
 
2.2.4 Identification of mice with the TnI-203 mutation 
Mice harbouring the human cardiac TnI-G203S transgene were identified by PCR 
amplification of a portion of the transgene and visualised by gel electrophoresis.  The 
method used multiplex PCR in which both the human transgene and the wild-type 
endogenous mouse gene were amplified.  The reaction mixture was identical to that 
described in Section 2.2.3, with the exception of the primers.  Forward and reverse 
primers were designed to anneal to the human transgene, denoted by hTnI TgF and 
hTnI TgR, respectively.  The second primer set was designed as a positive control to 
amplify the endogenous mouse allele, denoted Mus TnI F and Mus TnI R (Table 2.2).  
Primers were used at the following final concentrations:  0.8 µM Mus TnI F, 0.8 µM 
Mus TnI R, 1.2 µM hTnI F and 1.6 µM hTnI R.  The PCR cycling conditions were as 
follows:  95˚C for 5 minutes; followed by 35 cycles of 95˚C for 30 seconds, 63˚C for 30 
seconds, and 72˚C for 40 seconds.  PCR products were separated on 2% agarose gel, 
electrophoresed at 90V for 30-60 min and visualised as previously.  A single band at 
1           2           3        
1353 bp - 
1078 bp - 
872 bp - 
603 bp - 
310 bp - 
281 bp - 
234 bp - 
194 bp - 
118 bp - 
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161 bp indicates the presence of the endogenous mouse TnI gene.  A second band at 
429 bp indicates the presence of the human transgene (Figure 2.2). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 2.2.  Identification of mice carrying the human TnI transgene.  The 
presence of a band at 161 bp indicates the endogenous mouse TnI gene is present, 
and thus acts as a positive control.  The presence of a larger, second band of 429 bp 
indicates the mouse carries the human transgene.  Lane 1, DNA Molecular Weight 
Marker IX (Roche); lane 2, PCR product for TnI-203 mouse; lane 3, PCR product for 
NTG mouse. 
 
 
2.2.5 Gender determination of mice 
Mouse gender was determined by physical inspection and confirmed by PCR-based 
genotyping.  PCR primers were designed to target SMC, a gene with different variants 
in the X- and Y- chromosomes.  Sample reaction mixture contained 2 µL diluted 
(1:100) DNA, 1X Green GoTaq® Flexi Buffer, 1.25 mM MgCl2, 200 µM dNTPs, 1.2 µM 
forward primer (SMCX1F), 1.2 µM reverse primer (SMC41R) (Table 2.2) and 0.25 U of 
GoTaq® Flexi DNA polymerase.  PCR cycling conditions were as follows:  95˚C for  
5 minutes; followed by 35 cycles of 95˚C for 30 seconds, 58˚C for 30 seconds and 
72˚C for 30 seconds.  PCR products were separated on a 3% agarose gel, and 
visualisation as described previously.  Female animals have a single product at 330 bp 
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(X chromosome amplification), while males have two products at 330 bp and 301 bp  
(X and Y chromosome amplification) (Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.  Identification of gender in mice.  The presence of one band indicates 
the presence of only X chromosomes, and thus female gender of mouse.  The 
presence of two bands indicates the mouse is male.  Lane 1, DNA Molecular Weight 
Marker IX (Roche); lane 2, PCR product for female genotype; lane 3, PCR products for 
male mouse genotype. 
 
 
2.3 PLASMID DNA AMPLIFICATION AND ISOLATION 
2.3.1 Materials and media 
Reagents required for preparation of bacterial media, transformation and plasmid DNA 
extraction are outlined in Table 2.4.  All Escherichia coli (E. coli) strains were grown in 
sterilised S.O.C or Luria Bertani (LB) medium (5 g tryptone, 2.5 g yeast, 2.5 g NaCl 
made up to 500 mL triple distilled water), or on LB agar plates (LB medium with the 
addition of 7.5g agar), supplemented with 10 µg/mL chloramphenicol or 50 µg/mL 
kanamycin, as indicated.  All bacterial incubations were conducted at 37˚C with liquid 
cultures incubated in an Orbital Mixer Incubator (Ratek, Boronia, VIC, Australia) and 
plated bacteria incubated in a Heraeus B-12 incubator (Kendro Laboratory Products 
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GmbH, Langenselbold, Germany).  Bacterial strains used in this study are shown in 
Table 2.5. 
  
Table 2.4.  Reagents used for plasmid DNA amplification and isolation. 
Reagent Supplier 
Tryptone Sigma-Aldrich (St. Louis, MO, USA) 
Yeast Sigma-Aldrich (St. Louis, MO, USA) 
NaCl Sigma-Aldrich (St. Louis, MO, USA) 
Agar Sigma-Aldrich (St. Louis, MO, USA) 
S.O.C. medium Invitrogen (Carlsbad, CA, USA) 
Chloramphenicol Sigma-Aldrich (St. Louis, MO, USA) 
Kanamycin Sigma-Aldrich (St. Louis, MO, USA) 
QIAprep® Spin Miniprep Kit Qiagen GmbH (Hilden, Germany) 
QIAGEN® EndoFree Plasmid Maxi Kit Qiagen GmbH (Hilden, Germany) 
DEPC-treated water Ambion (Austin, Texas, USA) 
 
 
Table 2.5.  Bacterial strains used in this study. 
Bacterial strain  Resistance Source 
E. coli TOP10 Streptomycin Invitrogen (Carlsbad, CA, USA) 
E. coli XL-10 Gold Tetracycline and chloramphenicol Stratagene (La Jolla, CA, USA) 
E. coli DH10β Streptomycin 
Gene Therapy Laboratory, Centenary Institute 
(Sydney, NSW, Australia) 
[Original source: Invitrogen] 
 
2.3.2 Transformation of competent cells 
Competent cells (supplied Table 2.5) thawed on ice and plasmid DNA was added.  The 
transformation mixture was incubated for 60 minutes on ice, then heat shocked at 42˚C 
for 90 seconds in a pre-heated water-bath, before further incubation on ice for  
2 minutes.  S.O.C or LB medium (pre-warmed to 37˚C) was added to the 
transformation mixture, incubated for 1 hour at 37˚C and subsequently plated on LB 
agar plates with appropriate antibiotic selection.  Further details pertaining to plasmid 
transformation into E. coli strains are described in detail in Chapter 5. 
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2.3.3 Small-scale plasmid DNA preparations 
Plasmid DNA was isolated using the QIAprep® Spin Miniprep kit, as per the 
manufacturer’s instructions.  In brief, single bacterial colonies were selected from agar 
plates and transferred to 10 mL LB medium supplemented with the appropriate 
antibiotic.  The culture was incubated overnight (14-16 hours) at 37˚C, with shaking at 
220 rpm, then centrifuged to pellet the bacterial cells (>7 500 xg).  Supernatant was 
discarded and the pellet resuspended in 250 µL of pre-chilled Buffer P1.  To lyse cells, 
250 µL Buffer P2 was added, and inverted 6 times to mix.  Within 5 minutes, the lysis 
reaction was neutralised by the addition of 350 µL of Buffer N3 and inverting 6 times to 
mix.  Mixture was centrifuged at ~18 000 xg for 10 minutes to clear lysate.  
Supernatant was applied to QIAprep spin column and centrifuged for 1 minute at  
~18 000 xg and flow through was discarded.  To remove any trace nuclease activity, 
the spin column was washed; 500 µL Buffer PB was applied to column and centrifuged 
as before (1 minute, ~18 000 xg).  750 µL PE was added to column, centrifuged as 
previously and flow through discarded.  To remove residual wash buffer, empty spin 
column was centrifuged for 1 minute.  Column was transferred to clean microcentrifuge 
tube and 50 µL of DEPC-treated water added to the centre of the column membrane.  
The column was incubated at room temperature for 2 minutes, centrifuged and the 
plasmid containing eluent was collected. 
 
2.3.4 Large-scale plasmid DNA preparations 
Plasmids required in large amounts were prepared using Qiagen’s EndoFree Plasmid 
Maxi Kit, largely following the manufacturer’s instructions.  Briefly, 100 mL of LB 
medium containing the appropriate antibiotic for selection, was inoculated with a single 
bacterial colony picked from an LB agar plate.  The culture was incubated for 
approximately 18 hours, at 37˚C with shaking (~250 rpm).  Bacterial cells were 
harvested by centrifugation at 6 000 xg for 15 minutes at 4˚C.  The bacterial pellet was 
resuspended in 10 mL Buffer P1, then 10 mL of Buffer P2 was added to lyse the cells 
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and was mixed by inverting.  The lysate was then incubated at room temperature for 5 
minutes.  10 mL of pre-chilled Buffer P3 was added and mixed by inverting 6 times.  
The lysate was subsequently poured directly into the barrel of the QIAfilter Cartridge, 
and was left to incubate at room temperature for 10 minutes.  Following incubation, 
lysate was passed through the QIAfilter cartridge, by plunging into a clean 50 mL falcon 
tube.  2.5 mL of Buffer ER was added to the filtered lysate, and mixed by inverting 
approximately 10 times, followed by a 30 minute incubation on ice.  To equilibrate the 
‘QIAGEN-tip 500’, 10 mL of Buffer QBT was loaded and allowed to pass through (by 
gravity only).  Following equilibration, the filtered lysate was passed through the 
QIAGEN-tip, which was subsequently washed twice with 30 mL of Buffer QC.  Plasmid 
DNA was eluted by adding 15 mL of Buffer QN into the QIAGEN-tip and DNA was 
precipitated by addition of 10.5 mL isopropanol, mixing then centrifuging at ≥15 000 xg 
for 30 minutes at 4˚C, to form a DNA pellet.  The pellet was washed with 5 mL of 70% 
ethanol, air dried and dissolved in TE buffer diluted 1:10 with DEPC-treated water. 
 
2.4 MAMMALIAN CELL CULTURE 
Two cell lines were used within the course of this study.  These are HEK293T, a 
human embryonic kidney cell line and HL-1, a cardiomyocyte cell line. 
 
2.4.1 Materials and media preparation for HEK293T cells 
HEK293T cells were obtained from the DNA Repair Laboratory at Centenary Institute 
(Camperdown, NSW, Australia).  The reagents used are described in Table 2.6.  
HEK293T cells were maintained in ‘Complete Medium’ that consisted of Dulbecco’s 
Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum (FBS),  
2 mM L-Glutamine, 100 U/mL penicillin and 0.1 mg/mL streptomycin.  ‘Wash Medium’ 
which contains DMEM with 5% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin, 
was used for rinsing flasks during passaging.  ‘Freezing medium’ consisting of 90% 
FBS and 10% DMSO, was used for the cryopreservation of cells.  Cells were routinely 
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screened for mycoplasma, using the MycoAlert® Mycoplasma Detection kit, as per the 
supplier’s instructions. 
 
Table 2.6.  Reagents used in maintaining HEK293T cultures.  
Reagent Supplier / Source 
Dulbecco’s Modified Eagles Medium Sigma-Aldrich (St. Louis, MO, USA) 
GIBCO Fetal Bovine Serum Invitrogen (Penrose, Auckland, New Zealand) 
L-Glutamine solution (200 mM) Sigma-Aldrich (St Louis, MO, USA) 
Penicillin (10 000 units/mL) –  
Streptomycin (10 mg/mL) solution Sigma-Aldrich (St Louis, MO, USA) 
Trypsin-EDTA, 1X Sigma-Aldrich (St Louis, MO, USA) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (St. Louis, MO, USA) 
MycoAlert® Mycoplasma Detection kit Lonza (Rockland, ME, USA) 
Dulbecco’s Phosphate Buffered Solution (PBS) Sigma-Aldrich (St Louis, MO, USA) 
 
2.4.2 Culturing HEK293T cells 
Cells were cultured in T25 or T75 flasks, grown in Complete Medium and maintained at 
37˚C, 5% CO2.  Cells were passaged upon reaching 70-90% confluency.  Between 
passages media was changed as required, using the pH indicator within the phenol red 
media.  To split cells, media was aspirated and cells washed with phosphate buffered 
solution (PBS).  Adherent cells were detached by incubating with 1X trypsin-EDTA at 
37˚C for 2 minutes (1 mL/T25, 3 mL/T75) and visualised microscopically to ensure cells 
had been successfully lifted.  An equal volume of wash medium was added to 
neutralise trypsin, and cells were pelleted at 500 xg for 3 minutes at room temperature.  
Pelleted cells were resuspended in pre-warmed Complete Medium, and split at 1:3 to 
1:4 into new flasks containing appropriate volumes of Complete Medium (5 mL/T25, 
10-15 mL/T75).  Cells were passaged twice a week. 
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2.4.3 Cryopreservation of HEK293T cells 
To freeze down cells, a T75 flask of cells that had reached 70-80% confluency were 
trypsinised and pelleted, as per section 2.4.2.  The cell pellet was resuspended in 1 mL 
of Freezing Medium, the suspension transferred to a sterile cryovial.  The cryovial was 
placed in a Nalgene® Mr Frosty (Sigma-Aldrich, St Louis, MO, USA) which was stored 
in the -80˚C freezer overnight, allowing for a gradual freezing of cells.  Within the 
following few days, cells were transferred to liquid nitrogen for long-term storage. 
 
2.4.4 Thawing of cryopreserved HEK293T cells 
Cells stored in liquid nitrogen were thawed in a 37˚C water bath.  The cell solution was 
added to 10 mL of Wash Medium and pelleted at 500 xg for 3 minutes at room 
temperature, in order to remove DMSO contained in the Freezing Medium.  The cell 
pellet was resuspended in 10 mL of Complete Medium, and transferred to a T75 flask. 
 
2.4.5 Materials and media preparation for HL-1 cells 
Maintaining the HL-1 cell line, freezing cells for cryopreservation and thawing frozen 
stocks, were carried out in accordance with the guidelines provided by Prof. William’s 
Claycomb (LSU Health Sciences Center, New Orleans, LA, USA), from whom the cells 
were received (Claycomb et al., 1998).  Reagents used in HL-1 culturing are outlined in 
Table 2.7.  HL-1 cells are fastidious and require a specific batch number of FBS and 
high cell density for optimal growth and normal cardiomyocyte phenotypic behaviour.  
HL-1 cells are an adherent cell line and require flasks to be coated in gelatin/fibronectin 
in order for proper adhesion to occur. 
 
HL-1 cardiomyocytes were maintained in ‘Supplemented Claycomb Medium’, 
consisting of Claycomb Medium with 10% FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 0.1 mM of norepinephrine and 2 mM of L-glutamine.  ‘Wash Claycomb 
Medium’ consisted of Claycomb Medium made up with 5% FBS and 100 U/mL 
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penicillin and 100 µg/mL streptomycin.  When trypsinising HL-1 cells, trypsin was 
neutralised using the Soybean Trypsin Inhibitor Solution.  This consisted of 25 mg 
soybean trypsin inhibitor dissolved in 100 mL of Dulbecos PBS and filter sterilised.  
Gelatin/fibronectin was a sterile mixture, made up of 1 mL fibronectin to 200 mL of 
0.02% gelatin.  ‘HL-1 Freezing Medium’ is 95% FBS and 5% DMSO.  HL-1 cells were 
routinely screened for mycoplasma contamination using the MycoAlert® Mycoplasma 
Detection kit. 
 
Table 2.7.  Reagents used in culturing HL-1 cells. 
Reagent Source / Supplier 
Claycomb medium SAFC Biosciences (Lenexa, Kansas, USA) 
Fetal bovine serum, Batch 8A0177 SAFC Biosciences (Lenexa, Kansas, USA) 
Penicillin (10 000 units/mL) –  
Streptomycin (10 mg/mL) solution Sigma-Aldrich (St Louis, MO, USA) 
Norepinephrine [(±)-Arterenol] Sigma-Aldrich (St Louis, MO, USA) 
L-Ascorbic acid, sodium salt Sigma-Aldrich (St Louis, MO, USA) 
Water, double-processed, tissue culture grade Sigma-Aldrich (St Louis, MO, USA) 
L-Glutamine solution (200 mM) Sigma-Aldrich (St Louis, MO, USA) 
Dulbecco’s PBS Sigma-Aldrich (St Louis, MO, USA) 
Trypsin-EDTA, 1X Sigma-Aldrich (St Louis, MO, USA) 
Soybean trypsin inhibitor Sigma-Aldrich (St Louis, MO, USA) 
Dulbecco’s PBS (Ca2+- and Mg2+- free) Sigma-Aldrich (St Louis, MO, USA) 
Gelatin from bovine skin Sigma-Aldrich (St Louis, MO, USA) 
Fibronectin Sigma-Aldrich (St Louis, MO, USA) 
DMSO Sigma-Aldrich (St Louis, MO, USA) 
MycoAlert® Mycoplasma Detection kit Lonza (Rockland, ME, USA) 
 
 
2.4.6 Culturing HL-1 cells 
Prior to culturing cells, all flasks and plates were required to be gelatin/fibronectin 
coated, to allow for adhesion of the HL-1 cells.  Plasticware was coated with the 
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gelatin/fibronectin mixture (2 mL/T25, 6 mL/T75, 1 mL/well of 6 well plate), incubated 
for at least 1 hour at 37˚C prior to use and the gelatin/fibronectin mixture was aspirated 
immediately before transferring cells. 
 
The HL-1 cardiomyocyte cell line was grown in Supplemented Claycomb Medium, in a 
37˚C, 5% CO2 incubator.  These cells require high cell density, thus were only split 
once full confluence was reached.  Medium was replaced daily.  To split HL-1 cells, 
media was aspirated and cells washed with trypsin-EDTA to remove trace media.  
Following this step, HL-1 cells were incubated with trypsin-EDTA for 2 minutes  
(1 mL/T25, 3 mL/T75) and trypsin-EDTA was carefully aspirated.  To detach cells, a 
subsequent 2 minute incubation with trypsin-EDTA was required, at which stage the 
flask was sharply tapped to dislodge cells.  Cells were examined microscopically to 
ensure all cells had detached.  An equal amount of Soybean Trypsin Inhibitor Solution 
(1 mL/T25, 3 mL/T75) was added directly to the cells to inactivate the enzyme.  Cells 
were transferred to a 15 mL centrifuge tube.  Wash Claycomb Medium was used to 
rinse flasks to ensure a maximum number of cells were collected.  Cells were pelleted 
at 500 xg for 5 minutes at room temperature.  Supernatant was aspirated and the 
remaining cell pellet was resuspended in 3 mL of Supplemented Claycomb Medium.  1 
mL of the cell suspension was transferred to a new flask for a 1:3 split.  Cells were split 
twice a week. 
 
2.4.7 Cryopreservation of HL-1 cells 
HL-1 cardiomyocytes were cryopreserved once cells had reached full confluence.  
Cells were trypsinised and pelleted as per section 2.4.6, with the resulting cell pellet 
resuspended in 1 mL of the HL-1 Freezing Medium, transferred to a cryovial and 
subsequently placed in Nalgene® Mr Frosty in -80˚C overnight.  Cells were transferred 
to liquid nitrogen for long-term storage within 48 hours. 
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2.4.8 Thawing of HL-1 cells 
Cells were thawed in a 37˚C water bath and added to 10 mL of Wash Claycomb 
Medium.  Cells were centrifuged for 5 minutes at 500 xg, room temperature.  The cell 
pellet was resuspended in 10 mL of Supplmented Claycomb Medium, and transferred 
to a gelatin/fibronectin coated T75 flask. 	  	  
       
     51 
 
 
 
 
CHAPTER 3 
LOSARTAN TREATMENT IN A MOUSE 
MODEL OF MULTIPLE MUTATION 
HYPERTROPHIC CARDIOMYOPATHY
Chapter 3.  Losartan Treatment in a Mouse Model of Multiple Mutation HCM 
     52 
3 LOSARTAN TREATMENT IN A MOUSE MODEL OF MULTIPLE 
MUTATION HYPERTROPHIC CARDIOMYOPATHY 
 
3.1 INTRODUCTION 
While significant advances have been made in understanding the genetic basis of 
HCM, there are currently no pharmacological therapies which have been shown to 
prevent, delay onset of, or cause regression of this disease in humans.  Identifying 
novel therapies is crucial and animal models have proven useful in evaluating potential 
therapies, as outlined in Section 1.4.1. 
 
Losartan, a selective angiotensin II type 1 receptor (AT1) antagonist, is the focus 
treatment of this thesis.  While it is commonly prescribed to treat hypertension it also 
has well-established anti-fibrotic effects in various diseased organs, including the heart 
(Günther et al., 2010, Teekakirikul et al., 2010).  Cardiac interstitial fibrosis is a 
pathogenic feature of HCM, contributing to mechanical stiffness causing cardiac 
dysfunction and in turn can lead to heart failure.  Fibrosis also disrupts electrical 
connections between cardiomyocytes, which provides a substrate for the development 
of arrhythmias and enhances the diffusion distance for plasma-derived substrates and 
oxygen to the cardiac cells (Manabe et al., 2002, Brown et al., 2005).  Hypothetically, 
pharmacological therapies aimed at reducing fibrosis would likely be of benefit in HCM. 
 
Losartan therapy has been previously investigated in three mouse models of HCM.  
The first study, carried out by Lim and colleagues in 2001, employed the cTnT-Q92 
model, which exhibits cardiac interstitial fibrosis and myocyte disarray, but does not 
develop significant cardiac hypertrophy (Lim et al., 2001).  Treatment in this model was 
found to reverse fibrosis, however any effect on cardiac hypertrophy or cardiomyocyte 
enlargement could not be studied.  Losartan therapy has also been investigated in 
MHC-R403Q and MHC-R719W mice.  Both models exhibit all HCM features and 
administration of losartan from a pre-emptive time-point was shown to prevent the 
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emergence of disease but did not cause regression of established disease 
(Teekakirikul et al., 2010).  While these studies have been useful for evaluating 
losartan as a therapy in HCM, the models harbour single causative mutations, in which 
the phenotype gradually develops and presents in adulthood.  To date, no treatment 
studies have been carried out on animal models of severe, rapidly progressing HCM. 
 
Up to 5% of HCM patients have multiple disease-causing mutations, correlating with a 
more severe phenotype, including earlier presentation of disease, increased heart wall 
thickness and an elevated incidence of sudden cardiac death events (Ingles et al., 
2005, Richard et al., 1999, Van Driest et al., 2005).  While previous animal model 
studies suggest losartan to be beneficial in patients exhibiting milder clinical 
manifestations, there is no indication of how effective losartan would be in multiple-
mutation disease.  This study sought to investigate the effects of losartan therapy in a 
double-mutant model of severe HCM. 
 
The TnI-203/MHC-403 mouse model (described in Section 1.2.3) mimics the multiple-
mutation HCM phenotype as reported in humans, including early onset, rapid 
progression and significantly increased mortality.  This model also exhibits differences 
in disease severity between genders.  Similar to human HCM in which males typically 
exhibit a more severe phenotype including earlier presentation of disease (Lind et al., 
2008, Kubo et al., 2010), TnI-203/MHC-403 male mice were reported to have a 
significantly shorter lifespan than females (Tsoutsman et al., 2008b).  A mechanistic 
finding in this model was the up-regulation of connective tissue growth factor (Ctgf) in 
diseased hearts (Tsoutsman et al., 2008b).  This pro-fibrotic molecule has been shown 
to stimulate fibroblast production (Ahmed et al., 2004), their differentiation towards 
myofibroblasts and to enhance extracellular matrix (ECM) production (Frazier et al., 
1996, Grotendorst, 1997, Grotendorst et al., 2004).  In addition, cardiac-specific over-
expression of CTGF has been shown to induce cardiomyocyte hypertrophy (Panek et 
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al., 2009).  Consequently, CTGF may be of central importance in the disease 
pathogenesis of the TnI-203/MHC-403 mouse model.  Losartan (as well as other AT1 
inhibitors) has been shown to repress the expression of CTGF in animal and cell 
models (Ahmed et al., 2004, Teekakirikul et al., 2010, Wang et al., 2009a). 
 
3.1.1 Aims 
This study sought to investigate the effect of losartan treatment in the TnI-203/MHC-
403 model, including survival, cardiac function, heart morphology, cardiac fibrosis and 
the expression of markers of hypertrophy.  Due to the accelerated phenotype 
development in male mice (Tsoutsman et al., 2008b), males and females have been 
analysed separately, where possible.  Further, this study examined the effect of 
losartan on the expression of CTGF, a potential regulator of HCM development, as well 
as the expression of other pro-fibrotic molecules that may interplay with CTGF in the 
pathogenesis of this model. 
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3.2 METHODS 
3.2.1 Materials, drugs and reagents 
Table 3.1 Materials and reagents 
Reagent Source 
Drug treatment 
Losartan (COZAAR®) Merck Sharp & Dohme, South Granville, NSW, Australia 
(+)-cis-Diltiazem Sigma, St Louis, MO, USA 
Triple distilled water Prepared by Centenary Institute, Camperdown, NSW, Australia 
Heart collection 
Nair hair removal cream Carter-Wallace, Frenchs Forest, NSW, Australia 
PBS tablets Sigma, St Louis, MO, USA 
Formalin solution, neutral buffered, 10% Sigma-Aldrich, St Louis, MO, USA 
RNA extraction, reverse transcription and qPCR 
TRIzol reagent Invitrogen, Carlsbad, CA, USA 
Chloroform ChemSupply, Gillman, SA, Australia 
Isopropanol Sigma-Aldrich, St Louis, MO, USA 
DEPC-treated water Ambion, Austin, Texas, USA 
SuperScript® VILO cDNA synthesis kit Invitrogen, Carlsbad, CA, USA 
Oligos Synthesised by Geneworks, Hindmarsh, SA, Australia 
EXPRESS Sybr® GreenER qPCR 
SuperMix Universal Master Mix Invitrogen, Carlsbad, CA, USA 
Protein extraction 
Tris-HCl Sigma-Aldrich, St Louis, MO, USA 
Sodium Chloride (NaCl) Sigma-Aldrich, St Louis, MO, USA 
Igepal Sigma-Aldrich, St Louis, MO, USA 
Ethylenediaminetetraacetic Acid (EDTA) Sigma-Aldrich, St Louis, MO, USA 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, St Louis, MO, USA 
Sodium deoxycholate Sigma-Aldrich, St Louis, MO, USA 
Complete ULTRA Tablets, EDTA-free 
Protease inhibitor cocktail tablets Roche Diagnostics, Mannheim, Germany 
Western blotting 
NuPAGE® Bis-Tris Precast Gels Invitrogen, Carlsbad, CA, USA 
NuPAGE® MOPS SDS Running Buffer 
20X Invitrogen, Carlsbad, CA, USA 
NuPAGE® Antioxidant Invitrogen, Carlsbad, CA, USA 
NuPAGE® LDS Sample Buffer (4X) Invitrogen, Carlsbad, CA, USA 
NuPAGE® Reducing Agent (10X) Invitrogen, Carlsbad, CA, USA 
NuPAGE® Transfer Buffer (20X) Invitrogen, Carlsbad, CA, USA 
Methanol Crown Scientific, Moorebank, NSW, Australia 
Glacial Acetic Acid Crown Scientific, Moorebank, NSW, Australia 
Coomassie Brilliant Blue R-250 Bio-Rad Laboratories, Hercules, CA, USA 
Immuno-Blot PVDF membrane Bio-Rad Laboratories, Hercules, CA, USA 
Sodium azide Chem Supply, Gillman, SA, Australia 
Tween-20 Bio-Rad Laboratories, Hercules, CA, USA 
PBS, phosphate buffered saline; PVDF, polyvinylidene fluoride. 
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3.2.2 Drug treatment and survival analysis 
 
Littermates of four genotypes (NTG, TnI-203, MHC-403 and TnI-203/MHC-403) were 
generated by TnI-203 x MHC-403 cross-breeding, however this thesis focuses on the 
NTG and TnI-203/MHC-403 mice.  Litters were randomly assigned into losartan 
treatment, diltiazem treatment or water treatment groups, resulting in 6 study groups:  
(i) water-treated NTG, (ii) water-treated TnI-203/MHC-403, (iii) losartan-treated NTG, 
(iv) losartan-treated TnI-203/MHC-403, (v) diltiazem-treated NTG, (vi) diltiazem-treated 
TnI-203/MHC-403.  To avoid bias, genotypes were kept blinded during treatment, 
organ measurements and sample collection. 
 
Losartan is readily absorbed in both rodents and humans when administered orally and 
is not available in intravenous form (Sica et al., 2005).  As such, oral administration of 
losartan was carried out in this study.  Losartan potassium tablets, COZAAR® were 
crushed into a fine powder and resuspended in triple distilled water at concentrations 
up to 100 mg/mL (of losartan component of tablet).  Treatment was administered from 
age 5 days, daily.  Dose increased incrementally with age, as shown in Table 3.2.  
Water control mice were treated orally with an equivalent volume of water. 
 
Table 3.2  Age-dependent dosage of losartan 
Age Dose administered Concentration Volume 
5 days 5 mg/kg 10 mg/mL 0.5 µL/g 
6 days 5 mg/kg 10 mg/mL 0.5 µL/g 
7 days 10 mg/kg 20 mg/mL 0.5 µL/g 
8 days 25 mg/kg 50 mg/mL 0.5 µL/g 
9 days 50 mg/kg 100 mg/mL 0.5 µL/g 
10 days 100 mg/kg 100 mg/mL 1.0 µL/g 
 
To investigate whether the effect of losartan in this study is due to reduced blood 
pressure, a control group was treated with diltiazem.  Diltiazem is an L-type calcium 
channel antagonist thus representing an appropriate blood pressure lowering control 
with a different mechanism of action to losartan.  Diltiazem was administered by 
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intraperitoneal (IP) injection at 25 mg/kg/day.  This dose was chosen as it has been 
effective in treatment studies of other HCM mouse models (Semsarian et al., 2002, 
Westermann et al., 2006).  Diltiazem solution was made by dissolving (+)-cis-Diltiazem 
hydrochloride (Sigma, St Louis, MO, USA) in triple distilled water at a concentration of 
2.5 mg/mL and 10 µL of diltiazem solution per gram body weight was administered 
from age 5 days onward.   
 
Mice were monitored daily at the time of treatment.  For survival analysis, the age of 
death was recorded for the day mice were found dead.  The study overview is 
presented in Figure 3.1 
 
Figure 3.1.  Timeline of disease development and experimental protocol.  Disease 
development in untreated TnI-203/MHC-403 mice is indicated.  Losartan therapy and 
water treatment were administered from age 5 days.  Echocardiography was carried 
out at age 16 to 17 days.  Hearts were harvested at ages 10, 14 and 17 days, 
corresponding with early, established and end-stage heart failure stages of disease.  In 
addition, weights of mice, hearts and lungs were collected at these time-points, and 
were used for RNA, protein and for histology analysis.  Diltiazem treatment was also 
carried out (not shown on timeline), with survival analysis being the only outcome 
investigated. 
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3.2.3 Mouse body, heart and lung weights 
At ages 10, 14 and 17 days, the body weights of littermates were measured using 
NHB-600 Electronics Balance (@weigh, Victoria, Australia).  Mice were sacrificed by 
cervical dislocation and their hearts and lungs excised, washed in 1X PBS (PBS tablets 
dissolved in triple distilled water, as per the manufacturer’s instructions), blotted dry on 
tissue paper, weighed using PB303-L Precision Balance (Mettler-Toledo GmbH, 
Giessen, Germany) and heart weight to body weight (HW:BW) and lung weight to body 
weight (LW:BW) ratios were calculated.  Whole heart photos were taken using a Lumix 
FZ-35 camera (Panasonic, Macquarie Park, NSW, Australia). 
 
3.2.4 Mouse echocardiography 
Two-dimensional and M-mode echocardiography was performed on mice aged 16-17 
days, that were either NTG or TnI-203/MHC-403 genotype, losartan- or water-treated.  
Transthoracic echocardiography was carried out using a 7- to 15- MHz linear-array 
probe and HDI 5000 ultrasonograph, as described previously (Semsarian et al., 2002, 
Tsoutsman et al., 2008b).  Fur was removed from the chest area prior to 
echocardiography, using Nair hair removal cream, and mice were taped gently to a 
restraining board to restrict movement.  2D images of the left ventricle in short-axis and 
long-axis views were obtained.  Dimensions for left ventricular end diastolic diameter 
(LVEDD) and left ventricular end systolic diameter (LVESD) were determined from  
M-mode tracings, based on measurements from three separate cardiac cycles.  LV 
fractional shortening was calculated using the formula FS = (LVEDD-
LVESD)/LVEDDx100%.  Heart rate was also recorded throughout this study.  An 
experienced investigator (Professor Christopher Semsarian) performed all 
echocardiography and measurements, blinded from both genotype and treatment. 
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3.2.5 Histopathology and fibrosis quantification 
Whole hearts of 10, 14 and 17 day old water- and losartan- treated mice were excised, 
washed in 1X PBS, fixed in 10% formalin solution for a minimum of 24 hours and 
subsequently embedded in paraffin.  Two to three consecutive transverse sections 
were cut per heart, at 5 µm thickness and stained with Milligan’s trichrome. 
Embedding, sectioning and staining were carried out by Shanna Trollip (Department of 
Pathology, University of Sydney, NSW, Australia).  Visualisation and digital images 
were captured using a Nikon Eclipse E800 fluorescence microscope (Nikon Instech, 
Kanagawa, Japan) with PCO Sensicam CCD camera (PCO computer optics GmbH, 
Kelheim, Germany).  Automated Cellular Imaging System III (ACIS III) and image 
analysis software (both from Dako, Carpinteria, CA, USA) were used for digital analysis 
of collagen quantification.  Fibrosis was determined as a percentage of extracellular 
regions stained blue (collagen positive), in comparison to total heart tissue area.  
Colour thresholds were set accordingly.  Heart valves and blood clots were masked 
using the freeform tool and thus these areas were excluded from analysis. 
 
3.2.6 RNA extraction 
Hearts excised from 5, 10, 14, and 17 day water- and losartan- treated male mice were 
washed in 1X PBS briefly, the atria removed and ventricles snap frozen in liquid 
nitrogen and stored at -80˚C until further use.  Total RNA was isolated from ventricular 
tissue.  The frozen tissue was added to 1 mL TRIzol Reagent and homogenised with 
Polytron pt-MR2100 homogeniser (Kinematica AG, Lucerne, Switzerland).  
Homogenised samples were incubated for 5 minutes at room temperature, 200 µL of 
chloroform was added and capped tubes shaken vigorously by hand for 15 seconds.  
Samples were incubated for a further 3 minutes at room temperature and subsequently 
centrifuged at 12000 xg for 15 minutes at 4˚C.  The upper colourless aqueous phase 
was transferred to a new tube and mixed with 500 µL of isopropanol.  Samples were 
incubated at room temperature for 10 minutes and then centrifuged at 12000 xg for  
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10 minutes at 4˚C.  Supernatant was removed, RNA pellet washed with 1 mL of 75% 
ethanol, vortexed and centrifuged at 7500 xg for 5 minutes at 4˚C.  The RNA pellet was 
briefly air dried, subsequently dissolved in DEPC-treated water and incubated for 10 
minutes at 55˚C. 
 
3.2.7 Determination of RNA quality and quantity 
RNA purity and quantity was measured using the Nanodrop-2000 spectrophotometer 
(Nanodrop Technologies, Wilmington, DE, USA) and quality assessed by gel 
electrophoresis. 
 
3.2.8 Reverse transcription 
cDNA synthesis was carried out using SuperScript® VILO cDNA synthesis kit, following 
the manufacturer’s instructions.  In brief, cDNA synthesis reaction mix consisted of  
700 ng of total RNA, 1X VILO™ Reaction Mix, 1X SuperScript® Enzyme Mix, made up 
with DEPC-treated water to 10 µL.  Two control samples were made including ‘No 
reverse transcriptase’ control (NoRT; SuperScript® Enzyme Mix replaced by DEPC-
treated water) and ‘No Template Control’ (NTC; RNA replaced with DEPC-treated 
water).  Tube contents were mixed by gently pipetting and incubated at 25˚C for  
10 minutes, 42˚C for 60 minutes and 85˚C for 5 minutes, using a Peltier Thermal 
Cycler.  Resulting cDNA was diluted 10X in DEPC-treated water prior to use in RT-
qPCR. 
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3.2.9 Quantitative polymerase chain reaction 
Reverse transcription quantitative polymerase chain reacton (RT-qPCR) was 
performed to quantitate the expression of pro-hypertrophic markers (natriuretic peptide 
A (Nppa) and B (Nppb)), as well as Ctgf, a potential regulator of HCM, pro-fibrotic 
molecules that may interplay with Ctgf, including transforming growth factor β (Tgf β) -1 
and -2, and genes involved in ECM accumulation (tissue inhibitor of metalloproteinase 
(Timp) 1), ECM degradation (matrix metalloproteinase (Mmp) 3) and ECM components 
(fibronectin (Fn) 1 and collagen (Col) 1a1).  Angiotensin II type 1 receptor (Agtr1a) 
expression was also investigated as this receptor is the direct target for losartan.  
Three reference genes were used, including β-2-microglobulin (β2M), hypoxanthine 
phosphoribosyltransferase (Hprt) and β-actin (Actb), to calculate the normalisation 
factor using geNorm v3.4 software (Vandesompele et al., 2002) for further qPCR 
calculations.  QPCR was performed on five samples for each group, as well as NoRT, 
NTC and water controls.  Sample reaction mixture consisted of 5 µL of EXPRESS 
SYBR® GreenER qPCR SuperMix Universal Master Mix, 3.5 µL of diluted cDNA and a 
final concentration of 0.3 µM of forward and reverse primers (see Table 3.3; Hprt_R 
was used at a final concentration of 0.6 µM), made up with DEPC-treated water to  
10 µL.  All primers used for qPCR were designed and optimised previously by Doctor 
Tatiana Tsoutsman.  qPCR thermal cycling conditions were as follows: 95˚C for 2 
minutes; followed by 40 cycles of 95˚C for 5 seconds then 20 seconds at the annealing 
temperature outlined in Table 3.3.  All reactions were performed using an Mx3000P 
real-time PCR system and data analysed using MxPro qPCR software version 2.0 
(Stratagene, La Jolla, CA, USA). 
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Table 3.3  RT-qPCR primer details and annealing conditions 
Gene Primer Sequence Annealing 
temperature 
Amplicon 
size (bp) 
Nppa Nppa_F 
Nppa_R 
5’-GGGCTTCTTCCTCGTCTTG-3’ 
5’-CGGCATCTTCTCCTCCAG-3’ 
66˚C 130 
Nppb Nppb_F 
Nppb_R 
5’-CTGCTTTTCCTTTATCTGTCACC-3’ 
5’-CCATTTCCTCCGACTTTTCTC-3’ 
64˚C 127 
Ctgf Ctgf_F 
Ctgf_R 
5’-CCCTGCGACCCACACAAG-3’ 
5’-TACACCGACCCACCGAAGAC-3’ 
67˚C 
 
113 
Tgfβ1 
 
Tgfb1_F 
Tgfb1_R 
5’-CCTGAGTGGCTGTCTTTTGA-3’ 
5’-CCCTGTATTCCGTCTCCTTG-3’ 
63˚C 71 
Tgfβ2 
 
Tgfb2_F 
Tgfb2_R 
5’-ACTTTGGTGTGTTGAGTGTCTG-3’ 
5’-CTGCCTTCGCCCTCTTTAC-3’ 
64˚C 138 
Timp1 
 
Timp1_F 
Timp2_R 
5’-GCATCTGGCATCCTCTTGTT-3’ 
5’-AAGGTGGTCTCGTTGATTTCTG-3’ 
65˚C 149 
Mmp3 
 
Mmp3_F 
Mmp3_R 
5’-ATCCCCTGATGTCCTCGTG-3’ 
5’-CGCCAAAAGTGCCTGTCT-3’ 
65˚C 144 
Fn1 
 
Fn1_F 
Fn1_R 
5’-CAGAACCAGAGGAGGCACAAG-3’ 
5’-AATGGCGTAATGGGAAACC-3’ 
61˚C 126 
Col1a1 
 
Col1a1_F4 
Col1a1_R4 
5’-AGAGGCGAAGGCAACAGTC-3’ 
5’-GTCCAAGGGAGCCACATC-3’ 
63˚C 144 
Agtr1a 
 
Agtr1a_F 
Agtr1a_R 
5’-GCTTCCTGTTCCCTTTCCTAA-3’ 
5’-CATTTCTTGGCTTGTTCTTCTG-3’ 
63˚C 99 
β2M b2M_F 
b2M_R 
5’-CTGGTCTTTCTGGTGCTTGTCT-3’ 
5’-GCAGTTCAGTATGTTCGGCTTC-3’ 
66˚C 117 
Actb Actb_F 
Actb_R 
5’-TTTTCCAGCCTTCCTTCTT-3’ 
5’-GAGGTCTTTACGGATGTCAAC-3’ 
61˚C 98 
Hprt Hprt_F 
Hprt_R 
5’-AGTTCTTTGCTGACCTGCTG-3’ 
5’-ACTTTTATGTCCCCCGTTGA-3’ 
61˚C 130 
Nppa, natriuretic peptide A; Nppb, natriuretic peptide B; Ctgf, connective tissue growth 
factor; Tgfβ1, transforming growth factor β1; Tgfβ2, transforming growth factor β2; 
Timp1, tissue inhibitor of metalloproteinase 1; Mmp3, matrix metalloproteinase 3;  
Fn1, fibronectin 1; Col1a1, collagen 1a1; Agtr1a, angiotensin II type 1 receptor a;  
β2M, β-2-microglobulin; Actb, β-actin; Hprt, hypoxanthine phosphoribosyltransferase. 
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3.2.10 Western blotting analysis 
3.2.10.1 Buffers and reagents 
Table 3.4  Recipes for buffers and solutions used in western blotting analysis 
Buffer Final Concentration 
RIPA buffer for protein extraction 50 mM Tris, pH 7.4 
150 mM NaCl 
1% Igepal 
1mM EDTA 
0.1% Sodium dodecyl sulfate 
0.5% Sodium deoxycholate 
Running buffer 1X NuPAGE® MOPS SDS Running Buffer 
diluted from 20X stock 
Transfer buffer 1X NuPAGE® Transfer Buffer diluted from 
20X stock 
20% Methanol 
0.1% NuPAGE® Antioxidant 
Blocking solution 5% w/v skim milk powder 
1X PBS 
0.1% Tween-20 
Antibody solution 1X PBS 
0.1% Tween-20 
0.02% sodium azide 
Membrane wash solution 1X PBS 
0.1% Tween-20 
Coomassie blue stain 40% Methanol 
10% Glacial Acetic Acid 
0.02% Coomassie Brilliant Blue R-250 
Rapid destain 40% Methanol 
10% Glacial Acetic Acid 
Final destain 10% Glacial Acetic Acid 
4% Glycerol 
 
3.2.10.2 Protein Extraction 
Ventricles were collected as described in Section 3.2.5.  Frozen ventricles were thawed 
on ice, weighed and 15 µL of RIPA buffer (supplemented with protease inhibitor 
cocktail tablets) per mg tissue weight was added. Samples were homogenised using a 
Polytron MR2100, nutated at 4˚C for 4 hours, then centrifuged at 18000 xg at 4˚C for 
30 minutes to clear insoluble material.  The supernatant was transferred to a clean tube 
and stored at -80˚C. 
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3.2.10.3 Polyacrylamide Gel Electrophoresis 
Protein samples were separated by polyacrylamide gel electrophoresis (PAGE) using 
the NuPAGE® Novex Bis-Tris Gels in an XCell SureLock™ Mini system.  Protein 
samples were mixed with 4X LDS sample buffer and 10X NuPAGE® reducing agent, 
and were heated to 70˚C for 10 minutes in a Peltier thermal cycler.  Equal volumes of 
protein samples were subsequently loaded into pre-cast NuPAGE® Bis-Tris Mini gels.  
Kaleidoscope pre-stained standard (Bio-Rad Laboratories, Hercules, CA, USA) and 
BenchMark™ pre-stained protein ladder (Invitrogen, Carlsbad, CA, USA) were run 
simultaneously on the gel in order to determine the size of resolved fragments.  Gels 
were electrophoresed in 1X running buffer supplemented with 0.5 mL of NuPAGE® 
antioxidant in the inner chamber of the XCell SureLock™ Mini System apparatus at 
125 volts for 90 minutes at room temperature.   
 
3.2.10.4 Western blotting for CTGF and visualisation 
Following electrophoresis, proteins were transferred from the NuPAGE® gel to PVDF 
membrane (presoaked in methanol).  Transfer was carried out using 1X transfer buffer 
in an XCell II Blot Module, at 30 volts for 90 minutes.  Following transfer, membrane 
was incubated in blocking solution for 1 hour at room temperature then washed for  
2 x 5 minutes in PBS-T.  The membrane was incubated with the primary antibody  
goat-anti-CTGF (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) diluted 1:200 in 
antibody solution, overnight at 4˚C.  The membrane was washed for 2 x 5 minutes in 
PBS-T, and incubated with the HRP-conjugated secondary antibody, rabbit-anti-goat 
(1:2000 dilution; Dako, Carpinteria, CA, USA), for 1 hour at room temperature.  Final 
washing of the membrane involved 5 x 10 minute vigorous washes in PBS-T.  To 
detect protein bands, the Immun-Star™ WesternC™ Chemiluminescence kit (Bio-Rad, 
Hercules, CA, USA) was used, and visualised using Kodak Image Station system 
(Eastman Kodak Co., Rochester, NY, USA). 
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Protein blots were quantified by densitometry using ImageJ version 1.44 software 
program.  To ensure equal protein loading between samples, post-transfer NuPAGE® 
gels were stained with Coomassie blue stain overnight, destained with rapid destain for 
2 x 1 hour washes, followed by several washes with final destain.  Gel images were 
scanned using Epson Perfection 4990 Photo scanner (Epson, North Ryde, NSW, 
Australia) and ImageJ was used to quantitate protein loading variation and 
subsequently used for normalisation of western blots. 
 
3.2.11 Statistics 
All data are expressed as mean ± standard error of the mean (SEM).  All statistical 
analysis was performed using the Prism software package (GraphPad Software, Inc., 
La Jolla, CA, USA).  Data that were not normally distributed required log transformation 
prior to statistical analysis.  The significance between groups was determined by 
ANOVA followed by Bonferroni post-hoc test, involving four comparisons between 
study groups (water-treated NTG vs losartan-treated NTG, water-treated NTG vs 
water-treated TnI-203/MHC-403, water-treated TnI-203/MHC-403 vs losartan-treated 
TnI-203/MHC-403, losartan-treated NTG vs losartan-treated TnI-203/MHC-403).  
Kaplan-Meier survival curves were compared by log-rank test.  Sample size 
calculations for survival studies were carried out post-hoc using StatMate 2 software 
(GraphPad Software Inc., La Jolla, CA, USA).  A probability value (P-value) of less than 
0.05 was considered to be statistically significant for all analyses. 
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3.3 RESULTS 
They study overview and samples numbers used for sub-studies is presented in  
Figure 3.2. 
Figure 3.2.  Study overview.  The number (n) of mice used per study group for each 
of the sub-studies is shown.  As study groups varied in size, the range of minimum to 
maximum sample sizes are indicated (n = min - max).  HW, heart weight; BW, body 
weight; LW, lung weight. 
 
3.3.1 Survival analysis for losartan-treated mice 
Survival analysis was conducted on water- and losartan- treated mice.  Due to the  
well-established gender differences in HCM cohorts, analysis was carried out 
separately for males and females.  A total of n=186 mice were used for survival 
analysis of water-treatment (n=94; NTG, n=20; TnI-203, n=24; MHC-403, n=23; TnI-
203/MHC-403, n=27) and losartan-treatment (n=92; NTG, n=24; TnI-203, n=18; MHC-
403, n=24; TnI-203/MHC-403, n=26).  No NTG, TnI-203 or MHC-403 mice, in either 
treatment group, died within this study.  One mouse (male, TnI-203/+, water-treated) 
was culled at age 12 days, due to runting and was excluded from analysis. 
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Water-treated TnI-203/MHC-403 mice demonstrated significantly reduced survival, with 
100% mortality by age 20 days and a mean lifespan of 17.3±0.3 days (P<0.0001).  
Consistent with previous findings (Tsoutsman et al., 2008b), a gender effect was 
observed, with the average life span of TnI-203/MHC-403 males significantly shorter 
than females (16.3±0.4 vs 17.9±0.3; P=0.0089) and 100% mortality at 19 days for male 
and 20 days for female mice (Figure 3.3). 
 
 
 
 
 
 
 
 
 
Figure 3.3.  Kaplan-Meier survival curves for water-treated TnI-203/MHC-403 male 
and female mice. 
 
The benefits of losartan therapy were evident in both genders of TnI-203/MHC-403 
mice.  The mean lifespan of males was extended by 44% with losartan treatment, from 
16.3±0.3 days to 23.4±0.5 days (P<0.0001).  Water-treated male mice had a maximum 
lifespan of 19 days, which improved by 42%, to 27 days with losartan-treatment (Figure 
3.4).  
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Figure 3.4.  Kaplan-Meier survival curves for TnI-203/MHC-403 male mice, with 
water- or losartan- treatment. 
 
Differences in survival were also observed in female TnI-203/MHC-403 mice, with 
losartan-treatment improving mean survival by 29%, from 17.9±0.3 days to 23.1±0.3 
days (P<0.0001) and maximum lifespan increasing from 20 days to 25 days with 
losartan treatment (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.  Kaplan-Meier survival curves for TnI-203/MHC-403 female mice, with 
water- or losartan- treatment. 
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The gender difference observed in TnI-203/MHC-403 water-treated mice was 
abrogated with losartan treatment (Figure 3.6), with no significant difference between 
genders (P=0.5185).  Mean survival for losartan-treated males was 23.4±0.4 days 
compared to the average female lifespan of 23.1±0.3 days.  All male and female  
TnI-203/MHC-403 losartan-treated mice were dead by 27 and 25 days, respectively.  
Losartan treatment had no effect on NTG mice for the duration of the survival study. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.  Kaplan-Meier survival curves for TnI-203/MHC-403 male and female 
losartan-treated mice. 
 
3.3.2 Survival analysis for diltiazem-treated mice 
To assess whether the beneficial effect of losartan on survival was due to reduced 
blood pressure, diltiazem treatment was performed.  A total of n=9 TnI-203/MHC-403 
mice were treated with diltiazem.  Due to the limited number of mice, genders were 
combined for analysis.  Survival of diltiazem-treated mice was compared to water-
treated mice from Section 3.3.1, in which water had been administered orally.  As 
diltiazem was delivered via IP injection, an additional control group was assessed in 
which TnI-203/MHC-403 mice were treated with equivalent volumes of water, 
administered by IP injection (n=4).    
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Diltiazem treatment did not alter the lifespan of TnI-203/MHC-403 mice (Figure 3.7):  
mean survival with diltiazem treatment was 17.7±0.6 days, compared to 17.3±0.3 days 
for mice administered water orally (P=0.6242) or 17.5±1.0 days by IP injection 
(P=0.8579).  There was no difference in survival between the different routes of 
administration for water treatment (P=0.6963).  Dilitazem had no effect on the survival 
of NTG or single mutant mice, for the duration of the study (100% survival at 30 days). 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  Kaplan-Meier survival curves for TnI-203/MHC-403 mice, with 
diltiazem- or water- treatment. 
 
3.3.3 Sample size calculations 
Calculations were carried out to determine whether appropriate sample sizes for overall 
survival analysis had been used.  The standard deviation for water-treated TnI-
203/MHC-403 mice (1.583 days) was used as the ‘estimated standard deviation’ of 
study groups, and input into the statistics program Stat Mate 2.  The sample sizes 
required for detectable changes in survival, with 80% power and a significance of 0.05 
(alpha, two-tailed) are shown in Table 3.5. 
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Table 3.5.  Number of mice required per study group, in order to detect 
differences between groups with 80% power (significance α=0.05, two-tailed). 
 
Difference to be 
detected (days) 
n per 
group 
4.61 3 
3.71 4 
3.19 5 
2.84 6 
2.59 7 
2.39 8 
2.23 9 
2.10 10 
1.99 11 
1.9 12 
1.68 15 
0.99 41 
n, sample number.  Equal sample sizes are assumed per group. 
 
3.3.3.1 Sample sizes for losartan-treatment study 
Sample size calculations showed that the losartan therapy survival study used an 
adequate number of mice (n≥11 per group) to detect a difference of 1.99 days or 
greater.  Sufficient numbers of mice were used for losartan survival analysis, as 
significant (P<0.0001) differences were determined in Section 3.3.1. 
 
3.3.3.2 Sample sizes for diltiazem-treatment study 
The sample numbers for the diltiazem study (n≥9 per group) were sufficient to detect a 
difference of 2.23 days or more (assuming study groups both had n=9).   No significant 
difference in survival was observed with diltiazem therapy (Section 3.3.2).  Due to this, 
as well as the control group having a large sample number (n=27), more accurate 
power calculations were carried out post-hoc, specific for the obtained data.  The 
sample number and standard deviation determined for diltiazem-treated (n=9, 
SD=1.871 days) and water (oral) control (n=27, SD=1.581 days) study groups were 
used, and a significance of 0.05 (alpha, two-tailed).  This power calculation suggests 
that a difference greater than 1.86 days would be required to detect a statistically 
significant change in survival, with 80% power. 
Chapter 3.  Losartan Treatment in a Mouse Model of Multiple Mutation HCM 
     72 
3.3.4 Whole heart morphology 
A previous study from our lab depicted the gross morphological differences between 
the hearts of TnI-203/MHC-403 mice and their NTG and single-mutant littermates, at 
age 14 days (Tsoutsman et al., 2008b).  As per the original findings, four-chamber 
enlargement and biatrial dilation in water-treated TnI-203/MHC-403 mice was observed 
in this study.  Treatment with losartan largely abrogated this effect at both age 14 and 
17 days (Figure 3.8).  This was further investigated by analysing heart weight (Section 
3.3.5) and echocardiographic measurements (Section 3.3.6).  Hearts from losartan-
treated NTG mice were slightly smaller than their water-treated counterparts, however 
they otherwise appeared anatomically normal. 
 
Figure 3.8.  Whole hearts from male NTG and TnI-203/MHC-403 mice, treated with 
water or losartan, at age (A) 14 days and (B) 17 days (scale bar = 2mm).  
 
 
 
A            B 
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3.3.5 Heart weight: body weight and lung weight: body weight ratios 
Body weight was measured for both NTG and TnI-203/MHC-403 genotypes, with 
losartan- and water-treatment, at ages 10, 14 and 17 days.  Body weights were 
compared and no significant differences were found between treatment or genotype 
groups of the same age (Table 3.6).  Further, there was no difference in body weight 
between genders (Figure 3.9).  The consistency of body weight within the same age, 
suggests that this is an acceptable reference for normalisation of heart weights. 
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Table 3.6:  Body weight, heart weight: body weight, lung weight: body weight in 10, 14 and 17 day old mice (both genders). 
Genotype Treatment N BW (g) P-value HW:BW (mg/g) P-value N LW:BW (mg/g) P-value 
10 days          
   NTG Water 18 4.746 ±0.1659  5.688 ± 0.1121  18 16.82 ± 0.3074  
   NTG Losartan 19 4.987 ± 0.1272 NS* 5.096 ± 0.09075 <0.01* 18 15.26 ± 0.3275 <0.01* 
   TnI-203/MHC-403 Water 15 4.575 ± 0.2297 NS* 6.138 ± 0.1196 <0.05* 15 18.49 ± 0.3925 <0.01* 
   TnI-203/MHC-403 Losartan 13 4.792 ± 0.1876 NS† NS‡ 5.041 ± 0.1543 
NS† 
<0.0001‡ 11 15.18 ± 0.3139 
NS† 
<0.0001‡ 
14 days          
   NTG Water 19 5.643 ± 0.177  6.239 ± 0.104  11 14.72 ± 0.45  
   NTG Losartan 17 5.851 ± 0.152 NS* 5.059 ± 0.069 <0.0001* 17 13.75 ± 0.27 NS* 
   TnI-203/MHC-403 Water 19 5.733 ± 0.137 NS* 6.973 ± 0.097 <0.0001* 17 16.80 ± 0.44 <0.01* 
   TnI-203/MHC-403 Losartan 13 5.795 ± 0.213 NS† NS‡ 5.205 ± 0.110 
NS† 
<0.0001‡ 13 13.97 ± 0.41 
NS† 
<0.0001‡ 
17 days          
   NTG Water 40 6.718 ± 0.105  6.330 ± 0.051  38 12.52 ± 0.18  
   NTG Losartan 19 6.253 ± 0.169 NS* 5.565 ± 0.116 <0.0001* 19 12.79 ± 0.18 NS* 
   TnI-203/MHC-403 Water 24 6.513 ± 0.148 NS* 7.920 ± 0.136 <0.0001* 22 15.01 ± 0.33 <0.0001* 
   TnI-203/MHC-403 Losartan 22 6.532 ± 0.155 NS† NS‡ 5.622 ± 0.117 
NS† 
<0.0001‡ 22 13.44 ± 0.29 
NS† 
<0.001‡ 
 
Values are mean ± SEM. 
ANOVA Bonferroni post-hoc test. 
ANOVA for 10 days, BW, P=0.4096; HW:BW, P<0.0001; LW:BW, P<0.0001. 
ANOVA for 14 days, BW, P=0.8268; HW:BW, P<0.0001; LW:BW, P<0.0001. 
ANOVA for 17 days, BW, P=0.1329; HW:BW, P<0.0001; LW:BW, P<0.0001. 
*, P-value compared to NTG, water-treated. 
†, P-value compared to NTG, losartan-treated. 
‡, P-value compared to TnI-203/MHC-403, water-treated. 
Chapter 3.  Losartan Treatment in a Mouse Model of Multiple Mutation HCM 
   75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
	  
	  
Figure 3.9.  Body weight for water- and losartan- treated littermates, aged (A) 10 
days, (B) 14 days and (C) 17 days.  M, male mice; F, female mice.  There were no 
significant differences between treatment, genotype or gender of the same age.	  
 
  
	  
A               B 
C 
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Heart weight can be indicative of cardiac hypertrophy.  The heart weight : body weight 
(HW:BW) ratio was compared in mice at age 10, 14 and 17 days.  Consistent with 
macroscopic findings, water-treated TnI-203/MHC-403 mice had a significantly 
increased HW:BW ratio compared to their NTG littermates at all age groups (Table 
3.6).  Treatment with losartan reduced HW, which was not significantly different to the 
NTG losartan-treated controls.  It was noted that losartan treatment lowered HW:BW of 
NTG mice, however not to the extent seen in TnI-203/MHC-403 mice (Table 3.6). 
 
Analysis for HW:BW was carried out specific for gender (Figure 3.10).  There was no 
difference in HW:BW between males and females within the same treatment and 
genotype group, at any age.  At age 10 days, there was no difference in HW:BW 
between water-treated NTG and TnI-203/MHC-403 mice of the same gender.  At age 
14 days, HW:BW was significantly increased for water-treated TnI-203/MHC-403 males 
compared to NTG (P<0.0001), but not for female mice.  By age 17 days, both male and 
female water-treated TnI-203/MHC-403 had significantly increased HW:BW compared 
to gender matched NTG controls (P<0.0001).  Losartan treatment reduced the HW:BW 
of TnI-203/MHC-403 mice, in both genders for all age groups, to a HW:BW 
indistinguishable from NTG, losartan-treated mice. 
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Figure 3.10.  Heart weight to body weight ratio of water- and losartan- treated 
littermates, aged (A) 10 days, (B) 14 days and (C) 17 days.  M, male; F, female;  
**, P<0.01; ****, P<0.0001; NS, P-value not significant (P>0.05).  HW, heart weight;  
BW, body weight. 
 
 
	  
C 
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Previous characterisation of the TnI-203/MHC-403 model showed an increase in 
LW:BW consistent with pulmonary oedema (Tsoutsman et al., 2008b), a complication 
associated with heart failure.  Here, water-treated TnI-203/MHC-403 mice displayed a 
significant increase in LW:BW, at ages 10, 14 and 17 days (Table 3.6).  Losartan 
treatment significantly reduced lung weight in TnI-203/MHC-403 mice at all ages, to a 
LW:BW not different to the NTG losartan-treatment group.   
 
There was no difference in LW:BW between genders within the same treatment and 
genotype group (Figure 3.11).  LW:BW of water-treated TnI-203/MHC-403 mice was 
increased as early as age 10 days in males and 14 days in females, however this was 
not significant for males at age 14 days.  The greatest increase in LW:BW for both 
genders was at age 17 days, which has previously been characterised as the ‘heart 
failure’ stage of disease (Tsoutsman et al., 2008a).  Losartan reduced the LW:BW of 
TnI-203/MHC-403 mice at all ages for females and at age 10 days for males.  The 
LW:BW ratios of losartan-treated TnI-203/MHC-403 mice were not significantly different 
from water-treated, gender-matched NTG controls, at any age (Figure 3.11). 
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Figure 3.11.  Lung weight to body weight ratio of water- and losartan- treated 
littermates, aged (A) 10 days, (B) 14 days and (C) 17 days.  M, male; F, female;  
*, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; NS, P-value not significant 
(P>0.05).  LW, lung weight; BW, body weight. 
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3.3.6 Echocardiographic analysis 
The effect of losartan treatment on cardiac function by two-dimensional 
echocardiography was summarised in Table 3.7.  Due to limited numbers, genders 
were combined for analysis.  Consistent with the previous characterisation of the  
TnI-203/MHC-403 model (Tsoutsman et al., 2008b), water-treated 16-17 day old mice 
developed severe dilation of the left ventricle.  This is indicated by a significant 
increase in LVESD (1.34±0.19mm vs 0.57±0.06mm, P<0.0001) and LVEDD 
(2.20±0.09mm vs 1.76±0.08mm, P<0.0001), and was accompanied by a significant 
reduction in fractional shortening (40±6% vs 68±2%, P<0.0001). 
 
Losartan treatment improved cardiac function in TnI-203/MHC-403 mice, including an 
improvement in cardiac dimensions and left ventricular systolic function.  Specifically, 
losartan reduced the mean LVESD by 0.43mm (to 0.91±0.03mm, P<0.01) and 
decreased LVEDD by 0.23mm (to 1.97mm±0.04), however the latter did not reach 
statistical significance.  Fractional shortening (FS) in TnI-203/MHC-403 mice also 
significantly improved with losartan treatment, compared to water treated controls 
(54±1% vs 40±6%, P<0.01).  LVESD and FS in losartan-treated TnI-203/MHC-403 
mice, were not significantly different to the losartan-treated, NTG mice.  Further, 
losartan-treatment had no effect on LVESD, LVEDD or fractional shortening in NTG 
mice.  Heart rate was monitored throughout this study and was not found to be 
statistically different between groups. 
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Table 3.7.  Echocardiographic analysis of age 16-17 day mice. 
 
Genotype Treatment N HR (bpm) P-value LVESD P-value LVEDD P-value FS (%) P-value 
NTG Water 6 539 ± 17  0.57 ± 0.06  1.76 ± 0.08  68 ± 2  
NTG Losartan 7 539 ± 13 NS* 0.65 ± 0.07 NS* 1.72 ±0.07 NS* 63 ± 3 NS* 
TnI-203/MHC-403 Water 5 503 ± 3 NS* 1.34 ± 0.19 <0.0001* 2.20 ± 0.09 <0.01* 40 ± 6 <0.0001* 
TnI-203/MHC-403 Losartan 10 505 ± 6 NS† NS‡ 0.91 ± 0.03 
NS† 
<0.01‡ 1.97 ± 0.04 
<0.05† 
NS‡ 54 ± 1 
NS† 
<0.01‡ 
 
 
Values are mean ± SEM. 
ANOVA Bonferroni post-hoc test. 
ANOVA for HR, P=0.0357; LVESD, P<0.0001; LVEDD, P=0.0004; FS, P<0.0001 
*, P-value compared to NTG, water-treated. 
†, P-value compared to NTG, losartan-treated. 
‡, P-value compared to TnI-203/MHC-403, water-treated. 
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3.3.7 Cardiac fibrosis 
To investigate whether the improvement in whole heart morphology and cardiac 
function were associated with changes in myocardial fibrosis, histopathological analysis 
was performed on transverse sections of heart tissue (minimum n=3 per group) stained 
with Milligan’s trichrome.  At age 10 days, sections showed an increase in collagen-
positive tissue in the water-treated TnI-203/MHC-403 hearts compared to NTG 
(2.43±1.27% vs 0.77±0.08%), however this did not reach statistical significance.  
Losartan treatment reduced fibrosis in TnI-203/MHC-403 hearts (0.86±0.13%) at this 
age.  While these trends were noted, there was no significant difference in fibrosis 
between the four study groups at this age (Figure 3.12). 
 
Tissue sections showed patchy, but significant, fibrosis in the hearts of water-treated 
TnI-203/MHC-403 mice (Figure 3.13) compared to NTG, at age 14 days (7.81±2.25% 
vs 1.20±0.16%, P<0.01) and 17 days (8.98±1.73% vs 1.12±0.13%, P<0.0001).  
Treatment with losartan reduced fibrosis in TnI-203/MHC-403 hearts at age 14 days 
(0.84±0.12%, P<0.01) and 17 days (2.30±0.36%, P<0.0001) to a level that was 
indistinguishable from the NTG, losartan-treated mice (1.34±0.11% and 0.70±0.06%, 
for 14 and 17 days, respectively) (Figure 3.12). 
 
 
 
 
 
 
 
 
Figure 3.12.  Quantification of fibrotic tissue in hearts.  *, P<0.05, vs NTG water-
treated; ‡, P<0.05, vs TnI-203/MHC-403, water-treated samples.  
* * 
‡ 
‡ 
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Figure 3.13.  Milligan’s trichrome stained heart sections, from age (A) 14 day and 
(B) 17 day mice.  Myocytes are stained pink/purple, collagenous tissue stained 
turquoise.  Scale bar = 50 µm. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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3.3.8 MRNA expression of hypertrophic markers 
Analysis of hypertrophy markers by RT-qPCR (Figure 3.14) showed Nppa and Nppb 
expression were significantly up-regulated (P<0.0001) in the ventricles of water-treated 
TnI-203/MHC-403 mice, compared to NTG age-matched controls, at age 10 days 
(Nppa, 9.9-fold; Nppb, 3.9-fold), 14 days (Nppa, 33.9-fold; Nppb, 8.2-fold) and 17 days 
(Nppa, 42.5-fold; Nppb, 10.6-fold).  Losartan treatment reduced Nppa expression to 
34.2% at 10 days (P<0.05), 24.3% at 14 days (P<0.001) and 23.3% at 17 days 
(P<0.01), compared to the mRNA expression levels of water-treated, age-matched  
TnI-203/MHC-403 mice.  Similarly, Nppb expression was reduced to 20.9% at age  
10 days (P<0.0001), 27.5% at 14 days (P<0.0001), and 33.0% at 17 days (P<0.0001) 
with losartan treatment in TnI-203/MHC-403 mice, compared to Nppb expression with 
water-treatment. 
 
 
Figure 3.14.  RNA analysis of hypertrophic markers: (A) Nppa, and (B) Nppb.  
Expression is relative to age-matched, water-treated NTG controls. *, P<0.05, vs NTG 
water-treated;  †, P<0.05, vs NTG losartan-treated;  ‡, P<0.05, vs Tn-203/MHC-403 
water-treated. 
A      B 
†‡ 
* 
* 
* 
* 
* 
* 
* 
* 
* * 
* 
* 
†‡ †‡ 
†‡ 
†‡ 
†‡ 
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3.3.9 MRNA and protein expression of CTGF 
RT-qPCR analysis showed Ctgf was up-regulated in water-treated TnI-203/MHC-403 
hearts (compared to water-treated NTG) and losartan treatment significantly reduced 
this expression at all time-points (10, 14, 17 days, Figure 3.15).   Western blotting 
analysis confirmed an increase in CTGF protein in water-treated TnI-203/MHC-403 
hearts at 14 and 17 days, and showed losartan treatment reduced CTGF in  
TnI-203/MHC-403 hearts at all time-points (Figure 3.16).  Losartan therapy in NTG 
mice decreased Ctgf expression, which reached statistical significance at age 17 days 
for both RNA analysis (P<0.0001) and quantification from western blotting (P<0.05).  
Ctgf expression was significantly increased in losartan-treated TnI-203/MHC-403 
compared to NTG samples, when analysed by RT-qPCR, however this finding was not 
reproduced at the protein level. 
 	  	  	  
 
 
 
 
 
 
Figure 3.15.  RNA analysis of Ctgf expression in mouse ventricles.  Expression is 
relative to age-matched, water-treated NTG controls. *, P<0.05, vs NTG water-treated;   
†, P<0.05, vs NTG losartan-treated;  ‡, P<0.05, vs Tn-203/MHC-403 water-treated. 
  
* 
* 
* 
* 
†‡ 
†‡ †‡ 
Chapter 3.  Losartan Treatment in a Mouse Model of Multiple Mutation HCM 
    86 
 
Figure 3.16.  Quantification of CTGF protein in mouse ventricles.  (A) CTGF 
western blot and respective coomassie-stained gel which was used as a loading 
control.  (B) Densitometry analysis of CTGF protein band in western blot corrected for 
loading variability.  Both RNA and protein quantification values are normalised to age-
matched, water-treated NTG samples. *, P<0.05, vs NTG water-treated; ‡, P<0.05, vs 
TnI-203/MHC-403 water-treated. 
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3.3.10 MRNA expression of pro-fibrotic molecules 
Tgfβ1 and Tgfβ2 are upstream regulators of Ctgf and were investigated in this study.  
Gene expression analysis by RT-qPCR in water-treated TnI-203/MHC-403 over the 
time-course of disease showed that both Tgfβ1 and Tgfβ2 were up-regulated in 
diseased hearts, from age 14 days and 10 days, respectively (Figure 3.17A-B).  
Losartan treatment in TnI-203/MHC-403 mice reduced expression of both Tgfβ1 and 
Tgfβ2 from ages 14 and 17 days.  As CTGF together with TGFβ are implicated in 
fibrosis (Frazier et al., 1996, Mori et al., 1999), the gene expression levels of ECM 
components were investigated.  RT-qPCR analysis showed Fn1 was significantly  
up-regulated as early as 10 days in disease (Figure 3.17C), whereas Col1a1 was  
up-regulated later, by age 14 days (Figure 3.17D).  Losartan treatment reduced the 
expression of these pro-fibrotic molecules in TnI-203/MHC-403 ventricles. 
 
Myocardial fibrosis can occur due to the over-production of ECM, but can also arise 
when ECM accumulates, and the integrity of the ECM network structure is dependent 
on the relationship between MMPs, TIMPs and their regulators, including TGFβ and 
CTGF.  Timp1 was assessed and found to be significantly up-regulated in  
TnI-203/MHC-403 water-treated mouse ventricles from age 10 days onward (Figure 
3.17E), in parallel with an increase in myocardial fibrosis.  Losartan treatment reduced 
Timp1 expression in TnI-203/MHC-403 at these time points, but had no effect on Timp1 
expression in NTG animals.  Mmp3 was up-regulated in TnI-203/MHC-403 ventricles at 
age 17 days, with losartan treatment significantly reducing Mmp3 expression (Figure 
3.17F).  Expression of the direct target of losartan, Agtr1a, was also investigated and 
found to be significantly down-regulated in TnI-203/MHC-403 ventricles during the 
heart failure phase (age 17 days), but also at earlier time points in disease (ages 10 
and 14 days).  Treatment with losartan significantly increased, and partially restored, 
Agtr1a gene expression in the TnI-203/MHC-403 ventricles (Figure 3.17G). 
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Figure 3.17.  Expression of genes involved in fibrosis.  Regulators of Ctgf: (A) 
Tgfβ1, (B) Tgfβ2; ECM components (C) Fn1 and (D) Col1a1; genes involved in the 
regulation of ECM accumulation and degradation (E) Timp1 and (F) Mmp3.  
Expression is relative to NTG water-treated samples.  *, P<0.05 vs NTG water-treated; 
†, P<0.05 vs NTG losartan-treated; ‡, P<0.05 vs TnI-203/MHC-403 water-treated. 
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3.4 DISCUSSION 
Despite advances in the diagnosis and understanding of the genetic etiology of HCM, 
effective pharmacological therapies are lacking that prevent disease or cause its 
regression.  While HCM patients are typically managed using therapeutics that address 
symptoms and complications of disease, the underlying pathology of disease persists, 
including hypertrophy, disarray and interstitial fibrosis.  Effective treatments are needed 
that target pathological mechanisms and not just the symptoms.  The findings in this 
study suggest losartan is effective in preventing such mechanisms, resulting in 
significant improvement in survival, cardiac function and whole heart morphology in the 
TnI-203/MHC-403 mice. 
 
Losartan treatment was shown to significantly extend the survival of both male and 
female TnI-203/MHC-403 mice.  Certain blood-pressure lowering therapies, including 
beta-blockers and ACE inhibitors, have been shown to prolong survival in patients with 
heart failure (Shibata et al., 2001, Flather et al., 2000).  To determine whether the 
extended lifespan of TnI-203/MHC-403 mice with losartan treatment was due to 
reduced blood pressure alone, a blood pressure lowering control group was studied in 
which TnI-203/MHC-403 mice (and their littermates) were treated with diltiazem.  Due 
to the young age of mice in this study, no techniques were available for measuring 
blood pressure and thus any differences in blood pressure between losartan- and 
diltiazem- groups are unknown.  While this is a limitation of the study, it should be 
noted that the dose of diltiazem administered (25 mg/kg/day) was sufficient to cause 
beneficial cardiac effects in other mouse studies, including a single mutant HCM 
mouse model (Westermann et al., 2006, Semsarian et al., 2002).  However, these 
previous studies were carried out in adult mice and to date the effects of diltiazem or 
losartan on blood pressure in juvenile mice has not been reported.   
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Another limitation of the diltiazem treatment survival study was the small number of 
TnI-203/MHC-403 mice used.  Power calculations suggest that small, yet significant, 
changes in survival (<1.86 days) may have not been detected with the sample 
numbers used (statistical type II error).  A larger number of mice would be required to 
determine with greater certainty that diltiazem therapy did not effect the survival of this 
mouse model (see Table 3.5 for sample numbers required to detect smaller changes).  
In the event that a small improvement in survival with diltiazem was detected, it may 
suggest that reduced blood pressure contributed to the benefit of losartan therapy.  
This would not detract from the findings in this chapter, but would explain in part the 
mechanisms behind losartan’s beneficial effect.  The data presented in this chapter, 
however, infers that diltiazem treatment did not prolong the lifespan of  
TnI-203/MHC-403 mice suggesting that decreased blood pressure per se does not 
affect survival in this model, and that the effect induced by losartan treatment may be 
due to interference with pathological signalling, such as pro-fibrotic pathways.  To 
investigate whether extended survival was due to slowed progression of the HCM 
phenotype, studies into heart morphology and histopathology were performed. 
 
Investigation of gross heart morphology showed four-chamber enlargement at ages  
14 and 17 days in water-treated TnI-203/MHC-403 mice, with losartan treatment largely 
abrogating this.  To quantitate evidence for hypertrophy, cardiac mass was measured 
and normalised to body weight.  Body weight was deemed a suitable means of 
normalisation, with no significant difference between mice of different genders, 
genotypes or treatments, of the same age.  When genders were combined to 
strengthen statistical analysis, a significant increase in HW:BW was seen in water-
treated TnI-203/MHC-403 mice as early as age 10 days, which increased considerably 
during the time-course.  Gender-specific analysis showed HW:BW ratios were 
increased in water-treated TnI-203/MHC-403 mice, as early as 14 days in males and 
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17 days in females.  This concurs with survival analysis, which suggests male mice are 
more advanced in their progression of disease.   
 
Phenotypic disparities based on gender have been previously reported in the  
TnI-203/MHC-403 model (Tsoutsman et al., 2008b), as well as other animal models of 
HCM in which male mice tend to exhibit more severe disease (Geisterfer-Lowrance et 
al., 1996, Olsson et al., 2001, Freeman et al., 2001), and in human HCM, in which 
males present with disease earlier than female patients (Lind et al., 2008, Isobe et al., 
2003, Spirito et al., 2000, Van Driest et al., 2005).  The differences between gender 
may be attributed to sex hormones.  Estrogen has been reported to have a protective 
effect in the cardiac hypertrophic response in mice (Xin et al., 2002), whereas 
androgens have been shown to promote a significant hypertrophic response in 
cardiomyocytes (Marsh et al., 1998).  Treatment with losartan was shown to 
significantly reduce the HW:BW in both genders of TnI-203/MHC-403 mice, at all 
investigated ages.  HW:BW for losartan treated TnI-203/MHC-403 mice did not differ 
significantly to that of losartan-treated NTG mice.  These findings were largely 
confirmed by analysis of hypertrophy markers (Nppa, Nppb), which were significantly 
elevated in water-treated TnI-203/MHC-403 hearts, at all time-points, and were 
reduced with losartan treatment.  The expression of these markers are sensitive to the 
pro-hypertrophic mechanisms involved at the cellular level, thus changes are observed 
in Nppa and Nppb prior to changes observed at the whole organ level. 
 
A decrease in HW:BW and hypertrophic markers was noted for NTG mice treated with 
losartan.  The effect of losartan therapy in decreasing heart weight has been reported 
in other animal studies (Lim et al., 2001, Torp et al., 2007, Koprdová et al., 2009).  
Given there was no change in survival or cardiac dimensions or function, reduced heart 
weight was deemed not to be detrimental.  It can be speculated that decreased heart 
weight in NTG mice is due to a reduction in cell size (given hypertrophy markers were 
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reduced but fibrosis was not), however further studies measuring both cell size and 
number would need to be carried out to verify this. 
 
LW:BW ratios were also analysed, an increase which may indicate pulmonary 
congestion, a complication arising due to heart failure.  Trends in LW:BW were not 
consistent within the same genotype, treatment and gender study group, across ages 
10 and 14 days.  This inconsistency may in part be explained by limited numbers in 
some groups, and by the higher numerator (LW) and small denominator (BW) with 
subtle variations having a significant impact on LW:BW values.  At age 17 days, there 
was strong statistical evidence of increased LW:BW in water-treated TnI-203/MHC-403 
mice, of both genders.  The increased LW:BW correlates with pulmonary oedema, as 
previously published by Tsoutsman et al (2008), a study in which histological 
examination verified this finding.  Losartan therapy reduced LW:BW in  
TnI-203/MHC-403 mice, to a LW:BW indistinguishable from NTG controls, suggesting 
pulmonary congestion, and hence heart failure, was not present in losartan-treated  
TnI-203/MHC-403 mice at this age. 
 
The effects of losartan on cardiac dimensions and function were investigated.  
Consistent with the previous characterisation of the untreated TnI-203/MHC-403 
model, water-treated TnI-203/MHC-403 mice develop severe dilation of the left 
ventricle by age 16-17 days, accompanied by a significant reduction in FS.  Treatment 
with losartan did not statistically alter LVEDD in TnI-203/MHC-403 mice, showing these 
hearts were still dilated, however there was a significant reduction in LVESD, indicating 
increased contraction, consistent with improved cardiac function.  FS of losartan-
treated TnI-203/MHC-403 mice was not statistically different to losartan-treated NTG 
control mice.  These results may suggest disease is not as advanced with losartan 
therapy, but also concur with findings by others that show losartan therapy in both mice 
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and humans with heart failure, improves LV function (Günther et al., 2010, Crozier et 
al., 1995, Dickstein et al., 1995). 
 
Cardiac fibrosis, a feature of HCM, is an inappropriate accumulation of ECM proteins in 
the heart.  It is an important contributor to increased mechanical stiffness of the heart 
muscle, causing reduced contraction and relaxation ability, decreasing cardiac function 
and leading to heart failure.  Histological analysis showed at ages 14 and 17 days, 
water-treated TnI-203/MHC-403 mice exhibited significant, patchy cardiac fibrosis.  
Planimetry-based quantification of collagen-stained tissue confirmed significant cardiac 
fibrosis in the water-treated TnI-203/MHC-403 mice, which was reduced with losartan 
therapy.  The improvements in cardiac function may be attributed to the reduction in 
fibrosis.  Losartan treatment has been shown to reduce cardiac fibrosis in other mouse 
models (Günther et al., 2010, Teekakirikul et al., 2010) and modify related 
complications including decreased vulnerability to arrhythmias (Stein et al., 2010), 
reduced mortality and improved cardiac function (Günther et al., 2010). 
 
Expression of the pro-fibrotic protein, CTGF, was significantly upregulated in diseased 
mice, with elevated RNA and protein levels correlating with disease progression.  
CTGF has been shown to stimulate fibroblast proliferation, their differentiation towards 
myofibroblasts and to enhance ECM production (Frazier et al., 1996, Grotendorst, 
1997, Grotendorst et al., 2004).  Mouse and rat models have been developed that 
over-express CTGF in a cardiac-specific manner, with these models exhibiting cardiac 
hypertrophy, diastolic and systolic dysfunction, followed by ventricular dilatation and 
finally heart failure (Panek et al., 2009).  Interestingly, histopathological analysis 
revealed enlarged cardiomyocytes in these models, but did not show increased 
fibrosis.  This finding gives an interesting insight into the role of CTGF in the heart, 
suggesting that while upregulation of CTGF alone may be enough to induce 
cardiomyocyte hypertrophy, switching on the pro-fibrotic pathway may require the 
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involvement of other co-factors, such as TGFβ.  Previous studies in mice and rats 
investigated the subcutaneous injection of CTGF and TGFβ alone, or co-injected, and 
showed that separately each protein caused the formation of granulated tissue, 
however the co-injection of both resulted in persistent fibrosis (Frazier et al., 1996, Mori 
et al., 1999). 
 
Gene expression analysis by RT-qPCR on the ventricles of water-treated  
TnI-203/MHC-403 mice, showed significant mRNA upregulation of both Ctgf and Tgfβ 
by heart-failure stage of disease, concurring with previous studies that both molecules 
may be involved in disease pathogenesis.  Losartan has been implicated in the 
inhibition of TGFβ-signalling and has been shown to decrease fibrosis in various 
diseases (Teekakirikul et al., 2010, Molina-Molina et al., 2006, Yang et al., 2009).  
Results herein showed that treatment with losartan reduced both Ctgf and Tgfβ 
expression and resulted in a significant reduction of myocardial fibrosis in severe HCM 
mice. 
 
Myocardial fibrosis occurs when ECM constituents are overexpressed or when ECM 
accumulates, which may develop when MMP action is suppressed due to an 
abundance of TIMP molecules.  The integrity of the ECM network structure is 
dependent on the relationship between matrix production, MMPs, TIMPS, and their 
regulators including TGFβ and CTGF.  Results showed elevated mRNA expression of 
ECM components (Fn1 and Col1a1) and increased Timp1 in water-treated  
TnI-203/MHC-403 mice.  Interestingly, Mmp3 was upregulated at 17 days in these 
mice, which may be a protective, compensatory mechanism as MMPs promote ECM 
degradation.  Losartan treatment resulted in reduced expression of pro-fibrotic 
molecules Ctgf, Tgfβ, Fn1, Col1a1 and Timp1, in diseased mice. 
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The other gene expression investigated by RT-qPCR was Agtr1a, and was shown to 
be significantly decreased in the ventricles of water-treated TnI-203/MHC-403 mice.  
This receptor is selectively downregulated in failing human ventricles (Asano et al., 
1997), however, here analysis showed downregulation as early as age 10 days, which 
far precedes heart failure.  The decreased expression of this receptor in disease and 
the positive effect its antagonist, losartan, has in this model suggests the 
downregulation of Agtr1a may be a protective mechanism against heart failure, and 
that losartan may elicit the same downstream effect, leading to improved disease 
outcome.  The higher levels of Agtr1a expression with losartan treatment in diseased 
mice, likely reflects that the disease is not as progressed in this model. 
 
The study presented here suggests CTGF may be a valuable biomarker in HCM 
prognosis and is a potential target for pharmacological intervention.  While this study 
supports the notion that CTGF is involved in pathogenesis, losartan does not 
specifically target CTGF.  Thus it can be argued that the beneficial effects elicited with 
treatment may be due to losartan interacting with other proteins, and that CTGF 
suppression may be a secondary response.  To clarify the role of CTGF in the  
TnI-203/MHC-403 model, studies need to be conducted that specifically target this 
protein, such as a by neutralising antibody, genetic ablation or siRNA knockdown 
studies.  To elucidate the mechanisms underpinning the advantageous effects of 
losartan therapy, mRNA and miRNA expression profiling was carried out and is 
presented in Chapter 4. 
 
Collectively, these results show losartan therapy administered from a preventative 
time-point improved survival, ameliorated cardiac morphology and function, reduced 
fibrosis and decreased hypertrophic signalling in TnI-203/MHC-403 mice.  While 
previous studies have shown losartan improves survival and cardiac function in heart 
failure, the evidence in this chapter supports the notion that losartan is not merely 
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acting to improve hemodynamic functions during heart failure, but rather is delaying the 
onset of disease and slowing its progression, as is indicated in HW:BW, fibrosis and 
hypertrophy marker studies.  The findings are supported by studies in single-mutant 
HCM mouse models that gradually develop disease in adulthood (Teekakirikul et al., 
2010, Lim et al., 2001).  While animal models that genetically and phenotypically 
recapitulate disease are valuable for the preliminary assessment of drug therapies, 
there are several issues that may arise when extrapolating such findings to humans.  
First, genetic variability can affect drug interaction.  While the TnI-203/MHC-403 mouse 
harbours two particular HCM-causing mutations, this disease is genetically complex 
and can be caused by over 1000 different mutations.  Previous treatment studies have 
shown that animal models with different HCM-causing mutations can respond 
differently to the same treatment.  This was the case for Cyclosporin A, which was 
shown to improve or worsen disease in rodent models of HCM, dependent on the 
disease-causing mutation present (Sussman et al., 1998, Fatkin et al., 2000). 
 
In addition to genetic variability, losartan therapy may not translate to human patients 
due to differences in cardiac physiology (such as heart rate or calcium flux) or drug 
metabolism.  While losartan is already safely used in humans and its major active 
metabolite (EXP3174) is the same in both humans and rodents, there may be other 
unknown differences in the metabolism of this drug.  Further, although it is assumed 
that the antagonism of the AT1 receptor is responsible for improved prognosis, it is 
possible that unknown drug-receptor interactions are involved, which do not translate 
between species.  Another consideration for clinical translation includes an appropriate 
dose of losartan.  In this study, 100 mg/kg/day was used in mice, which far exceeds the 
recommended dose in humans (up to 100 mg/day).  If high concentrations are required 
to elicit a beneficial effect, side effects such as hypotension may be an issue.  Further, 
losartan has a short half-life of 2 hours (6-9 hours for EXP3174), so the use of an 
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alternate AT1 receptor antagonist with a longer half-life may want to be considered for 
human studies. 
 
To date, losartan treatment has been investigated in two small human HCM cohorts 
(Yamazaki et al., 2007, Araujo et al., 2005).  These studies demonstrated slight, but not 
clinically significant, improvements with losartan therapy, however it is likely that the 
absence of benefit may have been related to the timing of treatment (established 
disease) and the short follow-up period (6-12 months). 
 
The findings presented, in conjunction with previous studies, provide mounting 
evidence to form the basis of a clinical trial of losartan in HCM.  Such a study would 
require a significant follow-up period and treatment would need to be initiated from a 
preclinical time-point.  Due to advances in genetic screening, many individuals have 
now been identified who harbour an HCM-causing mutation, but who have not yet 
developed disease (genotype-positive/phenotype-negative) (Maron and Semsarian, 
2010, Maron et al., 2011).  Such patients would be ideal as treatment would be initiated 
prior to disease presentation with the goal to either prevent disease, delay its onset, or 
slow disease progression.  A multicentre human trial assessing the role of candesartan 
(a related AT1 receptor antagonist) in pre-disease HCM-mutation carriers is currently 
being established (personal communication, Dr Carolyn Ho, Harvard Medical School, 
Boston, MA, USA).  The current study provides further evidence for the favourable 
outcome elicited by losartan therapy and suggests it may be beneficial in a broad 
clinical spectrum of HCM patients, including those who carry multiple mutations and 
are at risk of developing severe disease. 
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MIRNA AND MRNA EXPRESSION 
PROFILING IN TNI-203/MHC-403 MICE WITH 
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4 MIRNA AND MRNA EXPRESSION PROFILING IN TNI-203/MHC-403 
MICE WITH LOSARTAN TREATMENT 
 
4.1 INTRODUCTION 
In recent times, miRNAs have been identified as powerful regulators in cardiac 
development and disease.  As miRNAs have a number of direct downstream mRNA 
targets, which are often related genes functioning in comparable cellular processes, the 
manipulation of individual miRNAs may alter the expression of multiple mRNAs, 
thereby affecting an entire network of dysregulated genes.  The ability to manipulate 
miRNA expression and function through the delivery of miRNA inhibitors (anti-miRs) or 
miR-mimics, has opened up the potential for miRNAs as promising novel therapeutic 
targets.  MiRNA and mRNA profiling studies are important for giving insight into 
pathogenic pathways, and identifying miRNAs which may be targetted for therapeutic 
intervention. 
 
Cardiac miRNA profiles have been shown to differ in models of cardiac hypertrophy.  
These include pressure overload in mice by transverse aortic constriction (TAC) (van 
Rooij et al., 2006, Cheng et al., 2007, Sayed et al., 2007) and the cardiac-specific over-
expression of pro-hypertrophic transgene calcineurin A (CnA) (van Rooij et al., 2006).  
Most recently, we performed miRNA profiling on ventricle tissue from the  
TnI-203/MHC-403 double mutant mouse model across various stages of disease 
development (Bagnall et al., 2012).  A number of miRNAs were differentially expressed 
across all studies.  This suggests that dysregulation of miRNA expression in these 
different models may contribute to the disease. 
 
 
 
 
 
Chapter 4.  Expression Profiling in TnI-203/MHC0493 Mice with Losartan Treatment  
    100 
4.1.1 Aims 
This study investigated whether miRNA expression differed in the ventricles of  
TnI-203/MHC-403 mice, treated with losartan therapy compared to control treatment.  
TaqMan® Low Density Arrays (TLDAs) were employed for the initial miRNA profiling 
and RT-qPCR was used to confirm miRNA candidate expression across stages of 
disease development.  Global mRNA expression profiling was carried out using 
GeneChip® arrays, and differentially expressed mRNAs were investigated to see if 
changes in mRNA expression pattern were a result of differences in miRNA 
expression.  The current study builds on the findings by Bagnall et al (2012), allowing 
for further clarification into miRNAs that may be beneficial for therapeutic intervention. 
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4.2 METHODS  
MicroRNA and mRNA profiling were performed using TaqMan® Low Density Arrays 
(TLDAs; Applied Biosystems, Foster City, California, USA) and GeneChip® Mouse 
Gene 1.0 ST arrays (Affymetrix, Santa Clara, California, USA), respectively.  Profiling 
was carried out on ventricle RNA from water- and losartan- treated male  
TnI-203/MHC-403 mice, at age 17 days.  MiRNAs found to be differentially expressed 
(>1.5 fold change, P<0.05) according to the TLDA analysis were validated by 
performing individual RT-qPCRs specific for the miRNA of interest and a time-course 
study was performed to investigate the expression of these miRNAs throughout 
disease development.  MRNA targets of miRNAs of interest were predicted using the 
online microRNA target prediction software, TargetScan 5.1.  Functional annotation 
was carried out using the online bioinformatics database, DAVID Bioinformatics 
Resources 6.7.  Study overview is outlined in Figure 4.1. 
 
4.2.1 RNA preparation 
RNA was extracted from the ventricles of water- and losartan- treated NTG and  
TnI-203/MHC-403 mice, in Section 3.2.6.  Quantity and purity of RNA was analysed by 
NanoDrop 2000 (Thermo Scientific, Wilmington, Delaware, USA) and integrity 
assessed by RNA 6000 Nano assay (Agilent, Waldbronn, Germany), as per the 
manufacturer’s instructions.  RNA samples had an RNA integrity number above 9 for all 
samples used in TLDA and GeneChip studies. 
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Figure 4.1.  Study outline.  RNA from ventricles of NTG and TnI-203/MHC-403 mice 
across different stages of disease were collected in Chapter 3.  Samples from age 17 
day TnI-203/MHC-403 mice (water- and losartan-treated) were assessed by 
bioanalyser; only samples with an RNA integrity number (RIN) >9.0 were used for 
miRNA and mRNA profiling.  Differentially expressed miRNAs were validated by 
individual RT-qPCR TaqMan® assays, in addition to NTG and TnI-203/MHC-403 RNA 
samples across the time-course of disease development. Differentially expressed 
mRNAs were functionally annotated using DAVID.  TargetScan was used to predict 
miRNA/mRNA pairs that changed in a complementary fashion, with losartan therapy. 
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4.2.2 Reverse transcription for TaqMan® low density arrays 
RNA was reverse transcribed using the TaqMan® MicroRNA Reverse Transcription Kit 
and Megaplex™ reverse transcription primers for rodent pool A (Applied Biosystems, 
Foster City, California, USA).  Reverse transcription (RT) master mix consisted of 1X 
Megaplex RT primers, 2.6 mM dNTPs (with dTTP), 75 U MultiScribe Reverse 
Transcriptase, 1X RT buffer, 3 mM MgCl2 and 2 U of RNase inhibitor made up to a total 
of 4.5 µL with nuclease-free water, and mixed by inverting six times.  450 ng of RNA 
was added and mixed by inversion.  Reaction mixture was incubated on ice for 5 
minutes, then incubated in a Peltier Thermal Cycler under the following conditions: 40 
cycles at 16˚C for 2 minutes, 42˚C for 1 minute and 50˚C for 1 second; followed by an 
85˚C incubation for 5 minutes. 
 
4.2.3 TaqMan® low density arrays 
The TLDA cards used were TaqMan® rodent microRNA Array A v2.0 (Applied 
Biosystems), which simultaneously measure the expression levels of 335 mouse 
miRNAs by RT-qPCR.  A separate PCR mix was prepared for each array, consisting of 
1X TaqMan® Universal PCR Master Mix (No AmpErase® UNG), 6 µL of Megaplex™ 
RT product, made up to 900 µL with nuclease-free water, and mixed by inverting the 
tube six times and centrifuging briefly.  PCR mixture (100 µL) was loaded into each 
port of the TLDA card and centrifuged at 1200 rpm for 2 x 1 minute (Sorvall Heraeus, 
Thermo Scientific).  TLDA cards were sealed and run on a 7900HT Real Time PCR 
System using a 384-well plate block and SDS software v2.4 (Applied Biosystems).  
PCR cycling conditions were 50˚C for 2 minutes, 94.5˚C for 10 minutes followed by 40 
cycles of 97˚C for 30 seconds and 59.7˚C for 1 minute. 
 
Comparative threshold (Ct) values were calculated using RQ Manager software v1.2.1 
(Applied Biosystems), applying an automatic baseline setting and a threshold of 0.2.  
Ct data was imported into DataAssist v2.0 for further analysis, with Ct values >32 
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excluded from analysis.  DataAssist software was used for normalisation of miRNA 
expression, which normalises expression based on geNorm calculations 
(Vandesompele et al., 2002).  Reference genes used for geNorm include U6, 
snoRNA135, snoRNA202, U87, Y1 and miR-320.  Of these, Y1 and snoRNA202 were 
chosen for normalisation as they were found to be the most stable of the candidate 
reference genes, with the lowest M values (indicative of stability) of 0.2359 and 0.2371, 
respectively (Figure 4.2).  DataAssist software was further used for quality control 
analysis including investigation of overall variability in Ct values as well as the 
difference in Ct values of specific miRNAs, in biological replicates.  Fold change 
expression was calculated and miRNAs were deemed differentially expressed when 
groups had >1.5x fold change and P<0.05. 
 
 
 
Figure 4.2.  Ct variability of candidate reference genes (Y-axis) between samples 
(X-axis).  M values are shown in brackets. 
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4.2.4 Reverse transcription reaction for individual miRNA assays 
To validate TLDA findings, individual miRNA RT-qPCR assays were performed for 6 
miRNAs (miR-30c, -203, -409-3p, -146b, -199a-3p, -214, -21).  RT-qPCRs were also 
carried out for both NTG and TnI-203/MHC-403 samples, across the disease time 
course (5, 10, 14 and 17 days).  For all samples, cDNA was reverse transcribed using 
TaqMan® MicroRNA Reverse Transcription kit and primers specific for miRNA of 
interest (both from Applied Biosystems, Foster City, CA, USA).  RT mixture consisted 
of 10 ng RNA, 1 mM dNTPs (with dTTP), 50 U MultiScribe™ Reverse Transcriptase, 
1X reaction buffer, 3.8 U RNase inhibitor, 1 µL of each primer, made to a total of 15 µL 
with nuclease-free water.  (The RT mix was made up as a master mix prior to the 
addition of RNA.)  The primers used were specific for the miRNAs that were being 
amplified in the subsequent qPCR step, and included reference genes sno135 and 
sno202.  These reference genes were chosen for consistency, as these had been used 
in our previous study (Bagnall et al., 2012).  NTC and NoRT control samples were also 
included.  The RT reaction was performed in a Peltier Thermocycler, by incubating 
samples at 16˚C for 30 minutes, 42˚C for 30 minutes and 85˚C for 5 minutes. 
 
4.2.5 TaqMan® qPCR for individual miRNAs 
To quantitate relative levels of miRNAs, qPCR was performed using the TaqMan 
MicroRNA assay kit (Applied Biosystems), which includes the primer-probe mix for 
specific miRNAs.  CDNA from Section 4.2.4 was diluted 10X in DEPC-treated water.  
MiRNA qPCR mixture consisted of 3 µL of diluted cDNA, 1X TaqMan MicroRNA Assay, 
1X TaqMan Universal PCR Master Mix (No AmpErase UNG), made up to a total of  
10 µL with nuclease-free water.  Thermal cycling conditions were as follows: 95˚C for 
20 minutes; followed by up to 50 cycles of 95˚C for 15 seconds and 60˚C for 1 minute.  
Reactions were performed using an Mx3000P real-time PCR system and data 
analysed using MxPro qPCR software version 2.0 (Strategene, La Jolla, CA, USA).  
Microsoft® Excel® Version 14.0.1 software was used for delta-delta Ct analysis.  
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Statistical analysis was performed using the Prism software package (GraphPad 
Software Inc., La Jolla, CA, USA) as per section 3.2.10. 
 
4.2.6 Gene expression profiling 
Gene expression profiling was carried out using Affymetrix GeneChip® Mouse Gene 
1.0 ST arrays (Affymetrix, Santa Clara, California, USA), on RNA from ventricles of age 
17 day TnI-203/MHC-403 mice, with water- or losartan- treatment (n=3 per study 
group).  Microarrays were run at the Ramaciotti Centre (University of New South 
Wales, Randwick, NSW, Australia) according to the manufacturer’s instructions.  The R 
programming language and Bioconductor libraries were used for microarray analysis 
and were carried out by William Ritchie (Centenary Institute, Camperdown, NSW, 
Australia).  Arrays were normalized using the RMA approach (Irizarry et al., 2003).   
P-value statistics were calculated by empirical Bayes shrinkage of the standard errors 
towards a common value.  Genes with a P-value <0.01 and mean fold change >1.5 
were flagged as differentially expressed. 
 
4.2.7   Functional classification of differentially expressed genes 
To identify how losartan therapy affects molecular functions in the diseased heart, gene 
ontology analysis was performed.  The online Database for Annotation, Visualization 
and Integrated Discovery (DAVID) version 6.7 was used to analyse the list of 
differentially expressed genes derived in Section 4.2.6.  The functional annotation tool 
was used, with up-regulated and down-regulated genes uploaded into the program as 
separate lists.  Gene ontology (GO) categories selected for analysis included biological 
processes, cellular components and molecular functions.  Enriched terms associated 
with gene list were considered significant when Benjamini-Hochberg score <0.05. 
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4.2.8 MicroRNA target prediction 
The effect of losartan therapy on miRNA expression and its downstream mRNA targets 
were investigated.  Differential expression of miRNA and mRNA were identified in 
Section 4.3.3 and 4.3.4, respectively.  MiRNA targets were predicted using TargetScan 
version 6.1 (http://targetscan.org/) and genes limited to conserved target sites.  MRNA 
expression profiling results were then searched through for mRNAs that were predicted 
targets of, and inversely correlated to, their respective miRNA  (i.e. miRNA increased 
and target mRNA decreased in the same study group are a inversely correlated pair, 
and vice versa). 
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RESULTS 
4.3.1 MicroRNA TLDA quality control 
TLDAs were used to screen the expression of 335 mouse miRNAs in the ventricles of 
TnI-203/MHC-403 mice, treated with water or losartan, at age 17 days (n=3 per group).  
DataAssist software was used to construct box plots (Figure 4.3) showing overall range 
and variability in Ct values for all samples, both between and within study groups.  No 
difference was observed in the Ct values between samples, indicating both cDNA 
template concentration and PCR amplification were consistent across arrays. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.  Box plots showing overall range of Ct values, displayed by sample.  
Samples are indicated by colour according to study group; red, losartan-treated  
TnI-203/MHC-403; blue, water-treated TnI-203/MHC-403.  Vertical lines extend to the 
minimum and maximum Ct values.  The box covers the middle 50% of Ct values  
(25-75%), horizontal black line represents the median Ct and black dot indicates the 
mean Ct value. 
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DataAssist was used to evaluate variations in miRNA expression of biological 
replicates (for samples with Ct<32).  Scatterplot analysis showed a high correlation of 
miRNA expression within study groups, as shown in Figure 4.4 (r>0.989; Pearson’s 
Product-Moment Correlation Coefficient). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Scatter plots demonstrating reproducibility of TLDA results between 
biological replicates. 
 
4.3.2 MicroRNA expression profiling 
TLDAs were used to determine the relative expression of 335 miRNAs from the 
ventricles of 17 day, male TnI-203/MHC-403 mice treated with losartan, in comparison 
to those treated with water.  Figure 4.5 shows the differential miRNA expression with 
losartan therapy, compared to water treatment.  Six miRNAs were identified as being 
significantly altered between treatment groups (fold change >1.5x, P<0.05).  MiR-30c 
and miR-203 were up-regulated while miR-21, miR-214, miR-31, miR-199-3p, miR-
409-3p, miR-146b were down-regulated in the losartan group. 
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Figure 4.5.  Volcano plot showing miRNA differential expression between 
ventricles of losartan-treated TnI-203/MHC-43 mice, compared to water-treated.  
MiRNAs up-regulated >1.5x with losartan therapy are shown in red; miRNAs  
down-regulated with losartan treatment are shown in green. 
 
4.3.3 Validation of miRNA expression by individual TaqMan assays 
Individual TaqMan RT-qPCR assays were carried out to validate TLDA findings, in  
17-day TnI-203/MHC-403 samples, and their expression was further investigated over 
an extended time-course to cover the different stages of disease development.   
RT-qPCR analysis confirmed the differential expression of 6 of the 8 miRNAs that were 
identified by TLDA analysis, as shown in Table 4.1.  TLDA findings were not 
reproduced for miR-409-3p and miR-146b in individual assays. 
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Table 4.1.  TLDA and RT-qPCR analysis of miRNAs in the ventricles of age 17 day 
TnI-203/MHC-403 male mice with losartan treatment, compared to water-treated 
control samples. 
 TLDA array (n=3) RT-qPCR (n=5) 
miRNA Fold Change P-value Fold Change P-value 
Up-regulated with losartan treatment 
miR-203 1.69 ± 0.16 0.0380 1.80 ± 0.09 0.0002 
miR-30c 1.52 ± 0.05 0.0014 1.43 ± 0.10 0.0078 
Down-regulated with losartan treatment 
miR-21 0.57 ± 0.03 0.0497 0.43 ± 0.06 0.0002 
miR-214 0.62 ± 0.04 0.0391 0.48 ± 0.02 0.0002 
miR-31 0.40 ± 0.01 0.0365 0.52 ± 0.03 0.0004 
miR-199a-3p 0.60 ± 0.04 0.0062 0.69 ± 0.04 0.0005 
miRNAs expression not replicable with RT-qPCR 
miR-409-3p 0.57 ± 0.03 0.0005 0.80 ± 0.10 0.2283 
miR-146b 0.58 ± 0.05 0.0044 0.84 ± 0.04 0.0943 
P-values determined by unpaired t-test. 
 
Time-course studies showed decreased levels of miR-203 and miR-30c in the 
ventricles of water-treated TnI-203/MHC-403 mice, from age 10 days onward.  
Losartan therapy coincided with increased levels of these miRNAs in TnI-203/MHC-403 
samples, as shown in Figure 4.6A and 4.6B.  Conversely, miRNAs-21, -214, -31 and  
-199a-3p were increased in water-treated TnI-203/MHC-403 samples compared to 
NTG controls.  This increase was statistically significant as early as 5 days for miR-31, 
10 days for miR-21 and miR-214, and 14 days for miR-199a-3p, with losartan treatment 
decreasing their expression, as shown in Figure 4.6C-F. 
 
 
 
 
 
 
 
 
 
 
 
     112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.  RT-qPCR analysis of ventricular miRNAs.  Fold change is shown 
relative to samples from 5 day, water-treated NTG mice.  Asterisks indicate 
significance between groups (*, P<0.05; **, P<0.01; ***, P<0.001; P<0.0001), with 
colour relevant for the comparison being made (blue, vs NTG water-treated; purple, vs 
NTG losartan-treated; red, vs TnI-203/MHC-403 water-treated). 
A      B 
 
 
 
 
 
 
 
 
 
C      D 
 
 
 
 
 
 
 
 
 
E      F 
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 4.3.4 Profiling and ontology of differentially expressed genes from the 
ventricles of TnI-203/MHC-403 mice, treated with and without losartan 
To explore which mRNAs were affected by losartan treatment in the diseased model, 
GeneChip arrays were run using ventricle RNA from losartan- and water- treated  
TnI-203/MHC-403 mice at age 17 days.  Analysis showed that treatment with losartan 
resulted in the up-regulation of 20 genes (Table 4.2), and the down-regulation of 130 
genes (Table 4.3) in TnI-203/MHC-403 hearts (>1.5x fold change, P<0.01). 
 
 
Table 4.2.  Genes up-regulated by at least 1.5 fold (P<0.01) in the ventricles of 17 
day TnI-203/MHC-403 mice, treated with losartan compared to water. 
 
Probe ID Gene Symbol Gene Name Fold change P-value 
10580635 Ces3 carboxylesterase  4.08 0.008 
10413492 Lrtm1 leucine-rich repeats and transmembrane domains 1 2.28 0.008 
10442584 Rpl3l ribosomal protein L3-like 2.17 0.010 
10341953   2.13 0.009 
10551626 Lgals4 lectin, galactose binding, soluble 4 2.07 0.010 
10409118 Wnk2 WNK lysine deficient protein kinase 2 1.91 0.008 
10409999 Fbp2 fructose biphosphatase 2 1.89 0.008 
10398824 A530016L24 RIKEN cDNA A530016L24 gene 1.88 0.008 
10387483 Efnb3 ephrin B3 1.84 0.010 
10341918   1.83 0.010 
10537712 Gstk1 Glutathione S-transferase kappa 1 1.82 0.010 
10555662 Art1 ADP-ribosyltransferase 1 1.75 0.010 
10347724   1.72 0.008 
10435019 2319919M2 ORik RIKEN cDNA 2310010M20 gene 1.72 0.010 
10483150 Fign fidgetin 1.71 0.008 
10590467 D9Ert402e DNA segment, Chr 9, ERATO Doi 402, expressed 1.68 0.008 
10342072   1.68 0.010 
10392152 Scn4a sodium channel, voltage-gated, type IV, alpha 1.66 0.008 
10536697 Asb15 Ankyrin repeat and SOCS box-containing 15 1.66 0.010 
10467162 Pank1 pantothenate kinase 1 1.60 0.009 
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Table 4.3.  Genes down-regulated by at least 1.5 fold (P<0.01) in the ventricles of 
17 day TnI-203/MHC-403 mice, treated with losartan compared to water. 
 
Probe ID Gene Symbol Gene Name Fold change P-value 
10583809 Cnn1 calponin 1 -7.57 0.010 
10408557 Serpinb1a serine (or cysteine) peptidase inhibitor, clade B, 
member 1a 
-6.36 0.010 
10587331 Gsta1 glutathione S-transferase, alpha 1 (Ya) -5.13 0.004 
10571054 Star steroidogenic acute regulatory protein -4.08 0.004 
10516765 Serinc2 serine incorporator 2 -4.00 0.008 
10371082 Itgb1bp3 integrin beta 1 binding protein 3 -3.94 0.010 
10411082 Thbs4 thrombospondin 4 -3.73 0.008 
10513739 Tnc tenascin C -3.12 0.010 
10383502 Slc16a3 solute carrier family 16 (monocarboxylic acid 
transporters), member 3 
-3.10 0.007 
10512470 Cd72 CD72 antigen -2.81 0.008 
10408613 Tubb2b tubulin, beta 2B -2.79 0.008 
10522208 Uchl1 ubiquitin carboxy-terminal hydrolase L1 -2.75 0.008 
10472426 Xirp2 xin actin-binding repeat containing 2 -2.71 0.009 
10476935 Tmem90b transmembrane protein 90B -2.71 0.004 
10514088 Frem1 Fras1 related extracellular matrix protein 1 -2.66 0.004 
10496727 Ddah1 dimethylarginine dimethylaminohydrolase 1 -2.58 0.008 
10574023 Mt2 metallothionein 2 -2.51 0.008 
10417212 Itgbl1 integrin, beta-like 1 -2.38 0.008 
10374908 Rtn4 reticulon 4 -2.36 0.004 
10340419   -2.36 0.004 
10586357 Cilp cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase 
-2.35 0.008 
10402783 Ahnak2 AHNAK nucleoprotein 2 -2.33 0.008 
10416057 Clu clusterin -2.33 0.008 
10362201 Ctgf connective tissue growth factor -2.27 0.010 
10545672 Mthfd2 methylenetetrahydrofolate dehydropgenase (NAD+ 
dependent), methenyltetrahydrofolate 
cyclohydrolase 
-2.27 0.008 
10364494 Fstl3 follistatin-like 3 -2.27 0.008 
10518069 Efhd2 EF hand domain containing 2 -2.27 0.008 
10358057 Shisa4 shisa homolog 4 (Xenopus laevis) -2.27 0.004 
10543067 Asns asparagine synthetase -2.25 0.008 
10349947 Fmod fibromodulin -2.23 0.008 
10401244 Actn1 actinin, alpha 1 -2.22 0.008 
10493114 Nes nestin -2.22 0.008 
10459335 Fam38b family with sequence similarity 38, member B -2.22 0.004 
10506714 Lrp8 low density lipoprotein receptor-related protein 8, 
apolipoprotein e receptor 
-2.20 0.008 
10387536 Cd68 CD68 antigen -2.19 0.008 
10507594 Slc2a1 solute carrier family 2 (facilitated glucose 
transporter), member 1 
-2.19 0.004 
10363070 Gp49a glycoprotein 49 A -2.14 0.010 
10402787   -2.14 0.008 
10578703 Spcs3 signal peptidase complex subunit 3 homolog (S. 
cerevisiae) 
-2.14 0.008 
10424400 Myc myelocytomatosis oncogene -2.14 0.004 
10522467 Rasl11b RAS-like, family 11, member B -2.13 0.008 
10555197 Mtap6 microtubule-associated protein 6 -2.13 0.006 
10494574 Prkab2 protein kinase, AMP-activated, beta 2 non-catalytic 
subunit 
-2.11 0.008 
10517213 Cnksr1 connector enhancer of kinase suppressor of Ras 1 -2.11 0.006 
10586744 Anxa2 annexin A2 -2.10 0.010 
10401527 Ltbp2 latent transforming growth factor beta binding 
protein 2 
-2.10 0.006 
10399419 Tubb2b tubulin, beta 2B -2.08 0.008 
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10408610 Tubb2a tubulin, beta 2A -2.07 0.008 
10574166 Cpne2 copine II -2.04 0.004 
10368289 Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 
1 
-2.04 0.004 
10423836 Cthrc1 collagen triple helix repeat containing 1 -2.03 0.008 
10359851 Uck2 uridine-cytidine kinase 2 -2.03 0.008 
10582275 Slc7a5 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 5 
-2.03 0.006 
10440993 Rcan1 regulator of calcineurin 1 -2.00 0.008 
10359034 Qsox1 quiescin Q6 sulfhydryl oxidase 1 -1.99 0.006 
10506571 Dhcr24 24-dehydrocholesterol reductase -1.97 0.010 
10385893 Slc22a4 solute carrier family 22 (organic cation transporter), 
member 4 
-1.97 0.004 
10457872 Slc39a6 solute carrier family 39 (metal ion transporter), 
member 6 
-1.96 0.010 
10440091 Col8a1 collagen, type VIII, alpha 1 -1.96 0.010 
10411519 Mtap1b microtubule-associated protein 1B -1.96 0.008 
10425808 Tspo translocator protein -1.95 0.006 
10459353   -1.93 0.010 
10458663 Dpysl3 dihydropyrimidinase-like 3 -1.91 0.010 
10593293 Ncam1 neural cell adhesion molecule 1 -1.91 0.010 
10522288 Shisa3 shisa homolog 3 (Xenopus laevis) -1.89 0.008 
10384458 Plek pleckstrin -1.89 0.008 
10523451 Anxa3 annexin A3 -1.88 0.008 
10406928 Cd180 CD180 antigen -1.88 0.007 
10537146 Akr1b8 aldo-keto reductase family 1, member B8 -1.87 0.010 
10583056 Mmp12 matrix metallopeptidase 12 -1.87 0.009 
10432404 Tuba1a tubulin, alpha 1A -1.85 0.006 
10498024 Slc7a11 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 11 
-1.84 0.008 
10501063 Cd53 CD53 antigen -1.82 0.010 
10493820 S100a6 S100 calcium binding protein A6 (calcyclin) -1.82 0.010 
10484307 Frzb frizzled-related protein -1.82 0.010 
10360764 Enah enabled homolog (Drosophila) -1.82 0.010 
10433114 Itga5 integrin alpha 5 (fibronectin receptor alpha) -1.80 0.010 
10475247 Tmem62 transmembrane protein 62 -1.80 0.010 
10477061 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) -1.80 0.008 
10562192 Fxyd5 FXYD domain-containing ion transport regulator 5 -1.79 0.010 
10492682 Fam198b family with sequence similarity 198, member B -1.79 0.008 
10545958 Anxa4 annexin A4 -1.78 0.008 
10407126 Plk2 polo-like kinase 2 (Drosophila) -1.77 0.010 
10505000 Nipsnap3b nipsnap homolog 3B (C. elegans) -1.77 0.010 
10500114 Mllt11 myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 11 
-1.77 0.008 
10571599   -1.77 0.008 
10497214 Tpd52 tumor protein D52 -1.75 0.010 
10493990 S100a11 S100 calcium binding protein A11 (calgizzarin) -1.74 0.009 
10476314 Prnp prion protein -1.74 0.008 
10569057 Rnh1 ribonuclease/angiogenin inhibitor 1 -1.74 0.008 
10587639 Nt5e 5' nucleotidase, ecto -1.74 0.008 
10420957 Ptk2b PTK2 protein tyrosine kinase 2 beta -1.73 0.010 
10595496 Snap91 synaptosomal-associated protein 91 -1.72 0.008 
10403604 Lyst lysosomal trafficking regulator -1.69 0.010 
10358434 Pla2g4a phospholipase A2, group IVA (cytosolic, calcium-
dependent) 
-1.69 0.009 
10399691 Id2 inhibitor of DNA binding 2 -1.68 0.010 
10526410 Hspb1 heat shock protein 1 -1.68 0.010 
10416215 Loxl2 lysyl oxidase-like 2 -1.67 0.008 
10467136 Ch25h cholesterol 25-hydroxylase -1.66 0.010 
10518570 Pgd phosphogluconate dehydrogenase -1.66 0.010 
10459747 Mapk4 mitogen-activated protein kinase 4 -1.66 0.010 
10468929 Nmt2 N-myristoyltransferase 2 -1.66 0.010 
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10590983 Panx1 pannexin 1 -1.66 0.010 
10567043 Rras2 related RAS viral (r-ras) oncogene homolog 2 -1.66 0.008 
10505132 Akap2 A kinase (PRKA) anchor protein 2 -1.66 0.008 
10540105 Tmem43 transmembrane protein 43 -1.65 0.010 
10579872 Tpd52 tumour protein D52 -1.65 0.010 
10408600 Serpinb6a serine (or cysteine) peptidase inhibitor, clade B, 
member 6a 
-1.64 0.009 
10364375 Cstb cystatin B -1.64 0.008 
10459363   -1.62 0.010 
10492021 Postn periostin, osteoblast specific factor -1.62 0.009 
10427910 Fam105b family with sequence similarity 105, member B -1.62 0.008 
10350136 Csrp1 cysteine and glycine-rich protein 1 -1.61 0.010 
10548879 Mgp matrix Gla protein -1.61 0.010 
10424543 Wisp1 WNT1 inducible signalling pathway protein 1 -1.61 0.008 
10557960 Tgfb1i1 transforming growth factor beta 1 induced transcript 
1 
-1.60 0.010 
10448307 Tnfrsf12a tumour necrosis factor receptor superfamily, 
member 12a 
-1.60 0.010 
10370721 Sbno2 strawberry notch homolog 2 (Drosophila) -1.60 0.010 
10601659 Srpx2 sushi-repeat-containing protein, X-linked 2 -1.60 0.008 
10408572   -1.58 0.010 
10393106 Trim47 tripartite motif-containing 47 -1.58 0.010 
10344990 Crispld1 cysteine-rich secretory protein LCCL domain 
containing 1 
-1.58 0.008 
10452485 Rab31 RAB31, member RAS oncogene family -1.58 0.008 
10342367   -1.57 0.010 
10505517 Tlr4 toll-like receptor 4 -1.57 0.010 
10498871 Tmem144 transmembrane protein 144 -1.56 0.010 
10595404 Fam46a family with sequence similarity 46, member A -1.56 0.010 
10542791 Pbfibp1 PTPRF interacting protein, binding protein 1 (liprin 
beta 1) 
-1.52 0.010 
10354309 Col5a2 collagen, type V, alpha 2 -1.51 0.010 
 
Functional annotation was sought for the up- and down-regulated genes listed.  GO 
terms were searched in databases specific for ‘biological processes’ (BP), ‘molecular 
functions’ (MF) and ‘cellular components’ (CC).  No GO terms were significantly 
associated with the gene list, from BP or MF databases.  Three CC ontology terms 
were enriched for the differentially expressed mRNAs;  ‘extracellular matrix’ (ECM) and 
‘proteinaceous extracellular matrix’ were associated with 8.1% of down-regulated 
genes (11 genes; Benjamini Hochberg (BH) adjusted P-values: 0.014 and 0.021, 
respectively), with genes overlapping entirely for these two terms (Table 4.4), the third 
term was ‘extracellular region part’ which was associated with 12.5% of genes (17 
genes, BH adjusted P-value 0.020), including all genes associated with the 
aforementioned two terms (Table 4.5).  All genes associated with these terms were 
significantly repressed with losartan therapy.  The number of genes associated with the 
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term ‘extracellular region’ are larger than those associated with the ‘extracellular 
matrix’, as the extracellular region incorporates all space external to cells, including the 
matrix structure as well as non-matrix proteins. 
 
Table 4.4.  Down-regulated genes associated with the terms ‘extracellular matrix’ 
and ‘proteinaceous extracellular matrix’ 
 
Gene symbol Gene name 
Frem1 Fras1 related extracellular matrix protein 1 
Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 
Cthrc1 collagen triple helix repeat containing 1 
Col5a2 collagen, type V, alpha 2 
Col8a1 collagen, type VIII, alpha 1 
Ctgf connective tissue growth factor 
Fmod fibromodulin 
Mmp12 matrix metallopeptidase 12 
Postn periostin, osteoblast specific factor 
Anxa2 annexin A2  or annexin A2 pseudogene 
Tnc tenascin C 
 
 
 
Table 4.5.  Down-regulated genes associated with the terms ‘extracellular region 
part’, in addition to those ‘extracellular matrix’ genes listed in Table 4.4. 
 
Gene symbol Gene name 
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 
Fstl3 follastatin-like 3 
Lrp8 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor 
Loxl2 lysyl oxidase-like 2 
Mgp matrix Gla protein 
Qsox1 quiescin Q6 sulfhydryl oxidase 1 
 
 
4.3.5 Cross-referencing of miRNAs with predicted mRNA targets 
A single miRNA can regulate the expression of a large number of genes.  TargetScan, 
an online software tool for predicting miRNA targets, was used to identify 
miRNA/mRNA pairs affected by losartan therapy.  MiRNA/mRNA pairs, which had 
inversely correlated expression, are listed in Table 4.6. 
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Table 4.6. MiRNAs and their predicted mRNA targets, which are altered by 
losartan treatment in TnI-203/MHC-403 ventricles 
 
miRNA mRNA target 
Up-regulated Down-regulated 
miR-203  Ncam1  
Postn 
Snap91 
miR-30c Actn1 
Cthrc1 
Frzb 
Mtap6 
Ncam1 
Nt5e 
Slc7a11 
Spcs3 
Down-regulated Up-regulated  
miR-214 Fign 
Pank1 
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4.4 DISCUSSION 
Losartan therapy was shown to be of benefit in the TnI-203/MHC-403 mouse model, in 
Chapter 3.  Characterisation of the miRNA and mRNA changes that occur with this 
treatment may help clarify the underlying mechanisms that lead to improvements in 
disease outcome.  MiRNA profiling by TLDA analysis identified eight differentially 
expressed miRNAs, of which six passed validation with individual RT-qPCR analysis.  
Of these, two were up-regulated with losartan treatment (miR-203 and miR-30c) and 
four miRNAs significantly down-regulated with losartan (miR-21, -214, -31, -199a-3p), 
at age 17 days. 
 
This miRNA profile is in stark contrast to the miRNA expression changes observed 
when diseased hearts were compared to NTG controls.  RT-qPCR studies (Figure 4.6) 
showed miR-203 and miR-30c were down-regulated and miR-21, -214, -31 and  
-199a-3p were up-regulated in disease, compared to NTG control.  We have previously 
profiled miRNA expression in the ventricles of TnI-203/MHC-403 mice during heart 
failure stage (Bagnall et al., 2012) and found that all of the aforementioned miRNAs, 
with the exception of miR-203, were differentially expressed compared to NTG controls 
(Table 4.7).  While both studies showed the same trend, miR-203 expression was not 
significantly altered in the previous study, and may have not reached significance due 
to one day age difference in the samples (16 days vs 17 days) in a rapidly progressing 
model, and fewer mice investigated in the original study (n=3 vs n=5).  Several other 
miRNAs were also dysregulated during heart failure, including miR-1, -34-3p, -132,  
-142, -222, -30-5p, -30e, -133a, -133b, -150, -486-5p and -499-5p (Bagnall et al., 
2012).  While these miRNAs may be involved in disease pathogenesis, data presented 
in this chapter suggests they are not significantly affected by losartan therapy, and thus 
losartan acts independently of these miRNAs. 
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Table 4.7  Summary of the differential expression of miRNAs. 
 
miRNA TnI-203/MHC-403 (untreated)* 
TnI-203/MHC-403 
(water-treated)† 
Losartan therapy in 
TnI-203/MHC-403‡ 
miR-21 é é ê 
miR-31 é é ê 
miR-34-3p é not investigated no change 
miR-132 é not investigated no change 
miR-142 é not investigated no change 
miR-214 é é ê 
miR-222 é not investigated no change 
miR-199a-3p é é ê 
miR-203 no change ê é 
miR-1 ê not investigated no change 
miR-30-5p ê not investigated no change 
miR-30c ê ê é 
miR-30e ê not investigated no change 
miR-133a ê not investigated no change 
miR-133b ê not investigated no change 
miR-150 ê not investigated no change 
miR-486-5p ê not investigated no change 
miR-499-5p ê not investigated no change 
*, miRNA expression changes in the ventricles of age 16 day TnI-203/MHC-403 mice, 
compared to NTG, as published by Bagnall et al (2012).  †, miRNA expression changes in the 
ventricles of age 17 day TnI-203/MHC-403 mice, compared to NTG, as shown in Section 4.3.3 
by RT-qPCR.  ‡, miRNA changes in the ventricles of age 17 day TnI-203/MHC-403 mice treated 
with losartan, compared to treatment with water, as shown in Section 4.3.2 by TLDA (and where 
relevant, confirmed by RT-qPCR). 
 
Time-course analysis of the differentially expressed miRNAs in this chapter, showed 
miR-203, miR-30c, miR-21 and miR-214 levels were altered in the hearts of water-
treated TnI-203/MHC-403 mice as early as age 10 days, corresponding to a preliminary 
stage of disease, while miR-31 was significantly dysregulated even earlier, at age 5 
days, correlating with a pre-disease time-point.  As these changes in miRNAs 
expression occur early in the course of disease development, they possibly contribute 
to pathogenic mechanisms or may be an early response to molecular pathways 
associated with disease.  Comparatively, miR-199a-3p was up-regulated at a later 
time-point of age 14 days, and is more likely to be a secondary change, in response to 
established disease.   
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The six miRNAs that were altered in the losartan treatment group have previously been 
found to be dysregulated in models of pathological cardiac hypertrophy, including 
pressure overload and genetically-induced hypertrophy, heart failure, myocardial 
infarction, as well as cellular models of hypertrophy (Table 4.8).  The pattern of miRNA 
expression in the TnI-203/MHC-403 model was similar to expression changes in these 
other models of cardiac stress and dysfunction.  Studies have been performed that 
investigate the phenotypic changes that occur when these miRNAs are altered, to give 
clarity on their role in the heart (Table 4.9). 
 
A previous study has shown that miR-30c is predominantly expressed in cardiac 
fibroblasts, not cardiomyocytes, in the rat heart and that miR-30c directly targets and 
represses Ctgf expression in cardiac fibroblasts (Duisters et al., 2009).  CTGF is also 
primarily expressed in fibroblasts (Chen et al., 2000) and induces ECM production 
(Frazier et al., 1996, Grotendorst, 1997).  Therefore it stands to reason that a decrease 
in miR-30c expression would result in increased CTGF in cardiac fibroblasts, which in 
turn would stimulate the production of ECM, leading to fibrosis.  The results in this 
chapter corroborate with these previous findings, as miR-30c was down-regulated in 
TnI-203/MHC-403 ventricles, with CTGF expression and fibrosis increased in these 
samples, as demonstrated in Chapter 3.  A recent study has shown that angiotensin II 
(Ang II) down-regulates miR-30 in cardiomyocytes (Pan et al., 2013) and Ang II has 
also been shown to induce CTGF expression in cardiac fibroblasts (Ahmed et al., 
2004).  The results in this chapter concur with these findings, and have demonstrated 
that blocking the action of Ang II by antagonism of the AT1 receptor, results in 
increased miR-30c expression, decreased CTGF and, in turn, reduced cardiac fibrosis.  
These results support the notion that miR-30c is an important in the development of the 
TnI-203/MHC-403 phenotype, and that restoring the expression of this miRNA may 
lead to reduced fibrosis in disease.  As such, miR-30c is a potential target for 
therapeutic intervention in HCM. 
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Table 4.8.  Models of cardiac disease showing dysregulation of miRNAs 
miRNA Pathology Model miRNA Expression Reference/s 
miR-30c Pressure overload hypertrophy (LV) TAC mouse Decreased 
(Sayed et al., 2007, 
Duisters et al., 2009, 
Tatsuguchi et al., 2007) 
miR-30c 
Pressure overload 
hypertrophy (RV) 
(afterload stress) 
PAC, mouse Decreased (Reddy et al., 2012) 
miR-30c Pressure overload hypertrophy Aortic stenosis, humans Decreased  (Duisters et al., 2009) 
miR-30c Severe HCM TnI-203/MHC-403 mouse Decreased (Bagnall et al., 2012) 
miR-30c Heart failure PAC, mouse Decreased (Reddy et al., 2012) 
miR-30c Heart failure Ren-2 rat model Decreased (Duisters et al., 2009) 
miR-203 Heart failure PAC, mouse Decreased (Reddy et al., 2012) 
miR-21 Cellular hypertrophy CM treated with AngII Increased (Cheng et al., 2007) 
miR-21 Cellular hypertrophy CM treated with PE Increased (Cheng et al., 2007, Tatsuguchi et al., 2007) 
miR-21 Pressure overload hypertrophy TAC, mouse Increased 
(Sayed et al., 2007, 
Cheng et al., 2007, 
Tatsuguchi et al., 2007, 
van Rooij et al., 2006) 
miR-21 Hypertrophy PAC, mouse Increased (Reddy et al., 2012) 
miR-21 Genetic induced cardiac hypertrophy CnA transgenic mouse Increased (van Rooij et al., 2006) 
miR-21 Severe HCM TnI-203/MHC-403 mouse Increased (Bagnall et al., 2012) 
miR-21 Heart failure PAC, mouse Increased (Reddy et al., 2012) 
miR-21 Heart failure Human Increased (Matkovich et al., 2009) 
miR-21 Myocardial infarction Human Increased (van Rooij et al., 2008) 
miR-21 Myocardial infarction Induced by occlusion of LCA in mice Increased (van Rooij et al., 2008) 
miR-214 Pressure overload hypertrophy TAC Increased 
(Sayed et al., 2007, 
Cheng et al., 2007) 
miR-214 Severe HCM TnI-203/MHC-403 mouse Increased (Bagnall et al., 2012) 
miR-214 Heart failure Human patients Increased (van Rooij et al., 2006) 
miR-214 Myocardial infarction Human patients Increased  (van Rooij et al., 2008) 
miR-214 Myocardial infarction MI induced by occlusion of LCA, in mice Increased (van Rooij et al., 2008) 
miR-31 Pressure overload hypertrophy TAC Increased (Sayed et al., 2007) 
miR-31 Severe HCM TnI-203/MHC-403 mouse Increased (Bagnall et al., 2012) 
miR-199a-3p Pressure overload hypertrophy TAC Increased (Sayed et al., 2007) 
miR-199a-3p Hypertrophy (afterload stress) PAC, mouse Increased (Reddy et al., 2012) 
miR-199a-3p Heart failure Human Increased (Matkovich et al., 2009) 
LV, left ventricle; RV, right ventricle; TAC, transverse aortic constriction; PAC, pulmonary artery 
constriction; HCM, hypertrophic cardiomyopathy;  CM, cardiomyocytes;  Ang II, angiotensin II;  
PE, phenylephrine;  CnA, calcineurin A;  MI, myocardial infarction;  LCA, left coronary artery. 
 
 
  
Chapter 4.  Expression Profiling in TnI-203/MHC-403 Mice with Losartan Treatment  
    123 
Table 4.9.  Phenotype associated with specific changes in miRNA expression. 
miRNA Expression Model Phenotype Reference 
miR-30c Increased CM transfected with miR-30c Increased cell size (Jentzsch et al., 2012) 
miR-30c Decreased Anti-miR in CM treated with PE Decreased cell size  (Jentzsch et al., 2012) 
miR-21 Decreased Inhibition of miR-21 using LNA, in CM 
Increased cell size, 
increased ANF 
(Tatsuguchi et al., 
2007) 
miR-21 Increased CM transfected with miR-21 duplex 
Decreased cell 
size, decreased 
ANF 
(Tatsuguchi et al., 
2007) 
miR-214 Increased CM transfected with miR-214 
No change in cell 
size (Jentzsch et al., 2012) 
miR-214 Increased 
Mouse model 
expressing miR-214 in 
heart 
No phenotypic 
effect (van Rooij et al., 2006) 
miR-214 Increased 
Over-expression of 
miR-214 in CM by 
adenovirus 
Increased cell size (van Rooij et al., 2006) 
miR-31 Increased CM transfected with miR-31 Increased cell size (Jentzsch et al., 2012) 
CM, cardiomyocytes;  PE, phenylephrine;  LNA, locked nucleic acid. 
 
MiR-21, miR-214, miR-31 and miR-199a-3p were all up-regulated in TnI-203/MHC-403 
hearts, and expression was reduced with losartan therapy.  These findings concur with 
previous publications in which various models of cardiac hypertrophy and stress 
demonstrated increased expression of all these miRNAs.  Previous studies have 
shown miR-21 expression is increased in failing myocardium, myocardial infarction and 
in both whole organ and cellular hypertrophy (van Rooij et al., 2006, Tatsuguchi et al., 
2007, Sayed et al., 2007, Cheng et al., 2007).  These studies involved transfection of 
cardiomyocytes with miR-21 duplexes in order to mimic miRNA “over-expression” and 
found a reduction in both cell size and the expression of hypertrophy marker, ANF 
(Tatsuguchi et al., 2007).  Conversely, inhibition of miR-21 was shown to augment 
hypertrophic growth and increase ANF expression (Tatsuguchi et al., 2007).  These 
results suggest miR-21 negatively regulates cardiomyocyte hypertrophy.  Similar to 
miR-30c, miR-21 is predominantly expressed in cardiac fibroblasts (Thum et al., 2008).  
MiR-21 was shown to be increased in the fibroblasts of failing myocardium, while the 
expression in cardiomyocytes of failing hearts remained unchanged, suggesting a 
limited role of miR-21 in cardiomyocyte cells (Thum et al., 2008).  Knockdown of miR-
Chapter 4.  Expression Profiling in TnI-203/MHC-403 Mice with Losartan Treatment  
    124 
21 in mice following TAC-induced cardiac hypertrophy, was found to decrease cardiac 
fibrosis and remodelling (Thum et al., 2008).  Collectively, these studies suggest miR-
21 plays a different role depending on cell type, is an important regulator of fibroblast 
activity and is less likely to play a major role in cardiomyocyte hypertrophy.  The 
dysregulation of both miR-30c and miR-21 have been reported in the  
TnI-203/MHC-403 model (Bagnall et al., 2012), and here losartan therapy was shown 
to significantly alter their expression, partially correcting their expression to be more 
similar to the NTG mice.  This corresponds with a significant reduction in fibrosis and 
concurs with previously published data. 
 
The role of the remaining four miRNAs that are differentially expressed with losartan 
therapy, are less well defined in the context of the heart.  Expression of miR-203 was 
reduced in TnI-203/MHC-403 hearts and is decreased in heart failure.  While this 
miRNA has not been investigated in a cardiac setting, periostin, a predicted down-
stream targets of miR-203, has been shown to promote differentiation of circulating 
cells into cardiac fibroblasts (Visconti and Markwald, 2006) and to stimulate 
extracellular matrix production  (Norris et al., 2008).  Genetic ablation of periostin in an 
HCM mouse model reduced non-myocyte proliferation and fibrosis, suggesting that in 
this model periostin is pro-fibrotic (Teekakirikul et al., 2010). 
 
miR-31 and miR-214, which are up-regulated in TnI-203/MHC-403 ventricles and 
down-regulated with losartan therapy, have been transfected or over-expressed in 
cardiomyocytes to investigate the effect of increased miRNA in these cells.  miR-214 is 
increased in hypertrophy and heart failure, however studies that specifically over-
expressed miR-214 in cardiomyocytes have found it induced myocyte hypertrophy (van 
Rooij et al., 2006) while another reported no difference in cell size (Jentzsch et al., 
2012).  This could be due to differences in the delivery of miRNA, with one study using 
transfection of synthetic miRNAs and the other introducing miRNA by means of 
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adenoviral transduction.  When miR-214 was overexpressed in the mouse heart, no 
phenotypic effect was observed (van Rooij et al., 2006).  This suggests that increased 
expression of miR-214 alone is not enough to induce a cardiac phenotype, and that 
changes in cardiac phenotype require the combined actions of multiple miRNAs.   
MiR-31 was identified to be up-regulated in a pressure-overload model of hypertrophy 
(Sayed et al., 2007) and its specific effect in cellular hypertrophy has been investigated 
by transfection of the synthesised miRNA into primary cardiomyocytes, which resulted 
in increased cell size (Jentzsch et al., 2012).  While this has not been confirmed in vivo, 
the altered expression of this miR-31 in TnI-203/MHC-403 hearts is the earliest miRNA 
change in this model, and is positively associated with a pro-hypertrophic response, 
which is inhibited with losartan therapy. 
 
The final miRNA differentially expressed with losartan therapy was miR-199a-3p, which 
was significantly up-regulated late in disease (age 14 days) and down-regulated with 
losartan treatment at the same time-point.  In addition to our study (Bagnall et al., 
2012), others have also shown an up-regulation of miR-199a-3p in cardiac models of 
hypertrophy and heart failure (Reddy et al., 2012, Matkovich et al., 2009).  Recently, it 
has been demonstrated that miR-199a-3p can stimulate cardiomyocyte proliferation, 
restore cardiac mass, and promote functional recovery after myocardial infarction in 
adult animals (Eulalio et al., 2012).  Regeneration of cardiac mass is important in a 
number of diseases associated with cardiomyocyte loss, including heart failure and 
dilated cardiomyopathy (Dorn, 2009).  TnI-203/MHC-403 mice display both a dilated 
cardiomyopathy phenotype at 16-17 days and die from heart failure (Tsoutsman et al., 
2008b).  Based on the literature, the increased expression of miR-199a-3p in end-stage 
disease in TnI-203/MHC-403 hearts is a beneficial change.  Losartan therapy at the 
same age shows reduced miR-199a-3p expression, most likely because disease is not 
as advanced (and signalling triggers for miR-199a-3p have not been initiated). 
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Overall, the changes in miRNA expression in this model support previous findings of 
the role of miRNAs in cardiac hypertrophy and fibrosis, and their position as novel 
therapeutic targets.  To better understand miRNA involvement in disease and losartan 
treatment, profiling should be carried out on specific cell types.  Studies involving the 
introduction of miR-mimics and anti-miRs into different cultures of single cardiac cell 
types, to clarify the miRNAs involved in the different cellular processes i.e. 
cardiomyocyte hypertrophy and increased ECM production are required. 
 
Losartan therapy altered the expression of miRNAs associated with extracellular matrix 
production and fibrosis (miR-30c and miR-21).  This complements the gene ontology 
analysis of differentially expressed mRNAs, which revealed three significantly enriched 
terms: extracellular matrix, proteinaceous extracellular matrix and extracellular part.  All 
pro-fibrotic genes that were associated with these terms were down-regulated with 
losartan therapy.  Findings for miRNA and mRNA expression supports results from the 
Chapter 3, in which losartan therapy significantly reduced cardiac fibrosis. 
 
While miRNA and their predicted mRNA targets have been identified in this study, 
proposed future experiments should include (1) validation of the expression of key 
mRNAs by RT-qPCR, (2) investigation of miRNA/mRNA pairs using luciferase assays, 
(3) introduction of miR-mimics and anti-miRs (in separate experiments) into cardiac  
-myocyte and -fibroblast cells to assess changes in phenotype, including hypertrophy, 
proliferation, apoptosis, or expression of pro-fibrotic and pro-hypertrophic genes.  
When investigating miRNA/mRNA pairs, consideration should be taken when selecting 
potential targets for validation and the predicted mRNA target listing may need to be 
adjusted for less conserved targets.  The miRNA/mRNA pairs listed in Table 4.6 were 
derived using a conservative approach, in order to avoid false positive matches.  The 
approach taken however, does mean that some important miRNA/mRNA targets may 
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potentially be missed, and may explain why miR-30c and its target Ctgf, which have 
been previously validated (Duisters et al., 2009), were missed in the analysis. 
 
This study has identified the miRNAs altered with losartan therapy in the hearts of  
TnI-203/MHC-403 mice, their predicted mRNA targets that are also altered with 
treatment, and suggests several potential miRNAs for therapeutic intervention.  The 
rationale for miRNA therapeutics is based on the assumption that aberrantly expressed 
miRNAs play a critical role in disease development, and that restoring miRNA 
expression will provide therapeutic benefit.  This, however, is unlikely to be the case for 
miR-199a-3p, whose over-expression is beneficial in pathological conditions of 
cardiomyocyte loss.   
 
These findings support previous studies that show miRNAs are aberrantly expressed in 
HCM.  It extends these findings by showing that losartan treatment is able to partially 
correct this expression and improve disease outcome, suggesting an important role for 
these miRNAs.  Further studies are warranted that investigate the therapeutic potential 
of manipulating miRNA expression in HCM. 
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5 DEVELOPMENT OF LENTIVIRAL PARTICLES FOR THE INTRODUCTION 
OF HCM-CAUSING MUTATIONS INTO THE HL-1 CELL LINE 
 
5.1 INTRODUCTION 
Pathogenic mutations, such as G203S in TNNI3 and R403Q in MYH7, have been 
identified in human HCM and genetically engineered animal models have provided 
definitive evidence that these mutations alone cause disease (as described in Sections 
1.2.2 and 1.2.1, respectively).  While such studies have been crucial in confirming the 
genetic basis of HCM, cell culture models are a valuable resource for investigating the 
molecular mechanisms of disease in a controlled environment without systemic 
influence.  Further, they can be useful for screening the therapeutic potential of 
pharmacological agents or miRNA-based treatments.  The HL-1 cell line is a unique 
tool in which immortalised cells possess the phenotype of contracting adult 
cardiomyocytes (described in 1.3.1).  The presence of sarcomeres and the contractile 
motion of these cells, make HL-1 cells an ideal candidate for HCM in vitro studies.  This 
study sought to engineer lentiviral particles for the delivery of TNNI3-G203S and 
MYH7-R403Q mutated genes into HL-1 cells. 
 
5.1.1 Lentiviral technology 
Lentiviruses are a genus of the retrovirus family, and are spherical particles 
approximately 80-100 nm in diameter, enveloped with proteins involved in host cell 
recognition and infection.  Lentiviral vectors derived from the human immunodeficiency 
virus (HIV-1) are a powerful tool for delivering genetic information into a target cell, as 
they are highly efficient at infecting a wide variety of dividing and non-dividing cells and 
stably integrate into the host genome resulting in persistent expression of the gene of 
interest.  As HIV-1 is a human pathogen, it is of critical importance from a biosafety 
perspective that engineered lentiviruses are replication-defective.  This is achieved by 
manufacturing lentiviral particles in ‘packaging’ cells, by co-transfecting with the 
plasmid containing the HIV-1 genome and several ‘helper’ plasmids each encoding for 
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different proteins required for lentiviral production and function.  Another precaution is 
the use of self-inactivating vectors, in which the viral promoter and enhancer of the  
3’ long terminal repeat (LTR) has been removed. 
 
This study employed a third-generation system in which five different plasmids were 
transfected into the packaging cell line HEK293T, to produce lentiviral particles.  These 
plasmids included three packaging plasmids, an envelope plasmid and the lentiviral 
transfer vector. The packaging plasmids encode the elements required for viral 
regulation including tat (trans-activator of transcription, essential for efficient 
transcription of the viral gene) and rev (regulator of expression of virion proteins, 
involved in regulation of viral mRNA production and facilitates nuclear export of RNAs), 
and genes involved in structural function, including gag (encodes a polyprotein which is 
cleaved into proteins that compose the basic physical infrastructure of the virus) and 
pol (encodes four proteins: reverse transcriptase, which copies the viral RNA into DNA; 
protease, which processes proteins made by the HIV genome;  RNase H, which breaks 
down the viral genome following infection of the target cell; Integrase, which is involved 
in integrating the DNA copy of the HIV genome into the target cell DNA).  The envelope 
plasmid contains the G glycoprotein coding sequence from vesicular stomatitis virus 
(VSV-G), which coats the lentiviral particles, and is commonly used due to its broad 
tropism.  The lentiviral transfer vector contains the transgene of interest, which is to be 
delivered to the target cell.  This transgene is flanked by LTRs, which are necessary for 
the integration of the transgene into the target cell DNA. 
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5.1.2 Aims 
The aim of this study was to produce lentiviral particles which could be used to 
introduce the encoding sequence of human cardiac sarcomere genes troponin I 
(TNNI3) and myosin heavy chain β (MYH7), into the cardiomyocyte cell line, HL-1.  
These genes were either wild-type or contained HCM-causing missense mutations: 
G203S in TNNI3 and R403Q in MYH7.  As the target cell endogenously expresses 
mouse sarcomere genes, lentiviral transfer vectors were used that encode fluorescent 
reporter proteins to allow for visual identification of cells expressing the transgenes.  
These vectors encode for cherry fluorescent protein (Cherry) or green fluorescent 
protein (GFP), which are upstream of TNNI3 or MYH7, respectively, and linked by a 23 
amino acid picornaviral 2A-like sequence from the porcine teschovirus-1, as previously 
described (Tiffen et al., 2010, Holst et al., 2006).  The 2A motif causes ribosomal 
skipping between the two genes upon translation, resulting in equimolar expression of 
both the reporter gene and the transgene of interest. 
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5.2 METHODS 
The methods described here cover the steps involved in construction of the lentiviral 
expression vector, lentiviral packaging and transduction into the mouse cardiomyocyte 
cell line HL-1.  As briefly overviewed in Figure 5.1, plasmids containing TNNI3 and 
MYH7 cDNA were obtained, the R403Q mutation was introduced into MYH7 by site-
directed mutagenesis, and the gene of interest was screened in all four plasmids.  The 
2A sequence was introduced immediately upstream of TNNI3 and MYH7 by PCR 
amplification.  PCR products were purified and ligated into lentiviral transfer vectors, 
which were transformed into E. coli DH10β cells and single colonies were grown, 
screened and sequenced.  The lentiviral transfer vectors were then transfected into 
HEK293T cells to investigate expression of the fluorescent reporter protein and 
sarcomere proteins.  LV particles were packaged in HEK293T cells and four of the six 
viruses made were transduced into the HL-1 target cell line. 
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Figure 5.1.  Study outline for the development of lentiviral particles. 
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5.2.1 Biological materials 
Plasmids containing full-length cDNA of TNNI3 and MYH7 were used as templates for 
PCR amplification and subsequent insertion into lentiviral vectors in this study.  
Plasmid details are outlined in Table 5.1.  YFP-TNI-WT and YFP-TNI-G203S contained 
the TNNI3 cDNA, wild-type and with the G203S mutation, respectively.  A SalI site had 
been previously introduced into each of the plasmids following the TNNI3 TGA stop 
codon.  Due to ample stocks of these two plasmids, no initial plasmid amplification was 
necessary. 
 
The pCMV6-XL4-MYH7 plasmid contained the full-length MYH7 cDNA.  This plasmid 
was transformed into E.coli TOP10 cells as described in Section 2.3.2, cultured in the 
presence of ampicillin (100 µg/mL) and small scale plasmid DNA stocks were prepared 
(Section 2.3.3) prior to further steps.  pCMV6-XL4-MYH7 was mutated to incorporate 
missense mutation R403Q in this study (Section 5.2.2.3). 
 
 
Table 5.1.  Plasmids used for preparing DNA inserts 
 
Plasmid name Description Source 
YFP-TNI-WT Contains full length TNNI3 Created by Ms Jessica Chung.  
(Centenary Institute, 
Camperdown, NSW, Australia) 
YFP-TNI-G203S Contains full length TNNI3, with 
G203S missense mutations 
Created by Ms Jessica Chung.  
(Centenary Institute, 
Camperdown, NSW, Australia) 
pCMV6-XL4-
MYH7 
Contains full length MYH7, ampicillin 
resistance gene 
OriGene Technologies (Rockville, 
Maryland, USA) 
pCMV6-XL4-
MYH7-R403Q 
Contains full length MYH7 gene with 
R403Q mutation, ampicillin 
resistance gene 
Created in this study, from  
pCMV-XL4-MYH7 (OriGene) 
 
 
Lentiviral starting vectors were pHIV1SDm-CMV-Cherry-2A-luc and pHIV1SDm-CMV-
GFP-2A-luc, which were obtained from the Gene Therapy Laboratory at Centenary 
Institute (Camperdown, NSW, Australia).  These plasmids were transformed into E. coli 
DH10β cells, as described in Section 2.3.2, cultured in the presence of 10 µg/mL 
chloramphenicol and small-scale DNA preparations were made.  Each of the plasmids 
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contained a CMV promoter, which drives the expression of the reporter gene and 
downstream luciferase gene, separated by the 2A motif.  In this chapter, the luciferase 
gene was removed and the sarcomere genes of interest were introduced.  Empty 
vector (EV) controls were also constructed in this study, which contained the 2A motif 
followed by an immediate TGA stop codon, in place of a sarcomere gene sequence.  
These lentiviral constructs also have other features, which assist to improve efficiency 
and expression of transgenes, including rev response element (RRE), central 
polypurine tract (cppt) and woodchuck hepatitis post-transcriptional regulatory element 
(wpre).  Starting vectors are shown in Figure 5.2 and all lentiviral vectors used in this 
study are described in Table 5.2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.  Features of lentiviral vectors (A) pHIV1SDm-CMV-Cherry-2A-luc and 
(B) pHIV1SDm-CMV-GFP-2A-luc.  Vectors contain 5’ and 3’ LTRs, long-terminal 
repeats; RRE, rev response element; cppt, central polypurine tract; CMV, 
cytomegalovirus promoter; mCherry, monomeric red (cherry) fluorescent protein; 
eGFP, enhanced green fluorescent protein; 2A, porcine teschovirus-1 2A motif; wpre, 
woodchuck hepatitis post-transcriptional regulatory element; and self-inactivating (SIN) 
3’LTR. 
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Table 5.2.  Lentiviral vectors used in this study 
Plasmid Fluorescent reporter Gene of interest 
Lentiviral starting vectors 
pHIV1SDm-CMV-Cherry-2A-luc Cherry Luciferase 
pHIV1SDm-CMV-GFP-2A-luc GFP Luciferase 
Lentiviral transfer vectors created in this thesis 
pHIV1SDm-CMV-Cherry-2A-EV Cherry STOP codon (empty vector) 
pHIV1SDm-CMV-Cherry-2A-TNNI3-WT Cherry Troponin I, wild-type 
pHIV1SDm-CMV-Cherry-2A-TNNI3-G203S Cherry Troponin I, G203S mutation 
pHIV1SDm-CMV-GFP-2A-EV GFP STOP codon (empty vector) 
pHIV1SDm-CMV-GFP-2A-MYH7-WT GFP Myosin heavy chain beta, wild-type 
pHIV1SDm-CMV-GFP-2A-MYH7-R403Q GFP Myosin heavy chain beta, R403Q mutation 
 
5.2.2 Analysis of template DNA 
Plasmids containing TNNI3 and MYH7 cDNA were verified prior to use in cloning.  PCR 
amplification of the TNNI3 insert and subsequent sequencing was carried out for  
YFP-TNI-WT and YFP-TNI-G203S plasmids.  pCMV6-XL4-MYH7 and  
pCMV6-XL4-MYH7-R403Q were screened by restriction enzyme digestion, PCR 
amplification and sequencing.  All PCR reagents, digestion enzymes and 
electrophoresis materials were obtained from sources as described in Section 2.2.1. 
 
5.2.2.1 Polymerase chain reaction amplification of TNNI3 cDNA 
The entire TNNI3 exonic sequence in the YFP-TNI and YFP-TNI-203 plasmids were 
amplified by PCR.  The annealing site for the forward primer (TNNI3-cDNA-F;  
5’-AATGTCGACCCAAACGCCCCTGTCCTC-3’) was located 37-63 base pairs 
upstream of the TNNI3 start codon, while the reverse primer (TNNI3-cDNA-R;  
5’-AATGTCGACGCAGTAGGCAGGAAGGCT-3’) annealed to the stop codon and 26 
base pairs downstream.  Sample reaction mixture contained 320 ng of plasmid DNA 
(YFP-TNI-WT or YFP-TNI-G203), 1X final concentration of GoTaq® Flexi Buffer,  
2.5 mM MgCl2, 200 µM dNTPs, 1.2 µM TNNI3-cDNA-F and 1.2 µM TNNI3-cDNA-R and 
0.5 U of GoTaq® Flexi DNA Polymerase, made up to a final volume of 25 µL with triple 
distilled water.  The PCR cycling conditions were as follows: 94˚C for 1 minute; 
followed by 30 cycles of 94˚C for 30 seconds and 68˚C for 30 seconds; and a final 
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extension at 72˚C for 3 minutes.  5 µL of PCR product was examined by agarose gel 
electrophoresis, with the remaining 20 µL used for DNA sequencing (Section 5.2.2.6). 
 
5.2.2.2 Restriction enzyme digestion: XbaI 
Plasmid preparations of pCMV6-XL4-MYH7 from single bacterial colonies were 
screened by digestion with XbaI, which cuts the plasmid once allowing for the 
linearisation.  Digestion reaction mixture contained 1 µg of plasmid DNA, 10 U XbaI 
restriction enzyme, 1X final concentration of Buffer 4, 10 µg of BSA, made up to a total 
of 10 µL with triple distilled water.  Sample reactions were incubated for 1 hour at 37˚C 
in a Peltier Programmable Thermal Controller.  XbaI-digested samples were separated 
on 1% agarose gel, electrophoresed at 90V for 2 hours and visualised. 
 
5.2.2.3 Site-directed mutagenesis 
A single point mutation (G>A) was introduced into the MYH7 cDNA sequence of 
pCMV6-XL4-MYH7, by PCR-based mutagenesis using the QuikChange II XL Site-
Directed Mutagenesis Kit (Stratagene®, La Jolla, CA, USA) according to the 
manufacturer’s instructions.  The introduced mutation changed a CGG codon 
sequence to a CAG sequence, resulting in a glutamine replacing the wild-type arginine 
at codon 403.  Mutagenic primers (Table 5.3) were designed according to the 
Stratagene® ‘mutagenic primer design’ guidelines and were obtained from 
GeneWorks.  In brief, reaction mixture contained 20 ng of the plasmid DNA template 
pCMV6-XL4-MYH7, 1X final concentration of reaction buffer, 125 ng of each mutagenic 
primer, 1 µL of dNTP mix, 3 µL of QuikSolution reagent, 2.5 U of PfuUltra High-Fidelity 
DNA polymerase, made up to a final volume of 50 µL with triple distilled water.  
Thermal cycling conditions were as follows: 95˚C for 1 minute; followed by 18 cycles of 
95˚C for 50 seconds, 60˚C for 50 seconds and 68˚C for 11 minutes; then a final 
extension incubation at 68˚C for 7 minutes.  Reaction mixture was subsequently held 
on ice for 2 minutes. 
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Table 5.3.  Oligonucleotides used for introducing the R403Q mutation into 
pCMV6-XL4-MYH7. 
Primer Direction Sequence 
MYH7 R403Q mut F Forward 5’-GCTGTGCCACCCTCAGGTGAAAGTGGGC-3’ 
MYH7 R403Q mut R Reverse 5’-GCCCACTTTCACCTGAGGGTGGCACAGC-3’ 
Target nucleotide altered by site-directed mutagenesis is highlighted in bold. 
 
10 U of DpnI restriction enzyme was added to the reaction mixture, mixed thoroughly 
by pipetting and incubated for 1 hour at 37˚C to digest the parental template DNA.  The 
DpnI-treated DNA was then transformed into E. coli XL10-Gold cells.  Transformation 
was carried out as described in Section 2.3.2, however 2 µL of beta-mercaptoethanol 
was added to 45 µL aliquot of cells prior to the addition of 2 µL of the DpnI-digested 
DNA, followed by a 30 second heat shock transformation.  Transformation mixture was 
added to 500 µL of pre-warmed SOC medium for 1 hour and subsequently plated onto 
LB agar plates containing 100 µg/mL of ampicillin, grown overnight at 37˚C.  Ampicillin 
was used for bacterial selection, as the pCMV6-XL4-MYH7 plasmid contains the 
ampicillin resistance gene.  Single bacterial colonies were selected for small-scale 
plasmid DNA preparations, followed by screening of plasmids by AvaI-digestion, 
visualisation of fragments by agarose gel electrophoresis and DNA sequencing. 
 
5.2.2.4 Restriction Enzyme digestion:  AvaI 
The presence of the R403Q mutation was confirmed by AvaI digestion in the mutated 
pCMV6-XL4-MYH7 plasmid samples.  AvaI was the enzyme of choice, as the mutation 
being introduced alters one base within the AvaI recognition site at this position.  
Digestion reaction mixture contained 1 µg of plasmid DNA, 10 U AvaI enzyme, 1X final 
concentration of NEB Buffer 4, made up to a total of 10 µL with triple distilled water.  
Samples were incubated for 5 hours at 37˚C in a Peltier Programmable Thermal 
Controller.  Digested samples were separated and visualised on a 1.5% agarose gel. 
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5.2.2.5 Polymerase chain reaction amplification of MYH7 cDNA 
Overlapping sections covering the entire MYH7 sequence were amplified by PCR, for 
plasmids pCMV6-XL4-MYH7 and pCMV-XL4-MYH7-R403Q, and visualised by gel 
electrophoresis.  PCR products subsequently underwent DNA sequencing (Section 
5.2.2.6).  Primers used for both PCR amplification and sequencing are shown in Table 
5.4.  PCR sample mixture contained 30 ng of plasmid DNA, 1X final concentration of 
GoTaq® Flexi Buffer, 1.5 mM MgCl2, 300 µM dNTPs, 1.4 µM forward primer, 1.4 µM 
reverse primer and 0.1 U of GoTaq® Flexi DNA Polymerase, made up to final volume 
of 25 µL with triple distilled water.  PCR cycling conditions were as follows: 95˚C for  
5 minutes; followed by 30 cycles of 95˚C for 30 seconds, 30 seconds at the appropriate 
annealing temperature, and 1 minute at 72˚C; and a final extension at 72˚C for 5 
minutes.  Annealing temperatures varied between PCRs and are shown in Table 5.4. 
 
Table 5.4.  Primers used for screening MYH7 cDNA by PCR amplification. 
Primer Direction Sequence Annealing 
location* 
Annealing 
temperature 
Amplicon 
size 
VP1.5 
MYH7 AR 
Forward 
Reverse 
5’-GGACTTTCCAAAATGTCG-3’ 
5’-ATTCTCCGGTGATCAGGATG-3’ 
-218 to -201 † 
519 to 538 
56˚C 756 bp 
MYH7 AF 
MYH7 BR 
Forward 
Reverse 
5’-CTCCGACAACGCCTATCAGT-3’ 
5’-TCGTAGGGGTTGTTGGTGAT-3’ 
471 to 490 
907 to 926 
64˚C 456 bp 
MYH7 BF 
MYH7 CR 
Forward 
Reverse 
5’-TCCAGCTGAAAGCAGAGAGAG-3’ 
5’-TCTCGATGAGGTCAATGCAG-3’ 
824 to 844 
1557 to 1576 
63˚C 753 bp 
MYH7 CF 
MYH7 DR 
Forward 
Reverse 
5’-GCTCTGCATCAACTTCACCA-3’ 
5’-AGCGCAAGTTGGTCATCAG-3’ 
1425 to 1444 
1972 to 1990 
66˚C 566 bp 
MYH7 DF 
MYH7 ER 
Forward 
Reverse 
5’-ACCCTGTTTGCCAACTATGC-3’ 
5’-CAGCGGCTTGATCTTGAAGT-3’ 
1855 to 1874 
2498 to 2517 
69˚C 663 bp 
MYH7 EF 
MYH7 FR 
Forward 
Reverse 
5’-AGGAAATGAGGGACGAGAGG-3’ 
5’-CTTCTCCTTGGTCAGCTTGG-3’ 
2321 to 2340 
2969 to 2988 
66˚C 668 bp 
MYH7 FF 
MYH7 GR 
Forward 
Reverse 
5’-TGATCTGGAGCTGACACTGG-3’ 
5’-AGGTCTGAGCGCAGCTTCT-3’ 
2865 to 2884 
3398 to 3416 
66˚C 552 bp 
MYH7 GF 
MYH7 HR 
Forward 
Reverse 
5’-GCTGCAGAAGAAGCTCAAGG-3’ 
5’-CTTCGCCTTAACCTCCTCCT-3’ 
3309 to 3328 
3959 to 3978 
69˚C 670 bp 
MYH7 HF 
MYH7 IR 
Forward 
Reverse 
5’-GGATGAGAAGGAGGCACTGA-3’ 
5’-GATGTTCCAGGGACTCCTCA-3’ 
3873 to 3892 
4464 to 4483 
67˚C 611 bp 
MYH7 IF 
MYH7 JR 
Forward 
Reverse 
5’-AAGTATGAGGAGTCGCAGTCG-3’ 
5’-GCGATGTTCTCCTTCAGGTC-3’ 
4375 to 4395 
4996 to 5015 
63˚C 641 bp 
MYH7 JF 
MYH7 KR 
Forward 
Reverse 
5’-CCCAGAAGCAAGTCAAGAGC-3’ 
5’-TGCAGCTTGTCTACCAGGTC-3’ 
4916 to 4935 
5596 to 5615 
69˚C 700 bp 
MYH7 KF 
XL39 
Forward 
Reverse 
5’-GTGAAGGGCATGAGGAAGAG-3’ 
5’-ATTAGGACAAGGCTGGTGGG-3’ 
5509 to 5528 
6057 to 6076 ‡ 
64˚C 568 bp 
*, Location where primers anneal is relative to the position of MYH7 cDNA start codon; 
†, VP1.5 is located upstream of the MYH7 cDNA insert; 
‡, XL39 is located downstream of the MYH7 cDNA insert. 
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5.2.2.6 DNA sequencing analysis 
TNNI3 and MYH7 PCR products amplified in Sections 5.2.2.1 and 5.2.2.5 underwent 
enzyme purification and subsequent DNA sequencing by Macrogen (Geumchen-gu, 
Seoul, Korea).  Enzyme purification removes contaminants from the PCR, including 
excess dNTPs and primers and enzymes.  Reaction mixture for purification included 
0.3 µL of Exonuclease I, 0.3 µL of Antarctic phosphatase (both from New England 
Biolabs; Beverly, MA, USA), and 3.4 µL of buffer (50 mM Tris-HCl), which was added 
to 20 µL of PCR product.  Samples were incubated at 37˚C for 30 minutes and 
enzymes inactivated by incubating at 80˚C for an additional 30 minutes.  Macrogen 
carried out standard DNA sequencing on these purified samples using the 
corresponding primers from Table 5.4, and sequencing data was analysed using 
Sequencher® version 4.8 (Gene Codes Corporation, Ann Arbour, MI, USA). 
 
5.2.3 Preparation of sarcomere cDNA inserts 
Preparation of TNNI3 and MYH7 inserts for cloning into expression vectors required 
the introduction of a 2A motif sequence immediately upstream of the start codon and a 
SalI site downstream of the stop codon, by PCR amplification using a high-fidelity DNA 
polymerase.  PCR products were digested with SalI, yielding a sticky end downstream 
of the sarcomere cDNA insert, allowing for directional cloning.  CDNA inserts required 
phosphorylation prior to ligation into the expression vector. 
 
5.2.3.1 Introduction of 2A sequence and SalI recognition site 
Primers used to introduce cloning sites are depicted in Table 5.5.  The first 21 
nucleotides of the forward primers contained the 2A sequence with the remaining 18 or 
20 nucleotides binding to the TNNI3 or MYH7 cDNA, respectively, from ATG start 
codon onwards.  Reverse primers contained the SalI recognition site, downstream of 
the stop codon. 
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Table 5.5.  Oligonucleotide sequences for the introduction of the 2A motif and 
SalI recognition sites flanking TNNI3 and MYH7. 
Primer Direction Sequence 
TNNI3 +2A F Forward 5’-GTGGAAGAAAACCCCGGGCCCATGGCGGATGGGAGCAGC-3’ 
TNNI3 SalI R Reverse 5’-AATGTCGACGCAGTAGGCAGGAAGGCT-3’ 
MYH7 +2A F Forward 5’-GTGGAAGAAAACCCCGGGCCCATGGGAGATTCGGAGATGGC-3’ 
MYH7 SalIR Reverse 5’-AAAGAGTCGACTACTCCTCATTCAAGCCC-3’ 
Red, indicates 2A sequence; bold, anneals to cDNA template; purple, SalI site; underlined, 
sequence encoding start or stop codon. 
 
Reaction mixture for the TNNI3 PCR contained 20 ng of plasmid DNA (either YFP-TNI 
or YFP-TNI-203), 1X final concentration of GC buffer, 200 µM dNTPs, 0.5 µM forward 
primer ‘TNNI3 +2A F’, 0.5 µM reverse primer ‘TNNI3 SalI R’, 3% DMSO and 2 U of 
high-fidelity DNA polymerase Phusion II, made up to a final volume of 100 µL with 
DEPC-treated water.  PCR cycling conditions were as follows: 98˚C for 30 seconds; 
followed by 35 cycles of 98˚C for 10 seconds, 70˚C for 30 seconds and 72˚C for 25 
seconds; then 72˚C for 10 minutes.   
 
MYH7 PCR contained 20 ng of plasmid DNA (either pCMV6-XL4-MYH7 or pCMV-XL4-
MYH7-R403Q), 1X final concentration of GC buffer, 200 µM dNTPs, 0.5 µM forward 
primer ‘MYH7 +2A F’, 0.5 µM reverse primer ‘MYH7 SalI R’, 3% DMSO and 2 U of 
Phusion II, made up to a final volume of 100 µL with DEPC-treated water.  PCR cycling 
conditions were as follows: 98˚C for 30 seconds; followed by 35 cycles at 98˚C for 10 
seconds, 70˚C for 30 seconds and 72˚C for 3 minutes; then 72˚C for 10 minutes. 
 
5.2.3.2 Gel extraction and purification 
PCR products from Section 5.2.3.1 were separated by agarose gel electrophoresis, 
and the appropriate size band was excised and purified using QIAquick Gel Extraction 
Kit Protocol, according to the manufacturer’s instructions (Qiagen).  The correct DNA 
band sizes for cDNA inserts with 2A and SalI sites incorporated, were 5838 bp for 
MYH7 and 681 bp for TNNI3.  In brief, the appropriate DNA band was excised, placed 
in a tube, and Buffer QG was added at a three-fold quantity to the gel weight excised.  
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Samples were incubated at 50˚C for 10 minutes, with vortexing, to dissolve gel.  
Isopropanol was added at a volume equivalent to the excised gel weight and pipetted 
to mix.  Reaction mixture was passed through a QIAquick spin column by 
centrifugation, allowing DNA to bind to the column membrane.  Column was then 
washed with 0.5 mL Buffer QG, and subsequently with 0.75 mL Buffer PE, passing 
through the column membrane by centrifugation.  50 µL of DEPC-treated water was 
added to the membrane, incubated at room temperature for 10 minutes, and 
centrifuged for 1 minute at >10,000 xg to elute DNA. 
 
5.2.3.3 Restriction enzyme digestion:  SalI 
Gel extracted and purified PCR products from Section 5.2.3.2 were digested with SalI 
restriction enzyme, which cleaves the sugar-phosphate DNA backbone at position 
G^TCGAC (^, denotes cleavage site).  This cleavage resulted in a four nucleotide  
5’ overhang and left the phosphate group on the 5’ end and a hydroxyl group on the  
3’ end of the strand.  TNNI3 cDNA products were digested in the following sample 
reaction mixture:  15 µL of gel extracted product, 1X final concentration of Buffer 3 
(New England Biolabs), 0.1 µg of BSA, 60 U of SalI, made up to 100 µL with DEPC-
treated water.  Samples were incubated at 37˚C for 16 hours, followed by 65˚C for 20 
minutes to heat inactivate the restriction enzyme. 
 
Similarly, MYH7 cDNA products were digested, however a greater amount of cDNA 
was used.  Reaction mixture contained 50 µL of gel extracted product, 1X final 
concentration of Buffer 3, 0.5 µg of BSA, 200 U of SalI, made up to 200 µL total 
volume, with DEPC-treated water.  Samples were incubated at 37˚C for 16 hours, 
followed by 65˚C for 20 minutes. 
 
To eliminate the restriction enzyme after digestion, products were cleaned up using 
QIAquick PCR Purification Kit Protocol, according to the manufacturer’s instructions 
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(Qiagen).  In brief, 500 µL of Buffer PB was added to each 100 µL of SalI-digested 
sample.  The DNA sample was applied to QIAquick column and centrifuged briefly 
(12,000 xg) to allow DNA to bind to the column membrane.  Buffer PE was added to 
the column and centrifuged to wash the membrane.  The column was centrifuged for 
an additional minute to remove residual ethanol from the previous step.  DNA was 
eluted from the column by applying DEPC-treated water to the membrane (50 µL for 
TNNI3 samples, 40 µL for MYH7 samples), standing for 5 minutes, and centrifuging for 
1 minute. 
 
5.2.3.4 Phosphorylation of TNNI3 and MYH7 cDNA inserts 
By this step, the TNNI3 and MYH7 cDNA inserts were blunt-ended upstream of the 2A 
sequence and had a sticky-end downstream of the cDNA insert.  This allowed for 
directional cloning into the expression vector.  The insert needed to be phosphorylated 
at both ends to successfully ligate into the (dephosphorylated) expression vector.  The 
sticky end was phosphorylated by SalI digestion, but to phosphorylate the blunt-end of 
the insert, T4 Polynucleotide Kinase (T4 PNK) was used to catalyse the transfer of the 
γ-phosphate from ATP (ATP was contained in the buffer solution), to the 5’-terminus of 
the DNA.   
 
SalI-digested DNA was denatured, by incubating at 95˚C for 5 minutes prior to 
phosphorylation.  Reaction mixtures contained denatured DNA (6 µL for TNNI3 
samples or 17 µL for MYH7 samples), 1X final concentration of T4 DNA ligase buffer 
and 10 U of T4 PNK (both buffer and enzyme from New England Biolabs Inc), and 
were incubated at 37˚C for 30 minutes, followed by 65˚C for 20 minutes to inactivate 
the enzyme.  Phosphorylated samples were held on ice until ligation into the 
expression vector (<1 hour). 
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5.2.4 Preparation of the empty vector insert 
‘Empty vector’ (EV) control inserts were designed which contained the 2A sequence, a 
stop codon, and a site for allowing sticky end ligation complementary to the SalI 
sequence into expression vectors in subsequent steps.  To create the EV insert, 
oligonucleotides were designed as shown in Table 5.6.  These were phosphorylated 
separately then annealed together, before being ligated into expression vectors. 
 
Table 5.6.  Oligonucleotides for empty vector control insert. 
Primer Direction Sequence 
EV-F Forward 5’-GTGGAAGAAAACCCCGGGCCCTGAG-3’ 
EV-R Reverse 5’-TCGACTCAGGGCCCGGGGTTTTCTTCCAC-3’ 
Red, indicates 2A sequence; underlined, stop codon; purple, SalI site (overhang). 
 
Oligonucleotides were phosphorylated as follows:  reaction mixture contained  
0.5 nmoles of EV-F or EV-R oligonucleotide, 1X final concentration of T4 DNA ligase 
buffer and 10 U of T4 PNK, made up with DEPC-treated water to a total 20 µL, and 
incubated as per Section 5.2.3.4.  Phosphorylated oligonucleotides were annealed 
together by combining 10 µL of each reaction, incubating at 95˚C for 1 minute, then 
decreasing incubation temperature by 1˚C per 30 seconds until 18˚C was reached.  
The resulting phosphorylated, double-stranded insert was then ligated into lentiviral 
vectors. 
 
5.2.5 Preparation of the lentiviral vector 
Vectors pHIV1SDm-CMV-Cherry-2A-luc and pHIV1SDm-CMV-GFP-2A-luc were 
described in Section 5.2.1.  The luciferase gene was removed from each of the cloning 
vectors and replaced with sarcomere inserts TNNI3 and MYH7, respectively.  SalI and 
BmgBI recognition sites flank the luciferase gene.  To remove this gene, vectors were 
digested with SalI and BmgBI, fragments separated by agarose gel electrophoresis and 
the appropriate band containing the cloning vector was extracted (leaving the fragment 
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containing the luciferase gene in the gel).  The lentiviral vectors were purified and 
dephosphorylated to prevent self-ligation. 
 
5.2.5.1 Restriction enzyme digestion:  SalI and BmgBI 
Digestion of pHIV1SDm-CMV-Cherry-2A-luc with BmgBI and SalI yields two fragments 
of size 1672 bp and 7618 bp, corresponding with the luciferase gene and cloning 
plasmid, respectively.  Digestion of pHIV1SDm-CMV-GFP-2A-luc results in three DNA 
fragments, sized 1672, 7594 and 24 bp, corresponding to the luciferase gene, the 
cloning plasmid and an additional 24 bp fragment downstream of the luciferase insert 
which is non-functional and was intentionally removed from the cloning plasmid in this 
study.  BmgBI cleaves DNA at position CAC^GTC (^, denotes cleavage site), resulting 
in blunt end digestion just upstream of the luciferase gene, with the SalI enzyme 
downstream of the luciferase stop codon. 
 
The digestion reaction contained 16 µg of plasmid DNA, 1X final concentration of 
Buffer 3 (New England Biolabs), 15 µg of BSA, 30 U of BmgBI and 60 U of SalI.  
Reaction mixture was incubated at 37˚C for 16 hours, followed by 20 minutes at 65˚C.  
Digested products were visualised on a 1.5% agarose gel, and the DNA band that 
represented the lentiviral vector (7618 bp for pHIV1SDm-CMV-Cherry and 7594 bp for 
pHIV1SDm-CMV-GFP) was excised and purified as per Section 5.2.3.2. 
 
5.2.5.2 Dephosphorylation of lentiviral vector 
Vectors were dephosphorylated to prevent self-annealing.  Antarctic phosphatase 
catalyses the removal of the 5’ phosphate groups from DNA.  The reaction mixture 
included 5 µg of lentiviral vector, 1X final concentration of Antarctic Phosphatase 
Reaction Buffer (New England Biolabs), 15 U of Antarctic phosphatase, made up to a 
total volume of 100 µL.  Reaction mixture was incubated at 37˚C for 1 hour, followed by 
5 minutes at 65˚C to heat inactivate the enzyme.  To concentrate DNA and remove 
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enzyme and reaction buffers, the entire reaction mixture was purified using QIAquick 
PCR purification kit (Section 5.2.3.3) and eluted in 25 µL of DEPC-treated water. 
 
5.2.6 Cloning of sarcomere inserts into lentiviral vectors 
TNNI3, MYH7 and EV phosphorylated inserts were directionally cloned into the vectors 
as outlined in Table 5.7.  Ligation reaction mixture contained 0.5 µL of 
dephosphorylated vector, 8 µL of phosphorylated insert, 1X final concentration of T4 
ligase buffer, 200 U of T4 ligase, and made to a total volume of 10 µL with DEPC-
treated water.  Ligation reaction mixture was incubated at 16˚C overnight and 
subsequently transformed into E. coli DH10β cells (25 µL) as per Section 2.3.2 and 
cultured on LB plates containing chloramphenicol. 
 
Table 5.7. Lentiviral transfer vectors: insert and vector components 
Insert Vector Resulting lentiviral transfer vector 
EV pHIV1SDm-CMV-Cherry pHIV1SDm-CMV-Cherry-2A-EV 
TNNI3-WT pHIV1SDm-CMV-Cherry pHIV1SDm-CMV-Cherry-2A-TNNI3-WT 
TNNI3-G203S pHIV1SDm-CMV-Cherry pHIV1SDm-CMV-Cherry-2A-TNNI3-G203S 
EV pHIV1SDm-CMV-GFP pHIV1SDm-CMV-GFP-2A-EV 
MYH7-WT pHIV1SDm-CMV-GFP pHIV1SDm-CMV-GFP-2A-MYH7-WT 
MYH7-R403Q pHIV1SDm-CMV-GFP pHIV1SDm-CMV-GFP-2A-MYH7-R403Q 
EV, ‘empty vector’ insert. 
 
5.2.7 Screening of transformants 
Single DH10β colonies were grown in LB (with chloramphenicol) and small-scale DNA 
preparations were made, screened by AvaI digestion (reaction mixture as per Section 
5.2.2.3) and fragments visualised by agarose gel electrophoresis.  Of the samples that 
passed the initial AvaI screening, one large-scale DNA preparation for each of the six 
transfer vectors were made and subsequently sequenced, in part, to confirm the 
sarcomere cDNA inserts were in frame and inserted in the correct direction.  
Sequencing was carried out on 5 µL of plasmid vector using the oligonucleotides 
described in Table 5.8, which were designed to anneal within the cloning vector, up- 
and down-stream of the cDNA inserts. 
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Table 5.8.  Primers used for sequencing transfer vectors.  
Primer Direction Sequence 
eGFP Cterm seq Forward 5’- AAGACCCCAACGAGAAGCG-3’ 
mCherry Cterm seq Forward 5’- CCATTATGATGCCGAAGTC-3’ 
wpre rev seq Reverse 5’- CAGCGTATCCACATAGCGT-3’ 
 
5.2.8 Transfection of HEK293T cells with lentiviral transfer vectors 
Once sequencing confirmed DNA inserts were correctly cloned into their relevant 
vectors, the lentiviral transfer vectors were transfected into HEK293T cells to 
investigate the expression of fluorescent reporters and the sarcomere genes of 
interest. 
 
5.2.8.1 Transfection of HEK293T cells 
HEK293T cells were transfected with lentiviral transfer vectors, using 
Lipofectamine™2000 (Invitrogen) according to the manufacturer’s instructions.  In brief, 
HEK293T cells were seeded on 6-well plates at a density of 2x105 cells per well in  
2 mL of Complete Medium (described Section 2.4.2) and grown for 18 hours prior to 
transfection.  Transfection complexes were prepared as follows:  4.0 µg of vector DNA 
was combined with 250 µL Opti-Mem I Reduced Serum Medium (Invitrogen) and mixed 
gently by pipetting.  In a separate tube, 10 µL of Lipofectamine™2000 was combined 
with 250 µL Opti-Mem I Reduced Serum Medium and mixed gently.  Both mixtures 
were incubated for 5-10 minutes at room temperature.  Following incubation, DNA/Opti-
Mem and Lipofectamine/Opti-Mem mixtures were combined, mixed by pipetting and 
incubated at room temperature for 20 minutes.  500 µL of DNA/Lipofectamine/Opti-
Mem mixture was added to each well containing HEK293T cells.  Medium was 
replaced with Complete Medium after 6 hour incubation in the 37˚C CO2 incubator.  
Cells were grown for an additional 42 hours prior to fluorescence microscopy or protein 
harvest. 
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5.2.8.2 Fluorescence microscopy 
To investigate the expression of fluorescent reporters, HEK293T cells were visualised 
using a Nikon Eclipse E800 fluorescence microscope (Nikon Instech, Kanagawa, 
Japan).  Prior to visualization, media was removed and replaced with  
2 mL of PBS per well.  Microscopic images were captured with PCO Sensicam CCD 
camera (PCO computer optics, Kelheim, Germany). 
 
5.2.8.3 Protein extraction from cell culture 
HEK293T cells were trypsinised, counted and 6.5 x 105 cells were pelleted by 
centrifugation at 500 xg for 5 minutes, at 4˚C.  Supernatant was removed and cells 
washed by resuspension of pellet in 1 mL of cold PBS and centrifugation as before.  
Supernatant was removed and discarded, and the remaining pellet was resuspended in 
150 µL of Normal lysis buffer (Table 5.9) containing protease inhibitor (Complete 
ULTRA, EDTA-free protease inhibitor cocktail tablets; Roche Diagnostics, Mannheim, 
Germany).  Cells in normal lysis buffer were incubated on ice for 20 minutes to allow 
for lysing of cells while keeping the proteins cold and intact.  The lysis mixture was 
centrifuged at 13000 xg for 20 minutes at 4˚C to pellet cellular debris, and the 
supernatant (containing protein) was harvested and used for western blotting analysis. 
 
Table 5.9.  Recipe for normal lysis buffer 
Reagent Final Concentration 
HEPES 
Sodium chloride 
Glycerol 
Triton X-100 
Magnesium chloride 
EGTA 
Sodium pyrophosphate 
Sodium fluoride 
50 mM, pH 7.5 
150 mM 
10% 
1% 
1.5 mM 
1 mM 
10 mM 
100 mM 
 
HEPES, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); EGTA, ethylene glycol-bis(2-
aminoethylether)-N,N,N’,N’-tetraacetic acid.  All reagents were supplied by Sigma-Aldrich (St. 
Louis, MO, USA). 
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5.2.8.4 Western blotting for sarcomere proteins 
Polyacrylamide gel electrophoresis was carried out as per Section 3.2.10.3.  13 µL of 
reduced and heated protein samples from HEK293T cells were loaded into gels 
(NuPAGE® Novex 12%/4% Bis-Tris Gels).  Western blotting analysis was carried out 
as per Section 3.2.10.4, with the antibodies adjusted accordingly.  Primary antibody 
incubations were carried out overnight at 4˚C and secondary antibody incubations were 
at room temperature for 1 hour. 
 
For detecting cardiac troponin I (cTnI) protein, membrane was probed with goat 
polyclonal antibody raised against the C-terminal epitope of human cTnI (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA) diluted 1:200 in antibody solution.  The 
secondary HRP-conjugated antibody used was rabbit-anti-goat, diluted 1:1000 (Dako, 
Carpinteria, CA, USA). 
 
Western blotting for cardiac myosin heavy chain beta (MHC-β) employed monoclonal 
mouse primary antibody, raised against MHC-β (Abcam, Cambridge, MA, USA) at a 
1:200 dilution, and secondary HRP-conjugated rabbit-anti-mouse antibody was used at 
a 1:2000 dilution (Dako, Carpinteria, CA, USA). 
 
 
5.2.9 Production of lentiviral particles 
To infect the HL-1 cell line, lentiviral particles were produced using HEK293T 
packaging cells.  Production of the lentivirus, involved the transfection of the lentiviral 
transfer vector (see Table 5.7) and ‘helper constructs’ shown in Figure 5.3, into the 
HEK293T cells.  Supernatant containing the viral particles were then harvested and 
concentrated by ultracentrifugation. 
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5.2.9.1 Calcium phosphate transfection 
HEK293T cells were seeded at a density of 5 x 106 cells per 150 mm dish, in 20 mL of 
Complete Medium and incubated overnight (approximately 16 hours).  Ms Cynthia Ng 
from the Gene Therapy Laboratory at Centenary Institute (Sydney, NSW, Australia) 
carried out the following methods.  Medium was aspirated and replaced with 20 mL of 
fresh, Complete Media containing 25 µM of chloroquine and incubated for one hour 
prior to transfection.  For calcium phosphate transfection, four buffers were required 
and are detailed in Table 5.10. 
 
Table 5.10.  Buffers used in calcium phosphate transfection protocol 
 
For each dish, a single lentiviral transfer vector was transfected along with four helper 
constructs, which are required for packaging of the lentivirus in the HEK293T 
packaging cells.  Buffers in Table 5.10 were used to make up two solutions for this 
transfection process.  For each dish, Solution A was made up consisting of 16.66 µL of 
phosphate buffer and 3.33 mL of HEPES buffer.  Plasmid DNA (0.6 µg 
pcDNA3.1tat101ml, 0.6 µg pHCMVwhvrevml, 3 µg pHCMVwhvgagpolml, 1.5 µg 
pHCMV-G, 30 µg of the transfer vector) was diluted in 3.0 mL of 1/10 TE buffer.  
Solution B was composed of 333 µL of calcium chloride buffer and the TE buffer 
containing DNA. 
 
Buffer Final Concentration 
Phosphate buffer 
195 mM Na2HPO4 
105 mM NaH2PO4 
pH 7.05 
HEPES buffer 
140 mM NaCl 
50 mM HEPES 
pH 7.05 
Calcium chloride buffer 2.5 M CaCl2 
1/10th TE buffer 
1 mM Tris-HCl 
0.1 mM EDTA 
0.2 pH 7.6 
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Both solutions were briefly vortexed, and Solution B was dripped slowly into Solution A, 
vortexed and incubated at room temperature for 1 minute to allow for precipitates to 
form.  The calcium phosphate precipitate mixture was carefully dripped onto the cells 
and incubated at 37˚C overnight.  Medium was removed the following day and replaced 
with 20 mL of the supplemented DMEM medium containing 5 mM sodium butyrate. 
 
Figure 5.3.  Helper constructs used in lentiviral packaging (Koldej et al., 2005).  
CMV, simian CMV (cytomegalovirus) immediate early promoter; hCMV, human 
cytomegalovirus immediate early promoter;	   , tat coding sequence; , bovine growth 
hormone gene polyadenylation signal; dashed line, splicing signals from rabbit β-globin 
gene; whv, woodchuck hepatitis virus post-transcriptional regulatory element; , rabbit 
β-globin polyadenylation signal; , the rev coding sequence; gagpolml, codon-
optimised gagpol gene; VSV-G, vesticular stomatitis virus G glycoprotein coding 
sequence.   
 
5.2.9.2 Preparation of virus 
Following media change, cells were incubated for 24 hours.  After this time, the cells 
were visualised by fluorescence microscopy to visually confirm Cherry or GFP 
expression.  At this stage, the media now contained the lentivirus, packaged by the 
HEK293T cells.  This media (‘viral supernatant’) was harvested and filtered through a 
0.45 µm syringe filter to remove any of the packaging cells.  Virus was concentrated by 
ultracentrifugation at 26,000 rpm for 2 hours, at 4˚C in a SW28 Beckman rotor.  
Supernatant was aspirated and the viral pellet was resuspended in 200 µL of Complete 
Chapter 5.  Development of Lentiviral Particles for the Introduction of HCM-Causing Mutations 
    152 
Medium.  Concentrated virus was aliquotted and snap frozen in liquid nitrogen.  
Aliquots were stored at -80˚C (until thawing for transduction of HL-1 cells).  
 
5.2.10 Transduction of HL-1 cells 
HL-1 cells were seeded at 4x105 cells per well in a 6-well plate and incubated for 24 
hours prior to lentiviral transduction.  Ms Cynthia Ng or Dr Charles Bailey from the 
Gene Therapy Laboratory at Centenary Institute (Camperdown, NSW, Australia) 
carried out lentiviral transduction, as follows.  Medium was aspirated and replaced with 
2 mL fresh supplemented Claycomb medium, containing 8 µg/mL of polybrene and the 
lentivirus.  Viruses were named dependent on the reporter and transgene.  To 
approximate an appropriate amount of virus to use for the transduction of HL-1 cells, 
various amounts of the concentrated ‘empty vector GFP’ control virus (GFP-EV) were 
transduced for each well; 0 µL, 0.5 µL, 1 µL, 2.5 µL, 5 µL or 10 µL.  Plates were spun 
at 500 xg for 1.5 hours at room temperature.  Cells were incubated for 24 hours prior to 
analysis by flow cytometry. 
 
‘Empty vector Cherry’ control virus (Cherry-EV) and viruses containing wild type- or 
G203S- mutated TNNI3 coding sequence (Cherry-TNNI3-WT and Cherry-TNNI3-
G203S, respectively) were transduced into HL-1 cells as described here, however 
using 5 µL for each virus. 
 
5.2.11 Flow cytometry 
Flow cytometry was carried out by Cynthia Ng from the Gene Therapy Laboratory at 
Centenary Institute.  HL-1 cells were trypsinised and pelleted.  Supernatant was 
aspirated and the pellet resuspended in 200 µL of FACS wash (2 mM EDTA, 2% FCS 
in PBS).  Cells were analysed using the BD LSR Fortessa Cell Analyser (BD 
Biosciences, CA, USA).  Flow cytometry data was subsequently analysed using FlowJo 
software (TreeStar, OR, USA).  
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5.3 RESULTS 
5.3.1 Verification of template DNA 
The TNNI3 sequence in YFP-TNI and YFP-TNI-203 plasmids were verified by PCR 
amplification and DNA sequencing.  pCMV6-XL4-MYH7 plasmids extracted from single 
colonies were screened by restriction enzyme digestion, the missense mutation R403Q 
was subsequently introduced into MYH7, and both wild-type (WT) and mutated 
plasmids were screened by AvaI digestion, PCR amplification and DNA sequencing. 
 
5.3.1.1 PCR amplification of TNNI3 cDNA 
TNNI3 amplified PCR products from YFP-TNI and YFP-TNI-203 plasmids were 
examined by agarose gel electrophoresis, and showed one clear band at the expected 
amplicon size of approximately 722 bp (Figure 5.4).  Negative control samples for the 
PCR showed no DNA contamination. 
 
 
 
 
 
 
 
 
 
Figure 5.4.  PCR amplification of TNNI3 from plasmids.  Lane 1, DNA molecular 
weight marker IX (Roche); lane 2, PCR product from YFP-TNI template; lane 3, PCR 
product from YFP-TNI-203 template; lane 4, negative control.  bp, base pairs. 
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5.3.1.2 DNA sequencing of TNNI3 cDNA 
DNA sequencing verified that the entire TNNI3 cDNA sequence was present and 
correct in YFP-TNI and YFP-TNI-203 plasmids.  Sequencing analysis confirmed the 
presence of the G203S mutation in TNNI3 insert of YFP-TNI-203 plasmid, which was 
not present in the YFP-TNI plasmid (Figure 5.5). 
 
 
 
 
 
 
Figure 5.5.  Chromatograms for TNNI3 sequence encoding codon 203 in 
plasmids (A) YFP-TNI and (B) YFP-TNI-203.  At this position, YFP-TNI sequence is 
GGC which encodes for the amino acid glycine, whereas the YFP-TNI-203 plasmid 
sequence is AGC encoding for the amino acid serine. 
 
5.3.1.3 Digestion of pCMV6-XL4-MYH7 with XbaI 
Following transformation of pCMV6-XL4-MYH7 into E.coli TOP10 cells, small-scale 
DNA preparations from single bacterial colonies were linearised with restriction enzyme 
XbaI and visualised by agarose gel electrophoresis.  All samples exhibited a single 
band of the correct plasmid size (10,696bp), as shown in Figure 5.6. 
 
 
 
 
 
 
 
Figure 5.6.  XbaI-digested mini-prep DNA extracted from single bacterial 
colonies.  Lane 1, DNA molecular weight marker II (Roche); lanes 2-11, DNA samples 
from bacterial colonies 1 to 10.  bp, base pairs. 
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5.3.1.4 Site-directed mutagenesis: screening plasmids by AvaI digestion 
Plasmid DNA was extracted from single E. coli XL10-Gold colonies transformed with 
pCMV6-XL4-MYH7 plasmids that had undergone site-directed mutagenesis.  Plasmid 
DNA samples were digested with AvaI, fragments visualised by agarose gel 
electrophoresis and banding patterns indicated samples in which the R403Q mutation 
had been successfully introduced (Figure 5.7).  Nine mutated samples were analysed: 
four samples exhibited a banding pattern consistent with the successful introduction of 
the R403Q mutation (lanes 5, 7, 8, 11; fragment sizes 3872, 1835, 1745, 1044, 696, 
486, 294, 279, 251 and 193 base pairs), three samples had a banding pattern 
consistent for the non-mutated parental plasmid (lanes 10, 12, 13; fragment sizes 
3872, 1835, 1170, 1044, 696, 575, 486, 294, 279, 251 and 193 base pairs), and two 
samples had unexpected fragment banding patterns (lanes 6, 9).  Digested fragments 
for parental samples were correct (lanes 2, 3, 4).  The MYH7 cDNA sequence was 
further verified by PCR and DNA sequencing for samples indicated (*) and these were 
used as the DNA template for further cloning throughout this study. 
Figure 5.7.  Agarose gel of AvaI-digested mutated and non-mutated pCMV6-XL4-
MYH7 plasmids.  Banding patterns are shown on the right.  Lane 1, hyperladder I; 
lane 2-4, parental pCMV6-XL4-MYH7 samples; lanes 5-13, plasmid samples that arise 
from site-directed mutagenesis procedure.  *, indicates samples used for further 
cloning procedures. 
*	   *	  
Parental    Post-mutagenesis   WT  R403Q 
1       2       3       4       5       6      7      8       9     10     11    12    13 *                                  * 
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5.3.1.5 PCR amplification of MYH7 cDNA 
Overlapping sections of MYH7 sequence were amplified by PCR, from pCMV6-XL4-
MYH7 and pCMV6-XL4-MYH7-R403Q plasmids.  Each of these reactions yielded a 
single PCR product of the expected size, when visualised by agarose gel 
electrophoresis (Figure 5.8).  Negative control samples for all PCRs showed no DNA 
contamination.  PCR products were subsequently analysed by DNA sequencing. 
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Figure 5.8.  PCR amplification of sections of MYH7 from pCMV6-XL4-MYH7 and 
pCMV6-XL4-MYH7-R403Q templates.  (A) Design of PCR amplification, showing 
primer binding location.  Blue text, indicates forward primer; red text, indicates reverse 
primer; blue box, shows the section amplified by PCR.  (B) MYH7 PCR products: lane 
1, Marker IX (Roche); lane 2, PCR product amplified from the pCMV6-XL4-MYH7 
template; lane 3, PCR product amplified from the pCMV6-XL4-MYH7-R403Q template; 
lane 4, negative control. 
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5.3.1.6 DNA sequencing of MYH7 
DNA sequencing verified that the MYH7 coding sequence was entirely present and 
correct in pCMV6-XL4-MYH7 and pCMV6-XL4-MYH7-R403Q.  Sequencing analysis 
confirmed the correct introduction of the missense mutation R403Q into the MYH7 in 
pCMV6-XL4-MYH7-R403Q, which was not present in the parental plasmid (Figure 5.9).  
No other mutations were introduced in the mutagenesis process. 
 
 
 
 
 
 
Figure 5.9. Chromatograms for MYH7 sequence encoding codon 403 in plasmids 
(A) pCMV6-XL4-MYH7 and (B) pCMV6-XL4-MYH7-R403Q.  At this position, pCMV6-
XL4-MYH7 sequence is CGG, which encodes for the amino acid arginine, whereas 
mutated plasmid pCMV6-XL4-MYH7-R403Q, has the sequence CAG, which encodes 
for glutamine. 
 
5.3.2 Preparation of sarcomere cDNA inserts; TNNI3 and MYH7 
The 2A motif sequence was introduced immediately upstream of the ATG start codon 
of both TNNI3 and MYH7 sequences, and SalI sites were introduced downstream of 
their stop codons by PCR amplification.  To avoid the contamination of any non-specific 
PCR products being used in subsequent cloning steps, TNNI3 and MYH7 PCR 
products were visualised by agarose gel electrophoresis (Figure 5.10) and the 
appropriate sized products were excised and purified.  The correct PCR product size is 
681 bp and 5838 bp for TNNI3 and MYH7, respectively.  Gel extracted PCR products 
appeared as a single band of the expected size when visualised by agarose gel 
electrophoresis (Figure 5.11). 
A                           B 
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Figure 5.10. Agarose gels of PCR amplified products, in which the 2A sequence 
and SalI recognition sites were introduced for (A) TNNI3 and (B) MYH7.  (A) Lane 
1, hyperladder I; lane 2 and 3, PCR product amplified from plasmid templates YFP-TNI 
and YFP-TNI-203, respectively.  (B) Lane 1, Hyperladder I; lanes 2 and 3, PCR product 
amplified from pCMV6-XL4-MYH7 and pCMV6-XL4-MYH7-R403Q, respectively. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5.11.  Gel-extracted and purified PCR products, containing the 2A 
sequence and SalI site.  Lane 1, hyperladder 1.  Lanes 2 and 3, TNNI3 (+2A/SalI) 
purified PCR product for unmutated TNNI3 and G203S-mutated TNNI3, respectively.  
Lanes 4 and 5, MYH7 (+2A/SalI) purified PCR product for unmutated MYH7 and 
R403Q-mutated MYH7 , respectively. 
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5.3.3 Preparation of lentiviral vectors 
Vectors pHIVSDm-CMV-Cherry-2A-luc and pHIV1SDm-CMV-2A-luc were described in 
Section 5.2.1.  The luciferase sequence (1672 bp) was removed from the cloning 
vectors by digestion with SalI and BmgBI, which cleave DNA either side of the 
luciferase cDNA insert.  Digested plasmid fragments were separated by agarose gel 
electrophoresis (Figure 5.12).  pHIV1SDm-CMV-Cherry-2A-luc was digested into two 
fragments, of 1672 and 7618 bp, with the latter corresponding to the lentiviral transfer 
vector.  Digestion of the pHIV1SDm-CMV-GFP-2A-luc yielded 3 fragments, of sizes 24, 
1672 and 7594 bp, again with the largest fragment being the cloning vector.  The 
appropriate DNA band containing the vector (~7600 bp) was extracted from the gel, 
purified and the resulting product was visualised by agarose gel electrophoresis (Figure 
5.13), showing a single band of the correct size.  The vectors were subsequently 
dephosphorylated to prevent self-annealing, prior to ligation with sarcomere cDNA 
inserts. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12.  Agarose gel of plasmid fragments following digestion with SalI and 
BmgBI.  Lane 1, hyperladder I; Lane 2, digested pHIV1SDm-CMV-Cherry-2A-luc; Lane 
3, digested pHIV1SDm-CMV-GFP-2A-luc. 
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Figure 5.13.  Agarose gel of purified lentiviral cloning vectors.  Lane 1, 
hyperladder I; lane 2, pHIV1SDm-CMV-Cherry; lane 3, pHIV1SDm-CMV-GFP. 
 
5.3.4 Screening of transformants 
Sarcomere or EV control inserts were ligated into lentiviral vectors as per Table 5.7, 
transformed into E. coli DH10β cells and small-scale plasmid preparations were 
screened.  Plasmid maps for lentiviral transfer vectors are shown in Figure 5.14.  To 
screen, DNA preparations were digested with AvaI and visualised by agarose gel 
electrophoresis.  pHIV1SDm-CMV-Cherry-2A-TNNI3 (WT and G203S) have six AvaI 
restriction sites, which are located at positions 971, 1010, 4041, 4178, 4531 and 4724.  
Digestion yields six fragments of sizes 4538, 3031, 353, 193, 137 and 39 bp.  Four 
pHIV1SDm-CMV-Cherry-2A-TNNI3-WT and four pHIV1SDm-CMV-Cherry-2A-TNNI3-
G203S clones were examined and all were found to have a fragment pattern consistent 
with the correctly cloned vector (Figure 5.15). 
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Figure 5.14.  Plasmid maps of lentiviral transfer vectors used within this study.   
(A), pHIV1SDm-CMV-Cherry-2A-TNNI3, contains the TNNI3 cDNA sequence, with 
location of the G203S mutation shown.  (B), pHIV1SDm-CMV-GFP-2A-MYH7 contains 
the MYH7 cDNA sequence, with location of R403Q mutation shown.  (C) pHIV1SDm-
CMV-Cherry-2A-EV and (D) pHIV1SDm-CMV-GFP-2A-EV, contain the empty vector 
(EV) ‘insert’ consisting of 2A sequence, stop codon, and SalI cloning site.  Vectors 
contain 5’ and 3’ LTRs, long-terminal repeats; RRE, rev response element; ccpt, 
central polypurine tract; CMV, cytomegalovirus promoter; eGFP, enhanced green 
fluorescent protein; mCherry, monomeric red (cherry) fluorescent protein; 2A, porcine 
teschovirus-1 2A motif; wpre, woodchuck hepatitis post-transcriptional regulatory 
element; and self-inactivating (SIN) 3’LTR. 
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Figure 5.15.  AvaI-digested fragments of pHIV1SDm-CMV-Cherry-2A-TNNI3 
plasmid samples.  Lane 1, hyperladder 1; lanes 2-5, pHIV1SDm-CMV-Cherry-2A-
TNNI3-WT; lanes 6-9, pHIV1SDm-CMV-Cherry-2A-TNNI3-G203S. 
 
pHIV1SDm-CMV-GFP-2A-MYH7-WT has 12 AvaI recognition sites, at positions 971, 
1010, 4005, 4171, 4364, 4643, 5218, 6388, 7432, 8169, 9857.  Digestion of this 
plasmid with AvaI generates 12 fragments; 4539, 2995, 1688, 1170, 1044, 575, 486, 
279, 251, 193, 166 and 39 bp in size.  The R403Q sarcomere mutation results in 
disruption of the AvaI site at plasmid position 5218, thus digestion of pHIV1SDm-CMV-
GFP-2A-MYH7-R403Q results in 11 fragments; 4539, 2995, 1745, 1688, 1044, 483, 
279, 251, 193, 166 and 39 bp.  AvaI digestion of both expression vectors resulted in 
fragments of the correct size (Figure 5.16). 
 
 
 
 
 
 
 
 
 
 
Figure 5.16.  AvaI-digested fragments of pHIV1SDm-CMV-GFP-2A-MYH7 plasmid 
samples.  Lane 1, hyperladder I; lanes 2-5, pHIVSDm-CMV-GFP-2A-MYH7-WT; lanes 
6-9, pHIV1SDm-CMV-GFP-2A-MYH7-R403Q. 
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Empty vector control plasmids have four AvaI recognition sites.  In pHIV1SDm-CMV-
Cherry-2A-EV, these sites are located at position 971, 1010, 4005 and 4052, with 
digestion generating fragments of sizes 36, 39, 3031 and 4538 bp.  AvaI restriction 
sites are located at positions 971, 1010, 4041 and 4077 in pHIV1SDm-CMV-GFP-2A-
EV, with AvaI-digestion yielding four fragments; 39, 47, 2995 and 4538 bp.  All empty 
vector samples digested with AvaI showed fragments of the approximate expected size 
(Figure 5.17). 
 
 
 
 
 
 
 
 
 
 
Figure 5.17.  AvaI-digested fragments of empty vector control plasmids.  Lane 1, 
hyperladder I; lanes 2-5, pHIV1SDm-CMV-Cherry-2A-EV; lanes 6-9, pHIV1SDm-CMV-
GFP-2A-EV. 
 
DNA sequencing confirmed sarcomere- and EV- inserts were completely present, 
inserted in the correct direction and were in frame in the lentiviral transfer vectors. 
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5.3.5 Testing lentiviral transfer vectors in mammalian cell line, HEK293T 
To verify that lentiviral transfer vectors were correctly constructed and functional in a 
mammalian cell line, they were transfected into HEK293T cells and subsequently 
investigated for the expression of fluorescent reporters and sarcomere proteins. 
 
5.3.5.1 Expression of fluorescent reporter proteins 
HEK293T cells transfected with lentiviral transfer vectors were observed to fluoresce 
appropriately by fluorescence microscopy, indicating that constructs and their reporter 
genes are functional.  No difference was observed between the fluorescence exhibited 
by HEK293T cells transfected with pHIV1SDm-CMV-Cherry vectors, regardless of 
whether the vector contained the TNNI3 or EV-inserts (Figure 5.18).  No changes in 
morphology were noted in the different samples. 
 
 
Figure 5.18.  Microscopic images of HEK293T cells transfected with lentiviral 
transfer vectors containing the Cherry reporter sequence, visualised by phase-
contrast microscopy and fluorescence microscopy.  Scale bar, 100 µm.  All 
fluorescence images were taken with 600 ms exposure. 
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HEK293T cells transfected with pHIV1SDm-CMV-GFP lentiviral transfer vectors all 
exhibited GFP reporter fluorescence (Figure 5.19), however those transfected with 
vectors containing the MYH7 inserts exhibited fainter fluorescence than the EV control 
cells.  In order to capture a similar level of fluorescence, cells containing pHIV1SDm-
CMV-GFP-2A-MYH7 (-WT or -R403Q) plasmids required a longer exposure time of 
600 ms compared to 60 ms for cells transfected with the pHIV1SDm-CMV-GFP-2A-EV 
control vector.  No morphology changes were noted. 
 
Figure 5.19.  Microscopic images of HEK293T cells transfected with lentiviral 
transfer vectors containing the GFP reporter sequence, visualised by phase-
contrast microscopy and fluorescence microscopy.  Scale bar, 100 µm.  
Fluorescence images were captured as follows:  60 ms exposure for empty vector 
control and 600 ms for plasmids containing the MYH7 sequence. 
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5.3.5.2 Expression of sarcomere proteins 
HEK293T protein samples were analysed by western blotting for the expression of 
sarcomere proteins, cardiac troponin I (cTnI) or myosin heavy chain-β (MHC-β).   
 
Western blotting analysis showed that HEK293T cells transfected with transfer vectors 
containing the TNNI3 inserts (both wild-type and G203S mutant variants) expressed a 
24kDa protein when blotted for cTnI (Figure 5.20).  This corresponds to the correct size 
for the full-length human cTnI protein and confirms successful cloning of both the wild-
type (pHIV1SDm-CMV-Cherry-2A-TNNI3-WT) and mutant (pHIV1SDm-CMV-Cherry-
2A-TNNI3-G203S) vectors.   
 
Negative control samples, from both the untransfected HEK293T cells and HEK293T 
cells transfected with the empty vector (pHIV1SDm-CMV-Cherry-2A-EV), showed no 
protein banding on the cTnI western blot, indicating no cTnI protein was expressed in 
these samples.  The positive control sample was protein harvested from mouse 
cardiomyocyte cell line, HL-1, and showed two protein bands on the cTnI blot.  The full-
length cTnI protein in this mouse sample had an expected size of 24.3 kDa, which 
corresponds with the larger protein band visualised.  The smaller band, as well as faint 
banding observed in all protein samples, can be explained by the non-specificity of the 
polyclonal primary antibody. 
 
The coomassie stained gel was used to confirm equal loading between samples.  
Densitometry analysis was used to quantify western blot findings, correct for loading 
variability, and confirmed approximately equal cTnI expression between cells 
transfected with WT and G203S vectors (1.04x fold expression of cTnI compared to 
WT), suggesting both vectors are equally efficient at producing cTnI protein in the 
HEK293T cell line and further confirms DNA sequencing findings that a single copy of 
the TNNI3 insert is present in each vector. 
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Figure 5.20.  Quantification of cardiac troponin I (cTnI) protein in HEK293T cells 
transfected with transfer vectors.  (A) cTnI western blot and respective coomassie-
stained gel.  (B) Densitometry analysis of cTnI protein band in western blot corrected 
for loading variability, normalised to WT.  HEK293T cells were transfected with vectors 
as follows:  EV, empty vector control (pHIV1SDm-CMV-Cherry-2A-EV);  WT, vector 
containing wild-type TNNI3 insert (pHIV1SDm-CMV-Cherry-2A-TNNI3-WT);  G203S, 
vector containing G203S mutated TNNI3 insert (pHIV1SDm-CMV-Cherry-2A-TNNI3-
G203S).  Neg, negative control, HEK293T cells were not transfected.  Pos, positive 
control protein sample, harvested from HL-1 cell line. 
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Western blotting for HEK293T cells transfected with MYH7 lentiviral vectors and their 
relevant controls are shown in Figure 5.21.  Cells transfected with transfer vectors 
containing the MYH7 inserts (either WT or R403Q variants) showed a single protein 
band of approximately 223 kDa when blotted for MHC-β, which is the correct size for 
the full length human MHC-β protein.  This infers successful cloning of the MYH7 
constructs, both the wild-type (pHIV1SDm-CMV-GFP-2A-MYH7-WT) and R403Q 
mutant (pHIV1SDm-CMV-GFP-2A-MYH7-R403Q) vectors.  Negative HEK293T control 
and empty vector samples showed no protein banding on MHC-β western blot 
indicating MHC-β is not expressed in these cells.  HL-1 positive control sample showed 
a single protein band at approximately 223kDa, corresponding to the correct size for 
mouse MHC-β protein. 
 
The Coomassie stained gel was used to correct for loading differences and 
densitometry analysis showed equal MHC-β protein expression between HEK293T 
cells transfected with WT or R403Q vectors (0.95x fold expression of MHC-β, relative 
to WT).  This implies WT and R403Q vectors are equally efficient at producing the 
MHC-β protein, confirming that only one copy of the MYH7 insert is present in each 
vector. 
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Figure 5.21.  Quantification of cardiac myosin heavy chain-β (MHC-β) in HEK293T 
cells transfected with transfer vectors.  (A) MHC-β western blot and respective 
coomassie stained gel.  (B) Densitometry analysis of MHC-β protein band in western 
blot, corrected for loading variability, normalized to WT.  HEK293T cells were 
transfected as follows:  EV, empty vector control (pHIV1SDm-CMV-GFP-2A-EV); WT, 
vector containing wild-type MYH7 insert (pHIV1SDm-CMV-GFP-2A-MYH7-WT); 
R403Q, vector containing the R403Q mutated MYH7 insert (pHIV1SDm-CMV-GFP-2A-
MYH7-R493Q).  Neg, negative control, untransfected HEK293T cells.  Pos, positive 
control, protein sample harvested from HL-1 cell line. 
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5.3.6 Lentiviral transduction of HL-1 cells 
5.3.6.1 Determining viral quantity for successful transduction of HL-1 cells 
Various quantities of empty-vector GFP control lentivirus (GFP-EV) were transduced 
into HL-1 cells and subsequently analysed by flow cytometry.  Gating strategy for 
removing cellular debris and doublets are shown in Figure 5.22A and B, respectively.  
Cells were subsequently analysed for the expression of GFP (Figure 5.22C).  Analysis 
showed a positive correlation between the volume of virus transduced and the 
percentage of fluorescent cells: non-transduced cells, 1.3%; 0.5 µL virus, 11.5%; 1 µL 
virus, 22.5 %; 2.5 µL virus, 44.8 %; 5 µL virus, 67.3%; 10 µL virus, 84.4%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22.  Flow cytometry analysis of HL-1 cells transduced with GFP-EV 
lentivirus.  Cells were seeded in 6-well plates and transduced with the volumes of 
GFP-EV virus as indicated.  (A) Gating to discard cellular debris: X-axis, forward 
scatter area; Y-axis, side scatter area.  (B) Gating to filter out doublets: X-axis, side-
scatter area; Y-axis, side scatter height.  (C) Gating for cells positive and negative for 
the GFP fluorescent reporter protein: Cells left of the ‘gate’ indicated are negative, cells 
to the right are positive.  X-axis, fluorescence as detected by B530 detector, Y-axis, 
side scatter area. 
A 
 
 
 
 
B 
 
 
 
 
C 
0 µL                    0.5 µL                 1.0 µL                 2.5 µL                   5 µL                   10 µL 
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From these results, it can be deduced that the GFP-EV lentivirus was successfully 
produced, the HL-1 cells transduced, and the reporter protein was correctly expressed.  
It warrants trialling the other five lentiviruses made in this study.  Further, it shows that 
even with the highest volume of virus used (10 µL) some cells were still GFP-negative.  
For establishing a stable cell line in future studies, cells would need to be sorted by 
fluorescence-activated cell sorting (FACS) in order to yield a uniform population.  As 
the majority of cells were transduced with 5 µL of GFP-EV virus, this was the volume 
chosen for further transductions carried out in a 6-well plate. 
 
5.3.6.2 Transduction of HL-1 cells with viruses for introducing TNNI3 
HL-1 cells were transduced with viruses for introducing TNNI3 into the host genome, 
both wild-type and G203S mutated variants (Cherry-TNNI3-WT and  
Cherry-TNNI3-G203S, respectively), as well as the empty vector cherry control virus 
(Cherry-EV).  Cells were analysed by flow cytometry and gating strategy for removing 
cellular debris, doublets and autofluorescent cells from analysis are shown in Figure 
5.23 (A-C).  Figure 5.23D shows cells expressing the Cherry fluorescent protein.  
77.3% of HL-1 cells transduced with Cherry-EV virus were positive for mCherry 
expression, compared to 74.6% and 76.5% of cells transduced with the Cherry-TNNI3-
WT and Cherry-TNNI3-G203S viruses, respectively.  The viral efficiency (as deduced 
by Cherry expression) is comparable between the three different viruses. 
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Figure 5.23.  Flow cytometry analysis of HL-1 cells transduced with lentivirus, as 
indicated.  (A) Gating to discard cellular debris; X-axis, forward scatter area; Y-axis, 
side scatter area.  (B) Gating to filter out doublets; X-axis, forward scatter area; Y-axis, 
forward scatter height.  (C) Gating to filter out autofluorescence: X-axis, fluorescence 
detected by B530 detector; Y-axis, fluorescence detected by V450 detector.  (D) Gating 
for cells positive and negative for mCherry expression:  X-axis, fluorescence as 
detected by YG582 detector, Y-axis, side-scatter height. 
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Microscopic images of transduced HL-1 cells, visually confirm flow cytometry findings, 
with approximately 70% of cells showing various levels of mCherry expression 
(observer approximation).  No changes in cell morphology were evident between  
HL-1 cells transduced with Cherry-EV or Cherry-TNNI3-WT (Figure 5.24).  HL-1 cell 
samples transduced with Cherry-TNNI3-G203S virus, contained some cells which 
appeared larger or with a more flattened morphology.  There was no evidence of cell 
death or cellular debris in transduced cells. 
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Figure 5.24.  Microscopic images of HL-1 cells transduced with lentivirus; which 
introduced the empty vector control insert (Cherry-EV), the TNNI3 wild-type gene 
(Cherry-TNNI3-WT) or TNNI3-G203S mutated gene (Cherry-TNNI3-G203S).  Arrows 
denote cells that appear larger.  Scalebar, 100 µm. 
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5.4 DISCUSSION 
This study sought to develop the tools for lentiviral-mediated delivery of transgenes 
containing HCM-causing mutations, into HL-1 cardiomyocytes.  The findings presented 
here show successful cloning of full-length TNNI3 and MYH7 coding sequences into 
lentiviral transfer vectors as confirmed by sequencing, and that the vectors were 
functional as shown by the expression of fluorescent and sarcomere proteins in 
HEK293T cells.  Further, lentiviral particles were produced and four of these viruses 
(GFP-EV, Cherry-EV, Cherry-TNNI3-WT, Cherry-TNNI3-G203S) were successfully 
transduced into the HL-1 target cell line. 
 
It is anticipated that the lentiviral particles produced in this chapter will be used to 
stably transduce the HL-1 cells, and that the resulting cell models will complement in 
vivo mouse model studies.  HL-1 cells transduced with the lentiviral vector harbouring 
the G203S-mutated TNNI3 transgene, were observed to have an altered phenotype in 
preliminary findings, with some cells appearing larger than the EV and WT control cells.  
No morphological differences were observed between the transduced control cells 
when compared to the non-transduced HL-1 parental cells.  These results complement 
previously published findings, in which mouse neonatal cardiomyocytes were 
transduced with adenoviral vectors introducing TNNI3-G203S and resulted in a 
significant increase in cardiomyocyte cell volume (Tsoutsman et al., 2006).  Together, 
these studies confirm that introduction of the TNNI3-G203S mutation alone elicits 
cardiomyocyte hypertrophy, that this effect is reproducible in both primary (neonatal) 
and secondary (HL-1) cells, and that the phenotype is not due to the choice of viral 
vector. 
 
Models that both genetically and phenotypically recapitulate human disease are 
valuable for dissecting out the molecular mechanisms leading from mutation to disease 
development.  Cell models allow for easy investigation of other factors that may affect 
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disease, including the introduction of secondary mutations, altering protein levels that 
may vary systemically between humans (by simply adding these proteins to cell 
media), or blocking such proteins by use of neutralising antibodies.  Further, 
manipulation of miRNAs can be investigated by transfection of miRNA mimics or 
miRNA inhibitors (Bader et al., 2010, Krützfeldt et al., 2005).  A greater understanding 
of how such factors alter cell phenotype in the presence of HCM-mutations, may help 
elucidate the mechanisms that account for clinical heterogeneity, specifically for 
individuals carrying the same disease-causing mutation. 
 
The establishment of biologically relevant cell models expressing TNNI3-G203S or 
MYH7-R403Q may provide useful tools for future studies however there are a number 
of crucial initial steps that need to be undertaken.  Flow cytometry analysis showed that 
the Cherry fluorescent reporter protein (and thus the sarcomere transgene) was 
expressed in most, but not all, HL-1 cells.  Consequently, cells need to be sorted by 
fluorescence-activated cell sorting (FACS) in order to yield pure cell lines with 
comparable transgene expression.  Subsequent characterisation of these cell lines 
should include quantification of cellular hypertrophy by measuring cell size and 
investigating the expression of markers of hypertrophy.  As both the TNNI3-G203S and 
MYH7-R403Q mutations in human and animal studies are accompanied by cardiac 
fibrosis, characterisation of cells should incorporate analysing the expression of pro-
fibrotic molecules, including regulators of ECM and ECM proteins themselves.  The 
effect of cardiomyocyte-specific mutations on paracrine signalling may also be 
investigated by co-culturing with-, or transfer of media to-, other non-myocyte cardiac 
cell types.  Non-myocyte cardiac cells have been shown to be more proliferative in the 
presence of cardiomyocytes expressing HCM-mutations in vivo (Teekakirikul et al., 
2010), and analysis in cell culture would allow for confirmation of these findings without 
systemic influence. 
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Characterisation of how mutations lead to disease may include investigating changes 
in apoptosis, as increased apoptosis has been identified in human HCM (Kavantzas et 
al., 2000).  Myofibrillar disarray is another hallmark feature of HCM, and therefore 
investigation of sarcomere organization is an important characteristic to investigate.  It 
is anticipated that introduced mutations will display this feature, as a previous study 
has shown that the introduction of MYH7-R403Q into adult feline cardiomyocytes, 
results in myofibrillar disarray and disruption of sarcomere structures (Marian et al., 
1995).  Such a study has not been carried out for TNNI3-G203S mutation in 
cardiomyocyte cells.  Further, studies that focus on contractility changes in the 
presence of mutations would be worth investigating.   
 
Ideally, future studies should include the transduction of lentiviral vectors containing 
both TNNI3-G203S and MYH7-R403Q transgenes into the HL-1 cell line, resulting in a 
novel, multiple-mutation model.  It is theoretically possible to develop this cell line using 
viral particles produced in this chapter, by transducing HL-1 cells with both the TNNI3-
G203S and MYH7-R403Q vectors and subsequently sorting by FACS, due to different 
reporter genes being associated with the sarcomere transgenes.   
 
While single HCM-causing mutations have already been introduced into primary 
cardiomyocytes, the lentiviral particles produced in this study allow for a novel, 
multiple-mutation model to be developed and molecular mechanisms to be investigated 
in a single cell type, without the limitations of primary cell studies (such as animal 
sacrifice).  Further transduction of the secondary cell line HL-1, in place of primary cells 
will provide a valuable resource that may be useful in initial screening of novel 
pharmacological or miRNA therapies, prior to animal trials. 
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6 SUMMARY AND CONCLUSIONS 
 
6.1 SUMMARY OF RESEARCH 
Genetic studies in hypertrophic cardiomyopathy (HCM) have identified many 
pathological mutations whose etiology has been validated in animal models expressing 
these mutations.  Advances in the identification of causative mutations and increasingly 
available genetic screening, now allow for individuals who harbour disease-causing 
mutations to be identified prior to the development of the disease phenotype.  As such, 
it is possible to administer treatments to this genotype-positive / phenotype-negative 
(G+/P-) sub-group of patients, in an attempt to prevent, delay onset of, or slow 
progression of disease pathogenesis.  This is currently not routinely practiced due to a 
lack of effective pharmacological therapies available for HCM. 
 
Recent studies in animal models, which express one HCM-causing mutation and 
develop disease gradually, have shown treatment with losartan to be effective in 
preventing the emergence of disease (Teekakirikul et al., 2010).  There have been no 
studies, however, that evaluate the effect of this treatment in multiple-mutation HCM, 
which is typically more severe than HCM caused by a single mutation. 
 
The overall aim for this thesis was to investigate treatment avenues in multiple-
mutation HCM.  This was accomplished by evaluating losartan as a preventative 
therapy in a mouse model of severe HCM (Chapter 3), identifying miRNAs affected by 
this treatment (Chapter 4) which may be novel targets for miR-based therapeutics, and 
working towards the development of cell models in which drug and miR-based 
therapies can be screened (Chapter 5). 
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6.1.1 Losartan therapy in multiple-mutation HCM 
While studies in animal models suggest losartan therapy would be beneficial in HCM 
caused by single mutations, studies in animal models of multiple-mutation disease are 
also important, as up to 5% of HCM patients have two or more HCM-causing mutations 
that presents as a more severe phenotype (Ingles et al., 2005).  The study presented in 
Chapter 3 demonstrated the benefits of losartan therapy in the multiple-mutation HCM 
mouse model, TnI-203/MHC-403.  While treatment with losartan has been shown to 
completely prevent disease in two single-mutant mouse models (Teekakirikul et al., 
2010) and reduce cardiac fibrosis in another model (Lim et al., 2001), treatment in the 
TnI-203/MHC-403 mice delayed the onset of disease and slowed its progression, but 
did not prevent disease completely.  Treatment of TnI-203/MHC-403 mice showed 
significant improvements in survival, cardiac function, whole heart morphology, 
reduced cardiac fibrosis and decreased expression of markers of hypertrophy, 
compared to the age-matched diseased mice.  This study provides evidence that 
losartan is beneficial in a significantly more severe form of HCM, which mimics the 
human disease where multiple mutations lead to a more aggressive disease including 
severe heart failure and sudden death. 
 
6.1.2 MiRNA changes in severe HCM with losartan treatment 
Following the evaluation of losartan therapy in the TnI-203/MHC-403 mouse model, 
changes in miRNA expression with this treatment were investigated.  As miRNAs 
typically have a number of direct downstream mRNA targets, which are often related 
genes functioning in comparable cellular processes, changes in a single miRNA may 
alter the expression of many mRNAs and affect entire gene networks.  As such, 
investigating miRNA changes in pathogenesis and in treatment can give valuable 
insight into potentially suitable miRNA targets for therapeutic intervention in disease. 
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Findings in Chapter 4 identified six miRNAs that were differentially expressed with 
losartan treatment, in the ventricles of TnI-203/MHC-403 mice.  Of these, miR-21, -30c, 
-31, -203 and -214 were dysregulated in the TnI-203/MHC-403 hearts prior to, or in 
early stage of, disease and were partially restored toward the NTG expression pattern 
when treated with losartan.  Comparatively, miR-199a-3p expression was altered in 
established disease, and concurs with other studies that show a beneficial role for this 
miRNA in cardiomyocyte proliferation in pathologies associated with cardiomyocyte 
loss (Eulalio et al., 2012).  As such, restoring the expression of miRNAs -21, -30c, -31, 
-203 and -214 may be of benefit in miR-based therapies, whereas therapeutically 
increasing miR-199a-3p expression would likely be of benefit in cases of 
cardiomyocyte loss, such as HCM that progressed to dilated cardiomyopathy or heart 
failure, which occurs in up to 10% of HCM patients.  These miRNAs present attractive 
targets for miR-based therapy and further studies are warranted that investigate the 
therapeutic potential of manipulating miRNA expression in HCM. 
 
6.1.3 Development of lentiviral transfer tools for creating a HCM cell line 
While animal models are valuable for evaluating drug and miR-based therapies both 
systemically and within the target organ, cell models that genetically and phenotypically 
recapitulate disease can be a useful resource for high-throughput screening.  The 
development of lentiviral particles to introduce HCM-causing mutations (TNNI3-G203S 
and MYH7-R403Q) into cells is described in Chapter 5, and the lentiviruses produced 
are theoretically able to establish both single- and double- mutant models of disease.  
Further studies are required in which the viruses described in this thesis should be 
transduced into cells, such as the HL-1 cardiomyocyte cell line, and the resulting cell 
models assessed for characteristics of HCM, such as cellular hypertrophy and 
stimulation of pro-fibrotic pathways.  Such in vitro models may provide a valuable 
resource for the screening of drug and miRNA therapies, as a precursor to studies in 
animal models of disease. 
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6.2 FUTURE RESEARCH 
The findings presented in this thesis have generated some interesting leads for future 
research. 
 
6.2.1 Treatment studies in mice 
Studies in chapter 3 showed that losartan therapy improved prognosis in the TnI-
203/MHC-403 model.  While this is a promising finding, one of the potential issues with 
this drug therapy is the short half-life of losartan.  It may be interesting to investigate 
the effect of other AT1 receptor antagonists that have a longer half-life, such as 
candesartan, in this mouse model.   
 
Losartan was also found to reduce CTGF expression in the ventricular tissue of TnI-
203/MHC-403 mice.  This supports findings by Tsoutsman and colleagues (Tsoutsman 
et al., 2008b, Tsoutsman et al., 2013), which suggest that CTGF plays a pivotal role in 
the disease pathogenesis of this model.  It would be appropriate to specifically block 
this protein through use of a neutralising antibody or genetic ablation, in order to 
determine if CTGF is indeed crucial in pathogenesis of the TnI-203/MHC-403 model.  
Similarly, other proteins that interact with CTGF and are up-regulated in TnI-203/MHC-
403 hearts (e.g. TGFβ), as well as proteins that are down-regulated with losartan 
therapy (e.g. calponin 1), are also candidates worthy of investigating using neutralising 
antibodies or specific inhibitors. 
 
Further, it would be interesting to assess losartan therapy in other animal models, with 
different HCM-causing mutations.  As there is substantial genetic variability in human 
HCM, the effect of losartan therapy in other models may better predict translation to 
clinical studies. 
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6.2.2 Cellular responses to losartan in TnI-203/MHC-403 mice 
While losartan was shown to reduce the expression of genes involved in hypertrophy 
and fibrosis (Sections 3.3.8 to 3.3.10), it would also be interesting to see what other 
cellular processes are being affected by treatment.  For example, changes in apoptosis 
or proliferation could be easily investigated by immunohistochemistry (IHC) or 
immunofluorescence (IF), using cardiac tissue obtained in Section 3.2.5, and probing 
for caspase-3 and Ki67, respectively.  Cardiac sections could also be used to assess 
changes in cell populations that occur with therapy, through use of cell-specific 
antigens.  Further, IHC or IF studies could be carried out to investigate any changes in 
the localisation or expression of proteins of interest (e.g. AT1 receptors, CTGF). 
 
6.2.3 The role of miRNAs in disease and treatment 
Chapter 4 identified miRNAs whose expression was altered with losartan therapy.  As a 
single miRNA can affect an entire network of genes, miRNAs that are aberrantly 
expressed in disease present as promising potential targets for therapeutic interaction.  
To better understand the involvement of miRNAs in this study, investigation into these 
miRNAs and their predicted mRNA targets should be carried out.  First the mRNA 
targets that were differentially expressed, as detected by gene profiling (Table 4.6), 
need to be validated by RT-qPCR.  Subsequently, luciferase reporter assays should be 
used to determine whether miRNAs repress the expression of their predicted targets.  
This would help elucidate the role that miRNAs play in the pathogenesis and treatment 
of this model. 
 
It would be intriguing to explore the role of miRNAs in different cardiac cell types, 
including cardiomyocytes, fibroblasts, endothelial cells and vascular smooth muscle 
cells.  Introduction of miR-mimics or anti-miRs into these cells and assessing changes 
in phenotype (including hypertrophy, proliferation, apoptosis etc) as well as changes in 
disease-related pathways (including assessing gene expression of pro-fibrotic and pro-
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hypertrophy molecules) would allow for further clarification into the role of these 
miRNAs in the heart.   
 
Once clarification into the role of these miRNAs in different cardiac cells is deduced, it 
may be interesting to assess the over-expression or antagonism of specific miRNAs in 
the mouse, and subsequently, in humans. 
 
6.2.4 Further development of the HL-1 cell model 
Lentiviral particles were developed for introducing sarcomere genes containing HCM-
causing mutations, into cells.  The next steps would be to transduce these particles into 
the HL-1 cell line.  As only a fraction of HL-1 cells were successfully transduced in 
preliminary testing (see Section 5.3.6), cells sorting by FACS would be required to yield 
pure cell lines expressing these transgenes.  Subsequent characterisation of cells 
should take place, including the investigation of disease-related pathways.  Co-
culturing the HL-1 cells with other types of cardiac cells (e.g. fibroblasts) would allow 
for investigation into the paracrine signalling in disease, in a very simple setting. 
 
The established cell model, if successful, could be used for screening pharmacological 
and gene therapies, prior to animal studies.  Ideally a series of cell models could be 
established with different HCM mutations, in order to personalize pharmacological and 
gene therapies. 
 
Ultimately, the goal of future studies should be to elucidate the pathogenic mechanisms 
in disease, and to manipulate such mechanisms through the use of proteins, 
neutralising antibodies, miRNA-mimics, anti-miRs and pharmacological therapies, 
using both cell culture and animal studies, prior to initiating any treatments in humans. 
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6.3 CLINICAL SIGNIFICANCE OF RESEARCH 
The findings presented in this thesis, coupled with previous studies, provide mounting 
evidence to form the basis of a clinical trial of losartan in HCM.  Such a study would 
require a significant follow-up period, and would need to target the G+/P- HCM 
population (Maron et al., 2011, Maron and Semsarian, 2010).  This sub-population of 
patients would be ideal for replicating the study presented here, as treatment initiated 
in the ‘pre-disease’ phase with the goal to prevent disease or delay it’s onset.  While a 
similar study has recently been initiated (treatment with candesartan in a G+/P- HCM 
population, (personal communication, Dr Carolyn Ho, Harvard Medical School, Boston, 
MA, USA)), the data presented in this thesis suggests that losartan would be beneficial 
in a broad clinical spectrum of HCM patients, including those at risk of developing 
severe disease who carry multiple mutations.  MiRNA expression profiling identified 
several miRNAs that may provide novel targets for therapeutic intervention, both in the 
mouse model and in a clinical setting.  With recent advancements in anti-miR and  
miR-mimic therapies, miRNAs present exciting new targets for therapeutic intervention.  
This is of important clinical consequence in diseases for which no pharmacological 
treatments have been shown to be effective, such as HCM. 
 
Furthermore, while the methodology described in Chapter 5 of this thesis has no direct 
clinical repercussions at this point in time, it should lead to the development of cell 
models which in turn will allow for high throughput screening of drug and miRNA based 
therapies, potentially assisting in the identification of effective HCM therapies. 
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6.4 CONCLUDING REMARKS 
At present, there are no pharmacological therapies that have been definitively proven 
to improve pathological features of HCM in humans.  The studies presented in this 
thesis support previous literature which suggests losartan may be beneficial as a 
preventative therapy in HCM patients, with this study suggesting that it would also be 
effective in severe HCM caused by multiple mutations.  Further, miRNAs were 
identified that were dysregulated in diseased hearts, but whose expression was 
corrected with losartan therapy, and these present novel targets for miR-based 
therapies.  Finally, steps have been taken toward developing cell models in which both 
drug and miRNA therapies may be able to be screened, in a high-throughput manner, 
giving insight into the probable effectiveness of the therapy in question, prior to animal 
and human studies.  Overall, these studies work toward a better understanding of 
potential therapies – both pharmacological and miRNA – which may ultimately lead to 
improved treatment strategies in HCM patients. 
 
  
  
    187 
 
 
 
 
REFERENCES 
 
  
    188 
ABDELLATIF, M. 2012. Differential expression of microRNAs in different disease 
states. Circulation Research, 110, 638-650. 
AHMED, M. S., ØIE, E., VINGE, L. E., YNDESTAD, A., ANDERSEN, G. Ø., 
ANDERSSON, Y., ATTRAMADAL, T. & ATTRAMADAL, H. 2004. Connective 
tissue growth factor - a novel mediator of angiotensin II-stimulated cardiac 
fibroblast activation in heart failure in rats. Journal of Molecular and Cellular 
Cardiology, 36, 393-404. 
ALCALAI, R., SEIDMAN, J. G. & SEIDMAN, C. E. 2008. Genetic Basis of Hypertrophic 
Cardiomyopathy: from Bench to the Clinics. Journal of Cardiovascular 
Electrophysiology, 19, 102-110. 
ARAUJO, A. Q., ARTEAGA, E., IANNI, B. M., BUCK, P. C., RABELLO, R. & MADY, C. 
2005. Effect of Losartan on left ventricular diastolic function in patients with 
nonobstructive hypertrophic cardiomyopathy. American Journal of Cardiology, 
96, 1563-1567. 
ARIMURA, T., BOS, J. M., SATO, A., KUBO, T., OKAMOTO, H., NISHI, H., KOGA, Y., 
MOULIK, M., DOI, Y. L., TOWBIN, J. A., ACKERMAN, M. J. & KIMURA, A. 
2009. Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic 
cardiomyopathy. Journal of the American College of Cardiology, 54, 334-342. 
ASANO, K., DUTCHER, D. L., PORT, J. D., MINOBE, W. A., TREMMEL, K. D., 
RODEN, R. L., BOHLMEYER, T. J., BUSH, E. W., JENKIN, M. J., ABRAHAM, 
W. T., RAYNOLDS, M. V., ZISMAN, L. S., PERRYMAN, M. B. & BRISTOW, M. 
R. 1997. Selective downregulation of the angiotensin II AT1-receptor subtype in 
failing human ventricular myocardium. Circulation, 95, 1193-1200. 
BADER, A. G., BROWN, D. & WINKLER, M. 2010. The promise of microRNA 
replacement therapy. Cancer Research, 70, 7027-7030. 
BAGNALL, R. D., TSOUTSMAN, T., SHEPHARD, R. E. & RITCHIE, W. 2012. Global 
microRNA profiling of the mouse ventricles during development of severe 
hypertrophic cardiomyopathy and heart failure. PLoS One, 7, e44744. 
BAKER, L. C., LONDON, B., CHOI, B.-R., KOREN, G. & SALAMA, G. 2000. Enhanced 
dispersion of repolarization and refractoriness in transgenic mouse hearts 
promotes reentrant ventricular tachycardia. Circulation Research, 86, 396-407. 
BAUERSACHS, J., STÖRK, S., KUNG, M., WALLER, C., FIDLER, F., HOYER, C., 
FRANTZ, S., WEIDEMANN, F., ERTL, G. & ANGERMANN, C. E. 2007. HMG 
CoA reductase inhibition and left ventricular mass in hypertrophic 
cardiomyopathy: a randomized placebo-controlled pilot study. European Journal 
of Clinical Investigation, 37, 852-859. 
  
    189 
BERS, D. M. 2000. Calcium fluxes involved in control of cardiac myocyte contraction. 
Circulation Research, 87, 275-281. 
BONOW, R. O., DILSIZIAN, V., ROSING, D. R., MARON, B. J., BACHARACH, S. L. & 
GREEN, M. V. 1985. Verapamil-induced improvement in left ventricular diastolic 
filling and increased exercise tolerance in patients with hypertrophic 
cardiomyopathy: short- and long-term effects. Circulation, 72, 853-864. 
BORISOV, A. B. & CLAYCOMB, W. C. 1995. Proliferative Potential and Differentiated 
Characteristics of Cultured Cardiac Muscle Cells Expressing the SV40T 
Oncogene. Annals of the New York Academy of Sciences, 752, 80-91. 
BROWN, R. D., AMBLER, S. K., MITCHELL, M. D. & LONG, C. S. 2005. The cardiac 
fibroblast: Therapeutic target in myocardial remodeling and failure. Annual 
Review of Pharmacology and Toxicology, 45, 657-687. 
CAI, X., HAGEDOWN, C. H. & CULLEN, B. R. 2004. Human microRNAs are 
processed from capped, polyadenylated transcripts that can also function as 
mRNAs. RNA, 10, 1957-1966. 
CARNIEL, E., TAYLOR, M. R., SINAGRA, G., DI LENARDA, A., KU, L., FAIN, P. R., 
BOUCEK, M. M., CAVANAUGH, J., MIOCIC, S., SLAVOV, D., GRAW, S. L., 
FEIGER, J., ZHU, X. A., DAO, D., FERGUSON, D. A., BRISTOW, M. R. & 
MESTRONI, L. 2005. Alpha-Myosin Heavy Chain: A sarcomeric gene 
associated with dilated and hypertrophic phenotypes of cardiomyopathy. 
Circulation, 112, 54-59. 
CARRIER, L., KNÖLL, R., VIGNIER, N., KELLER, D. I., BAUSERO, P., PRUDHON, B., 
ISNARD, R., AMBROISINE, M.-L., FISZMAN, M., ROSS, J., JR., SCHWARTS, 
K. & CHIEN, K. R. 2004. Asymmetric septal hypertrophy in heterozygous 
cMyBP-C null mice. Cardiovascular Research, 63, 293-304. 
CECCHI, F., OLIVOTTO, I., MONTEREGGI, A., SANTORO, G., DOLARA, A. & 
MARON, B. J. 1995. Hypertrophic cardiomyopathy in Tuscany: clinical course 
and outcome in an unselected regional population. Journal of the American 
College of Cardiology, 26, 1529-1536. 
CHARRON, P., CARRIER, L., DUBOURG, O., TESSON, F., DESNOS, M., RICHARD, 
P., BONNE, G., GUICHENEY, P., HAINGUE, B., BOUHOUR, J. B., MALLET, 
A., FEINGOLD, J., SCHWARTZ, K. & KOMAJDA, M. 1997. Penetrance of 
familial hypertrophic cardiomyopathy. Genetic Counseling, 8, 107-114. 
CHEN, M. M., LAM, A., ABRAHAM, J. A., SCHREINER, G. F. & JOLY, A. H. 2000. 
CTGF Expression is Induced by TGF-β in Cardiac Fibroblasts and Cardiac 
Myocytes: a Potential Role in Heart Fibrosis. Journal of Molecular and Cellular 
Cardiology, 32, 1805-1819. 
  
    190 
CHENG, Y., JI, R., YUE, J., YANG, J., LIU, X., CHEN, H., DEAN, D. B. & ZHANG, C. 
2007. MicroRNAs are aberrantly expressed in hypertrophic heart:  do they play 
a role in cardiac hypertrophy? The American Journal of Pathology, 170, 1831-
1840. 
CHIU, C., BAGNALL, R. D., INGLES, J., YEATES, L., KENNERSON, M., DONALD, J. 
A., JORMAKKA, M., LIND, J. M. & SEMSARIAN, C. 2010. Mutations in Alpha-
Actinin-2 Cause Hypertrophic Cardiomyopathy. Journal of the American College 
of Cardiology, 55, 1127-1135. 
CHIU, C., TEBO, M., INGLES, J., YEATES, L., ARTHUR, J. W., LIND, J. M. & 
SEMSARIAN, C. 2007. Genetic screening of calcium regulation genes in 
familial hypertrophic cardiomyopathy. Journal of Molecular and Cellular 
Cardiology, 43, 337-343. 
CHUNG, M.-W., TSOUTSMAN, T. & SEMSARIAN, C. 2003. Hypertrophic 
cardiomyopathy: from gene defect to clinical disease. Cell Research, 13, 9-20. 
CLAYCOMB, W. C., LANSON, N. A., JR., STALLWORTH, B. S., EGELAND, D. B., 
DELCARPIO, J. B., BAHINSKI, A. & IZZO, N. J., JR. 1998. HL-1 cells: a cardiac 
muscle cell line that contracts and retains phenotypic characteristics of the adult 
cardiomyocyte. Proceedings of the National Academy of Sciences of the United 
States of America, 95, 2979-2984. 
COHEN, L. S. & BRAUNWALD, E. 1967. Amelioration of angina pectoris in idiopathic 
hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation, 35, 
847-851. 
CROZIER, I., IKRAM, H., AWAN, N., CLELAND, J., STEPHEN, N., DICKSTEIN, K., 
FREY, M., YOUNG, J., KLINGER, G., MAKRIS, L. & RUCINSKA, E. 1995. 
Losartan in heart failure.  Hemodynamic effects and tolerability. Circulation, 91, 
691-697. 
DENLI, A. M., TOPS, B. B. J., PLASTERK, R. H. A., KETTING, R. F. & HANNON, G. J. 
2004. Processing of primary microRNAs by the microprocessor complex. 
Nature, 432, 231-235. 
DICKSTEIN, K., CHANG, P., EILLENHEIMER, R., HAUNSØ, S., REMES, J., HALL, C. 
& KJEKSHUS, J. 1995. Comparison of the effects of losartan and enalapril on 
clinical status and exercise performance in patients with moderate or severe 
chromic heart failure. Journal of the American College of Cardiology, 26, 438-
445. 
DOOLAN, A., LANGLOIS, N. & SEMSARIAN, C. 2004a. Causes of sudden cardiac 
death in young Australians. The Medical Journal of Australia, 180, 110-112. 
  
    191 
DOOLAN, A., NGUYEN, L. & SEMSARIAN, C. 2004b. Hypertrophic Cardiomyopathy: 
From "Heart Tumour" to a Complex Molecular Genetic Disorder. Heart Lung 
and Circulations, 13, 15-25. 
DOOLAN, A., TEBO, M., INGLES, J., NGUYEN, L., TSOUTSMAN, T., LAM, L., CHIU, 
C., CHUNG, J., WEINTRAUB, R. G. & SEMSARIAN, C. 2005. Cardiac troponin 
I mutations in Australian families with hypertrophic cardiomyopathy: clinical, 
genetic and functional consequences. Journal of Molecular and Cellular 
Cardiology, 38, 387-393. 
DORN, G. W., 2ND 2009. Apoptotic and non-apoptotic programmed cardiomyocyte 
death in ventricular remodelling. Cardiovascular Research, 81, 465-473. 
DUISTERS, R. F., TIJSEN, A. J., SCHROEN, B., LEENDERS, J. J., LENTINK, V., VAN 
DER MADE, I., HERIAS, V., VAN LEEUWEN, R. E., SCHELLINGS, M. W., 
BARENBRUG, P., MAESSEN, J. G., HEYMANS, S., PINTO, Y. M. & 
CREEMERS, E. E. 2009. miR-133 and miR-30 Regulate Connective Tissue 
Growth Factor. Circulation Research, 104, 170-178. 
EULALIO, A., MANO, M., DAL FERRO, M., ZENTILIN, L., SINAGRA, G., 
ZACCHIGNA, S. & GIACCA, M. 2012. Functional screening identifies miRNAs 
inducing cardiac regeneration. Nature, 492, 376-381. 
EVERETT, A. W., SINHA, A. M., UMEDA, P. K., JAKOVIC, S., RABINOWITZ, M. & 
ZAK, R. 1984. Regulation of myosin synthesis by thyroid hormone: relative 
change in the alpha- and beta-myosin heavy chain mRNA levels in rabbit heart. 
Biochemistry, 23, 1596-1599. 
FATKIN, D., MCCONNELL, B. K., MUDD, J. O., SEMSARIAN, C., MOSKOWITZ, I. G., 
SCHOEN, F. J., GIEWAT, M., SEIDMAN, C. E. & SEIDMAN, J. 2000. An 
abnormal Ca2+ response in mutant sarcomere protein-mediated familial 
hypertrophic cardiomyopathy. The Journal of Clinical Investigation, 106, 1351-
1359. 
FIELD, L. J. 1988. Atrial natriuretic factor-SV40 T antigen transgenes produce tumors 
and cardiac arrhytmias in mice. Science, 239, 1029-1033. 
FLATHER, M. D., YUSUF, S., KØBER, L., PFEFFER, M., HALL, A., MURRAY, G., 
TORP-PEDERSEN, C., BALL, S., POGUE, J., MOYÉ, L. & BRAUNWALD, E. 
2000. Long-term ACE-inhibitor therapy in patients with heart failure or left-
ventricular dysfunction: a systematic overview of data from individual patients. 
The Lancet, 355, 1575-1581. 
FRAZIER, K., WILLIAMS, S., KOTHAPALLI, D., KLAPPER, H. & GROTENDORST, G. 
R. 1996. Stimulation of fibroblast cell growth, matrix production, and granulation 
  
    192 
tissue formation by connective tissue growth factor. The Journal of Investigative 
Dermatology, 107, 404-411. 
FREEMAN, K., COLON-RIVERA, C., OLSSON, M. C., MOORE, R. L., WEINBERGER, 
H. D., GRUPP, I. L., VIKSTROM, K. L., IACCARINO, G., KOCH, W. J. & 
LEINWAND, L. A. 2001. Progression from hypertrophic to dilated 
cardiomyopathy in mice that express a mutant myosin transgene. American 
Journal of Physiology.  Heart and Circulation Physiology, 280, H151-H159. 
FREY, N., FRANZ, W. M., GLOECKNER, K., DEGENHARDT, M., MÜLLER, M., 
MÜLLER, O., MERZ, H. & KATUS, H. A. 2000. Transgenic rat hearts 
expressing a human cardiac troponin T deletion reveal diastolic dysfunction and 
ventricular arrhythmias. Cardiovascular Research, 47, 254-264. 
FUJINO, N., INO, H., HAYASHI, K., UCHIYAMA, K., NAGATA, M., KONNO, T., 
KATOH, H., SAKAMOTO, Y., TSUBOKAWA, T., OHSATO, K., MIZUNO, S. & 
YAMAGISHI, M. 2006. Abstract 915: A novel missense mutation in cardiac 
ryanodine receptor gene as a possible cause of hypertrophic cardiomyopathy: 
Evidence from familial analysis. Circulation, 114, II_165. 
GEIER, C., PERROT, A., OZCELIK, C., BINNER, P., COUNSELL, D., HOFFMAN, K., 
PILZ, B., MARTINIAK, Y., GEHMLICH, K., VAN DER VEN, P. F., FÜRST, D., 
VORNWALD, A., VON HODENBERG, E., NÜRNBERG, P., SCHEFFOLD, T., 
DIETZ, R. & OSTERZIEL, K. J. 2003. Mutations in the human muscle LIM 
protein gene in families with hypertrophic cardiomyopathy. Circulation, 107, 
1344-1346. 
GEISTERFER-LOWRANCE, A. A. T., CHRISTE, M., CONNER, D. A., INGWALL, J. S., 
SCHOEN, F. J., SEIDMAN, C. E. & SEIDMAN, J. 1996. A Mouse Model of 
Familial Hypertrophic Cardiomyopathy. Science, 272, 731-734. 
GEISTERFER-LOWRANCE, A. A. T., KASS, S., TANIGAWA, G., VOSBERG, H.-P., 
MCKENNA, W., SEIDMAN, C. E. & SEIDMAN, J. G. 1990. A Molecular Basis 
for Familial Hypertrophic Cardiomyopathy: A β Cardiac Myosin Heavy Chain 
Gene Missense Mutation. Cell, 62, 999-1006. 
GEORGAKOPOULOS, D., CHRISTE, M. E., GIEWAT, M., SEIDMAN, C. M., 
SEIDMAN, J. & KASS, D. A. 1999. The pathogenesis of familial hypertrophic 
cardiomyopathy: Early and evolving effects from an α-cardiac myosin heavy 
chain missense mutation. Nature Medicine, 5, 327-330. 
GERSH, B. J., MARON, B. J., BONOW, R. O., DEARANI, J. A., FIFER, M. A., LINK, M. 
S., NAIDU, S. S., NISHIMURA, R. A., OMMEN, S. R., RAKOWSKI, H., 
SEIDMAN, C. E., TOWBIN, J. A., UDELSON, J. E. & YANCY, C. W. 2011. 
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic 
  
    193 
cardiomyopathy: a report on the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. 
The Journal of Thoracic and Cardiovascular Surgery, 142. 
GILLIGAN, D. M., CHAN, W. L., JOSHI, J., CLARKE, P., FLETCHER, A., KRIKLER, S. 
& OAKLEY, C. M. 1993. A double-blind, placebo-controlled crossover trial of 
nadolol and verapamil in mild and moderatley symptomatic hypertrophic 
cardiomyopathy. Journal of the American College of Cardiology, 21, 1672-1679. 
GIROLAMI, F., HO, C. Y., SEMSARIAN, C., BALDI, M., WILL, M. L., BALDINI, K., 
TORRICELLLI, F., YEATES, L., CECCHI, F., ACKERMAN, M. J. & OLIVOTTO, 
I. 2010. Clinical Features and Outcomes of Hypertrophic Cardiomyopathy 
Associated with Triple Sarcomere Protein Gene Mutations. Journal of the 
American College of Cardiology, 55, 1444-1453. 
GISTRI, R., CECCHI, F., CHOUDHURY, L., MONTEREGGI, A., SORACE, O., 
SALVADORI, P. A. & CAMICI, P. G. 1994. Effect of verapamil on absolute 
myocardial blood flow in hypertrophic cardiomyopathy. The American Journal of 
Cardiology, 74, 363-368. 
GREGORY, R. I., YAN, K.-P., AMUTHAN, G., CHENDRIMADA, T., DORATOTAJ, B., 
COOCH, N. & SHIEKHATTAR, R. 2004. The Microprocessor complex mediates 
the genesis of microRNAs. Nature, 432, 235-240. 
GROTENDORST, G. R. 1997. Connective tissue growth factor: a mediator of TGF-β 
action on fibroblasts. Cytokine & Growth Factor Reviews, 8, 171-179. 
GROTENDORST, G. R., RAHMANIE, H. & DUNCAN, M. R. 2004. Combinatorial 
signaling pathways determine fibroblast proliferation and myofibroblast 
differentiation. The FASEB Journal:  Official publication of the Federation of 
American Societies for Experimental Biology, 18, 469-479. 
GÜNTHER, S., BABA, H. A., HAUPTMANN, S., HOLZHAUSEN, H.-J., GROΒMANN, 
C., PUNKT, K., KUSCHE, T., JONES, L. R., GERGS, U. & NEUMANN, J. 2010. 
Losartan reduces mortality in a genetic model of heart failure. Naunyn-
Schmiedeberg's Archives of  Pharmacology, 382, 265-278. 
HAN, J., LEE, Y., YEOM, K.-H., NAM, J.-W., HEO, I., RHEE, J.-K., SOHN, S. Y., CHO, 
Y., ZHANG, B.-T. & KIM, V. N. 2006. Molecular basis for the recognition of 
primary microRNAs by the Drosha-DGCR8 complex. Cell, 125, 887-901. 
HARRISON, D. C., BRAUNWALD, E., GLICK, G., MASON, D. T., CHIDSEY, C. A. & 
ROSS JR, J. 1964. Effects of beta adrenergic blockade on the circulation with 
particular reference to observations in patients with hypertrophic subaortic 
stenosis. Circulation, 29, 84-98. 
  
    194 
HAYASHI, T., ARIMURA, T., ITOH-SATOH, M., UEDA, K., HOHDA, S., INAGAKI, N., 
TAKAHASHI, M., HORI, H., YASUNAMI, M., NISHI, H., KOGA, Y., 
NAKAMURA, H., MATSUZAKI, M., CHOI, B. Y., BAE, S. W., YOU, C. W., HAN, 
K. H., PARK, J. E., KNÖLL, R., HOSHIJIMIA, M., CHIEN, K. R. & KIMURA, A. 
2004. Tcap gene mutations in hypertrophic cardiomyopathy and dilated 
cardiomyopathy. Journal of the American College of Cardiology, 44, 2192-2201. 
HO, C. Y. 2009. Hypertrophic Cardiomyopathy: Preclinical and Early Phenotype. 
Journal of Cardiovascular Translational Research, 2, 462-470. 
HO, C. Y. 2010. Genetics and clinical destiny:  improving care in hypertrophic 
cardiomyopathy. Circulation, 122, 2430-2440. 
HOLST, J., VIGNALI, K. M., BURTON, A. R. & VIGNALI, D. A. A. 2006. Rapid analysis 
of T-cell selection in vivo using T cell-receptor retrogenic mice. Nature Methods, 
3, 191-197. 
INGLES, J., DOOLAN, A., CHIU, C., SEIDMAN, J., SEIDMAN, C. & SEMSARIAN, C. 
2005. Compound and double mutations in patients with hypertrophic 
cardiomyopathy: implications for genetic testing and counselling. Journal of 
Medical Genetics, 42, e59. 
IRIZARRY, R. A., HOBBS, B., COLLIN, F., BEAZER BARCLAY, Y. D., ANTONELLIS, 
K. J., SCHERF, U. & SPEED, T. P. 2003. Exploration, normalization, and 
summaries of high density oligonucleotide array probe level data. Biostatistics, 
4, 249-264. 
ISOBE, N., TOYAMA, T., TANIGUCHI, K., OSHIMA, S., KUBOTA, S., SUZUKI, T., 
NAGAOKA, H., ADACHI, H., NAITO, S. & HOSHIZAKI, H. 2003. Failure to raise 
blood pressure during exercise is a poor prognostic sign in patients with 
hypertrophic non-obstructive cardiomyopathy. Circulation Journal, 67, 191-194. 
JAMES, J., ZHANG, Y., OSINSKA, H., SANBE, A., KLEVITSKY, R., HEWETT, T. E. & 
ROBBINS, J. 2000. Transgenic Modeling of a Cardiac Troponin I Mutation 
Linked to Familial Hypertrophic Cardiomyopathy. Circulation Research, 87, 805-
811. 
JAYATILLEKE, I., DOOLAN, A., INGLES, J., MCGUIRE, M., BOOTH, V., RICHMOND, 
D. R. & SEMSARIAN, C. 2004. Long-Term Follow-Up of Implantable 
Cardioverter Defibrillator Therapy for Hypertrophic Cardiomyopathy. The 
American Journal of Cardiology, 93, 1192-1194. 
JENTZSCH, C., LEIERSEDER, S., LOYER, X., FLOHRSCHÜTZ, I., SASSI, Y., 
HARTMANN, D., THUM, T., LAGGERBAUER, B. & ENGELHARDT, S. 2012. A 
phenotypic screen to identify hypertrophy-modulating microRNAs in primary 
cardiomyocytes. Journal of Molecular and Cellular Cardiology, 52, 13-20. 
  
    195 
JONES, W. K., GRUPP, I. L., DOETSCHMAN, T., GRUPP, G., OSINSKA, H., 
HEWETT, T. E., BOIVIN, G., GULICK, J., NG, W. A. & ROBBINS, J. 1996. 
Ablation of the Murine α Myosin Heavy Chain Gene Leads to Dosage Effects 
and Functional Deficits in the Heart. The Journal of Clinical Investigation, 98, 
1906-1917. 
KAVANTZAS, N. G., LAZARIS, A. C., AGAPITOS, E. V., NANAS, J. & DAVARIS, P. S. 
2000. Histological assessment of apoptotic cell death in cardiomyopathies. 
Pathology, 32, 176-180. 
KAZMIERCZAK, K., MUTHU, P., HUANG, W., JONES, M., WANG, Y. & SZCZESNA-
CORDARY, D. 2012. Myosin regulatory light chain mutation found in 
hypertrophic cardiomyopathy patients increases isometric force production in 
transgenic mice. The Biochemical Journal, 442, 95-103. 
KAZMIERCZAK, K., XU, Y., JONES, M., GUZMAN, G., HERNANDEZ, O. M., 
KERRICK, W. G. L. & SZCZESNA-CORDARY, D. 2009. The Role of the N-
terminus of the Myosin Essential Light Chain in Cardiac Muscle Contraction. 
Journal of Molecular Biology, 387, 706-725. 
KELLY, M., BAGNALL, R. D., PEVERILL, R. E., DONELAN, L., CORBEN, L., 
DELATYCKI, M. B. & SEMSARIAN, C. 2011. A polymorphic miR-155 binding 
site in AGTR1 is associated with cardiac hypertrophy in Friedreich ataxia. 
Journal of Molecular and Cellular Cardiology, 51, 848-854. 
KELLY, M. & SEMSARIAN, C. 2009. Multiple Mutations in Genetic Cardiovascular 
Disease: A Marker of Disease Severity? Circulation Cardiovascular Genetics, 2, 
182-190. 
KERRICK, W. G. L., KAZMIERCZAK, K., XU, Y., WANG, Y. & SZCZESNA-CORDARY, 
D. 2009. Malignant familial hypertrophic cardiomyopathy D166V mutation in the 
ventricular myosin regulatory light chain causes profound effects in skinned and 
intact papillary muscle fibers from transgenic mice. The FASEB Journal:  
Official publication of the Federation of American Societies for Experimental 
Biology, 23, 855-865. 
KHVOROVA, A., REYNOLDS, A. & JAYASENA, S. D. 2003. Functional siRNAs and 
miRNAs exhibit strand bias. Cell, 115, 209-216. 
KIMES, B. W. & BRANDT, B. L. 1976. Properties of a clonal muscle cell line from rat 
hearts. Experimental Cell Research, 98, 367-381. 
KIMURA, A., HARUHITO, PARK, J.-E., NISHI, H., SATOH, M., TAKAHASHI, M., 
HIROI, S., SASAOKA, T., OHBUCHI, N., NAKAMURA, T., KOYANAGI, T., 
HWANG, T.-H., CHOO, J.-A., CHUNG, K.-S., HASEGAWA, A., NAGAI, R., 
OKAZAKI, O., NAKAMURA, H., MATSUZAKI, M., SAKAMOTO, T., TOSHIMA, 
  
    196 
H., KOGA, Y., IMAIZUMI, T. & SASAZUKI, T. 1997. Mutations in the cardiac 
troponin I gene associated with hypertrophic cardiomyopathy. Nature Genetics, 
16, 379-382. 
KOLDEJ, R., CMIELEWSKI, P., STOCKER, A., PARSONS, D. W. & ANSON, D. S. 
2005. Optimisation of a multipartite human immunodeficiency virus based 
vector system; control of virus infectivity and large-scale production. The 
Journal of Gene Medicine, 7, 1390-1399. 
KOPRDOVÁ, R., CEBOVÁ, M. & KRISTEK, F. 2009. Long-term effect of losartan 
administration on blood pressure, heart and structure of coronary artery of 
young spontaneously hypertensive rats. Physiological Research, 58, 327-335. 
KRÜTZFELDT, J., RAJEWSKY, N., BRAICH, R., RAJEEV, K. G., TUSCHL, T., 
MANOHARAN, M. & STOFFEL, M. 2005. Silencing of microRNAs in vivo with 
'antagomirs'. Nature, 438, 685-689. 
KUBO, T., KITAOKA, H., OKAWA, M., HIROTA, T., YHAYATO, K., YAMASAKI, N., 
MATSUMURA, Y., YABE, T. & DOI, Y. L. 2010. Gender-specific differences in 
the clinical features of hypertrophic cardiomyopathy in a community-based 
Japanese population: results from Kochi RYOMA study. Journal of Cardiology, 
56, 314-319. 
KUUSISTO, J., KÄRJÄ, V., SIPOLA, P., KHOLOVÁ, I., PEUHKURINEN, K., 
JÄÄSKELÄINEN, P., NAUKKARINEN, A., YLÄ-HERTTUALA, S., PUNNONEN, 
K. & LAAKSO, M. 2012. Low-grade inflammation and the phenotypic 
expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart, 98, 
1007-1013. 
LANDSTROM, A. P., ADEKOLA, B. A., BOS, J. M., OMMEN, S. R. & ACKERMAN, M. 
J. 2011. PLN-encoded phospholamban mutation in a large cohort of 
hypertrophic cardiomyopathy cases: Summary of the literature and implications 
for genetic testing. American Heart Journal, 161, 165-171. 
LANDSTROM, A. P., WEISLEDER, N., BATALDEN, K. B., BOS, J. M., TESTER, D. J., 
OMMEN, S. R., WEHRENS, X. H., CLAYCOMB, W. C., KO, J. K., HWANG, M., 
PAN, Z., MA, J. & ACKERMAN, M. J. 2007. Mutations in JPH2-encoded 
junctophilin-2 associated with hypertrophic cardiomyopathy in humans. Journal 
of Molecular and Cellular Cardiology, 42, 1026-1035. 
LEE, Y., AHN, C., HAN, J., CHOI, H., KIM, J., YIM, J., LEE, J., PROVOST, P., 
RÅDMARK, O., KIM, S. & KIM, V. N. 2003. The nuclear RNase III Drosha 
initiates microRNA processing. Nature, 425, 415-419. 
  
    197 
LEE, Y., KIM, M., HAN, J., YEOM, K.-H., LEE, S., BAEK, S. H. & KIM, V. N. 2004. 
MicroRNA genes are transcribed by RNA polymerase II. The EMBO Journal, 
23, 4051-4060. 
LEWIS, B. P., SHIH, I.-H., JONES-RHOADES, M. W., BARTEL, D. P. & BURGE, C. B. 
2003. Prediction of mammalian microRNA targets. Cell, 115, 787-798. 
LIM, D.-S., LUTUCUTA, S., BACHIREDDY, P., YOUKER, K., EVANS, A., ENTMAN, 
M., ROBERTS, R. & MARIAN, A. J. 2001. Angiotensin II blockade reverses 
myocardial fibrosis in a transgenic mouse model of human hypertrophic 
cardiomyopathy. Circulation, 103, 789-791. 
LIND, J. M., CHIU, C., INGLES, J., YEATES, L., HUMPHRIES, S. E., HEATHER, A. K. 
& SEMSARIAN, C. 2008. Sex hormone receptor gene variation associated with 
phenotype in male hypertrophic cardiomyopathy patients. Journal of Molecular 
and Cellular Cardiology, 45, 217-222. 
LIND, J. M., CHIU, C. & SEMSARIAN, C. 2006. Genetic basis of hypertrophic 
cardiomyopathy. Expert Review of Cardiovascular Therapy, 4, 929-934. 
LOMBARDI, R., RODRIGUEZ, G., CHEN, S. N., RIPPLINGER, C. M., LI, W., CHEN, 
J., WILLERSON, J. T., BETOCCHI, S., WICKLINE, S. A., EFIMOV, I. R. & 
MARIAN, A. J. 2009. Resolution of established cardiac hypertrophy and fibrosis 
and prevention of systolic dysfunction in a transgenic rabbit model of human 
cardiomyopathy through thiol-sensitive mechanisms. Circulation, 119, 1398-
1407. 
LYNN, F. C. 2009. Meta-regulation: microRNA regulation of glucose and lipid 
metabolism. Trends in Endocrinology and Metabolism: TEM, 20, 452-459. 
MANABE, I., SHINDO, T. & NAGAI, R. 2002. Gene expression in fibroblasts and 
fibrosis. Circulation Research, 91, 1103-1113. 
MARIAN, A. J. 2005. On mice, rabbits and human heart failure. Circulation, 111, 2276-
2279. 
MARIAN, A. J., WU, Y., LIM, D.-S., MCCLUGGAGE, M., YOUKER, K., YU, Q.-T., 
BRUGADA, R., DEMAYO, F., QUINONES, M. & ROBERTS, R. 1999. A 
transgenic rabbit model for human hypertrophic cardiomyopathy. The Journal of 
Clinical Investigation, 104, 1683-1692. 
MARIAN, A. J., YU, Q. T., MANN, D. L., GRAHAM, F. L. & ROBERTS, R. 1995. 
Expression of a mutation causing hypertrophic cardiomyopathy disrupts 
sarcomere assembly in adult feline cardiac myocytes. Circulation Research, 77, 
98-106. 
MARON, B. J. 2002. Hypertrophic Cardiomyopathy: A Systematic Reviews. JAMA: the 
journal of the American Medical Association, 287, 1308-1320. 
  
    198 
MARON, B. J., CASEY, S. A., POLIAC, L. C., CGOHMAN, T. E., ALMQUIST, A. K. & 
AEPPLI, D. M. 1999. Clinical course of hypertrophic cardiomyopathy in a 
regional United States cohort. The Journal of the American Medical 
Association, 281, 650-655. 
MARON, B. J., GARDIN, J. M., FLACK, J. M., GIDDING, S. S., KUROSAKI, T. T. & 
BILD, D. E. 1995. Prevalence of Hypertrophic Cardiomyopathy in a General 
Population of Young Adults. Echocardiographic analysis of 4111 subjects in the 
CARDIA Study. Coronary Artery Risk Development in (Young) Adults. 
Circulation, 92, 785-789. 
MARON, B. J., MARON, M. B. & SEMSARIAN, C. 2012a. Genetics of hypertrophic 
cardiomyopathy after 20 years. Journal of the American College of Cardiology, 
60, 705-715. 
MARON, B. J., MARON, M. S. & SEMSARIAN, C. 2012b. Double or compound 
sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden 
death in the absence of conventional risk factors. Heart Rhythm, 9, 57-63. 
MARON, B. J., MCKENNA, W. J., DANIELSON, G. K., KAPPENBERGER, L. J., 
KUHN, H. J., SEIDMAN, C. E., SHAH, P. M., SPENCER III, W. H., SPIRITO, 
P., CATE, F. J. T., WIGLE, E. D., VOGEL, R. A., ABRAMS, J., BATES, E. R., 
BRODIE, B. R., DANIAS, P. G., GREGORATOS, G., HLATKY, M. A., 
HOCHMAN, J. S., KAUL, S., LICHTENBERG, R. C., LINDNER, J. R., 
O'ROUKE, R. A., POHOST, G. M., SCHOFIELD, R. S., TRACY, C. M., 
WINTERS JR, W. L., KLEIN, W. W., PRIORI, S. G., ALONSO-GARCIA, A., 
BLOMSTRÖM-LUNDQVIST, DE BACKER, G., DECKERS, J., FLATHER, M., 
HRADEC, J., OTO, A., PARKHOMENKO, A., SILBER, S. & TORBICKI, A. 
2003. American College of Cardiology / European Society of Cardiology clinical 
expert consensus document on hypertrophic cardiomyopathy: a report of the 
American College of Cardiology Foundation Task Force on Clinical Expert 
Consensus Documents and the European Society of Cardiology Committee for 
Practice Guidelines. Journal of the American College of Cardiology, 42, 1687-
1713. 
MARON, B. J., NICOLS III, P. F., PICKLE, L. W., WESLEY, Y. E. & MULVIHILL, J. J. 
1984. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by 
M-mode and two-dimensional echocardiography. The American Journal of 
Cardiology, 53, 1087-1094. 
MARON, B. J. & SEMSARIAN, C. 2010. Emergence of gene mutation carriers and the 
expanding disease spectrum of hypertrophic cardiomyopathy. European Heart 
Journal, 31, 1551-1553. 
  
    199 
MARON, B. J., SHIRANI, J., POLIAC, L. C., MATHENGE, R., ROBERTS, W. C. & 
MUELLER, F. O. 1996. Sudden death in young competitive athletes. Clinical, 
demographic, and pathological profiles. The Journal of the American Medical 
Association, 276, 199-204. 
MARON, B. J., SPIRITO, P., SHEN, W.-K., HASS, T. S., FORMISANO, F., LINK, M. 
S., EPSTEIN, A. E., ALMQUIST, A. K., DAUBERT, J. P., LAWRENZ, T., 
BORIANI, G., ESTES, N. A. M., FAVALE, S., PICCININNO, M., WINTERS, S. 
L., SANTINI, M., BETOCCHI, S., ARRIBAS, F., SHERRID, M. V., BUJA, G., 
SEMSARIAN, C. & BRUZZI, P. 2007. Implantable Cardioverter-Defibrillators 
and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. 
JAMA: the Journal of the American Medical Association, 298, 405-412. 
MARON, B. J., YEATES, L. & SEMSARIAN, C. 2011. Clinical challenges of genotype 
positive (+)-phenotype negative (-) family members in hypertrophic 
cardiomyopathy. The American Journal of Cardiology, 107, 604-608. 
MARSH, J. D., LEHMANN, M. H., RITCHIE, R. H., GWATHMEY, J. K., GREEN, G. E. 
& SCHIEBINGER, R. J. 1998. Androgen receptors mediate hypertrophy in 
cardiac myocytes. Circulation, 98, 256-261. 
MATKOVICH, S. J., VAN BOOVEN, D. J., YOUKER, K. A., TORRE-AMOINE, G., 
DIWAN, A., ESCHENBACHER, W. H., DORN, L. E., WATSON, M. A., 
MARGULIES, K. B. & DORN III, G. W. 2009. Reciprocal regulation of 
myocardial microRNAs and messenger RNA in human cardiomyopathy and 
reversal of the microRNA signature by biomechanical support. Circulation, 119, 
1263-1271. 
MCCONNELL, B. K., FATKIN, D., SEMSARIAN, C., JONES, K. A., 
GEORGAKOPOULOS, D., MAGUIRE, C. T., HEALEY, M. J., MUDD, J. O., 
MOSKOWITZ, I. P., CONNER, D. A., GIEWAT, M., WAKIMOTO, H., BERUL, 
C. I., SCHOEN, F. J., KASS, D. A., SEIDMAN, C. E. & SEIDMAN, J. 2001. 
Comparison of Two Murine Models of Familial Hypertrophic Cardiomyopathy. 
Circulation Research, 88, 383-389. 
MCCONNELL, B. K., JONES, K. A., FATKIN, D., ARROYO, L. H., LEE, R. T., 
ARISTIZABAL, O., TURNBULL, D. H., GEORGAKOPOULOS, D., KASS, D., 
BOND, M., NIIMURA, H., SCHOEN, F. J., CONNER, D., FISCHMAN, D. H., 
SEIDMAN, C. E. & SEIDMAN, J. G. 1999. Dilated cardiomyopathy in 
homozygous myosin-binding protein-C mutant mice. The Journal of Clinical 
Investigation, 104, 1235-1244. 
  
    200 
MEURS, K. M. & KUAN, M. 2011. Differential methylation of CpG sites in two isoforms 
of myosin binding protein C, an important hypertrophic cardiomyopathy gene. 
Environmental and Molecular Mutagenesis, 52, 161-164. 
MIYOSHI, K., MIYOSHI, T. & SIOMI, H. 2010. Many ways to generate microRNA-like 
small RNAs: non-canonical pathways for microRNA production. Molecular 
Genetics and Genomics, 284, 95-103. 
MOGENSEN, J., KLAUSEN, I. C., EGEBLAD, H., BAANDRUP, U. & BORGLUM, A. D. 
1999. Sudden cardiac death in familial hypertrophic cardiomyopathy is 
associated with a novel mutation in the troponin I gene. Circulation, 100, I-618. 
MOGENSEN, J., MURPHY, R. T., KUBO, T., BAHL, A., MOON, J. C., KLAUSEN, I. C., 
ELLIOTT, P. M. & MCKENNA, W. J. 2004. Frequency and Clinical Expression 
of Cardiac Troponin I Mutations in 748 Consecutive Families with Hypertrophic 
Cardiomyopathy. Journal of the American College of Cardiology, 44, 2315-
2325. 
MOLINA-MOLINA, M., SERRANO-MOLLAR, A., BULBENA, O., FERNANDEZ-
ZABALEGUI, L., CLOSA, D., MARIN-ARGUEDAS, A., TORREGO, A., 
MOLLOL, J., PICADO, C. & XAUBET, A. 2006. Losartan attenuates bleomycin 
induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax, 61, 
604-610. 
MORI, T., KAWARA, S., SHINOZAKI, M., HAYASHI, N., KAKINUMA, T., IGARASHI, 
A., TAKIGAWA, M., NAKANISHI, T. & TAKEHARA, K. 1999. Role and 
interaction of connective tissue growth factor with transforming growth factor-
beta in persistent fibrosis: A mouse fibrosis model. Journal of Cellular 
Physiology, 181, 153-159. 
MORITA, H., NAGAI, R., SEIDMAN, J. G. & SEIDMAN, C. E. 2010. Sarcomere Gene 
Mutations in Hypertrophy and Heart Failure. Journal of Cardiovascular 
Translational Research, 3, 297-303. 
MORITA, H., SEIDMAN, J. & SEIDMAN, C. E. 2005. Genetic causes of human heart 
failure. The Journal of Clinical Investigation, 115, 518-526. 
MUTHU, P., WANG, L., YUAN, C.-C., KAZMIERCZAK, K., HUANG, W., HERNANDEZ, 
O. M., KAWAI, M., IRVING, T. C. & SZCZESNA-CORDARY, D. 2011. 
Structural and functional aspects of the myosin essential light chain in cardiac 
muscle contraction. The FASEB Journal:  Official publication of the Federation 
of American Societies for Experimental Biology, 25, 4394-4405. 
MUTHUCHAMY, M., PIEPLES, K., RETHINASAMY, P., HOIT, B., GRUPP, I. L., 
BOIVIN, G. P., WOLSKA, B., EVANS, C., SOLARO, R. J. & WIECZOREK, D. 
  
    201 
F. 1999. Mouse model of a familial hypertrophic cardiomyopathy mutation in α-
tropomyosin manifests cardiac dysfunction. Circulation Research, 85, 47-56. 
NG, W. A., GRUPP, I. L., SUBRAMANIAM, A. & ROBBINS, J. 1991. Cardiac myosin 
heavy chain mRNA expression and myocardial function in the mouse heart. 
Circulation Research, 68, 1742-1750. 
NGUYEN, L., CHUNG, J., LAM, L., TSOUTSMAN, T. & SEMSARIAN, C. 2007. 
Abnormal cardiac response to exercise in a murine model of familial 
hypertrophic cardiomyopathy. International Journal of Cardiology, 119, 245-248. 
NORRIS, R. A., MORENO-RODRIGUEZ, R. A., SUGI, Y., HOFFMAN, S., AMOS, J., 
HART, M. M., POTTS, J. D., GOODWIN, R. L. & MARKWALD, R. R. 2008. 
Periostin regulates atrioventricular valve maturation. Development Biology, 316, 
200-213. 
O'HANLON, R., GRASSO, A., ROUGHTON, M., MOON, J. C., CLARK, S., WAGE, R., 
WEBB, J., KULKARNI, M., DAWSON, D., SULAIBEEKH, L., 
CHANDRASEKARAN, B., BUCCIARELLI-DUCCI, C., PASQUALE, F., COWIE, 
M. R., MCKENNA, W. J., SHEPPARD, M. N., ELLIOTT, P. M., PENNELL, D. J. 
& PRASAD, S. K. 2010. Prognostic significance of myocardial fibrosis in 
hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 
56, 867-874. 
OHE, T. 2009. Results from the Kochi RYOMA study.  Atrial fibrillation is a major risk of 
morbidity in patients with hypertrophic cardiomyopathy. Circulation Journal, 73, 
1589-1590. 
OKAMURA, K., HAGEN, J. W., DUAN, H., TYLER, D. M. & LAI, E. C. 2007. The 
mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. 
Cell, 130, 89-100. 
OLSSON, M. C., PALMER, B. M., LEINWAND, L. A. & MOORE, R. L. 2001. Gender 
and aging in a transgenic mouse model of hypertrophic cardiomyopathy. 
American Journal of Physiology.  Heart and Circulation Physiology, 280, 
H1136-H1144. 
OSIO, A., TAN, L., CHEN, S. N., LOMBARDI, R., NAGUEH, S. F., SHETE, S., 
ROBERTS, R., WILLERSON, J. T. & MARIAN, A. J. 2007. Myozenin 2 is a 
novel gene for human hypertrophic cardiomyopathy. Circulation Research, 100, 
766-768. 
PAN, W., ZHONG, Y., CHENG, C., LIU, B., WANG, L., AIQUN, L., XIONG, L. & LIU, S. 
2013. MiR-30-regulated autophagy mediates angiotensin II-induced myocardial 
hypertrophy. PLoS One, 8, e53950. 
  
    202 
PANEK, A. N., POSCH, M. G., ALENINA, N., GHADGE, S. K., ERDMANN, B., 
POPOVA, E., PERROT, A., GEIER, C., MORANO, R. D. I., BADER, M. & 
ÖZCELIK, C. 2009. Connective tissue growth factor overexpression in 
cardiomyocytes promotes cardiac hypertrophy and protection against pressure 
overload. PLoS One, 4, e6743. 
PATEL, R., NAGUEH, S. F., TSYBOULEVA, N., ABDELLATIF, M., LUTUCUTA, S., 
KOPELEN, H. A., QUINONES, M. A., ZOGHBI, W. A., ENTEMAN, M. L., 
ROBERTS, R. & MARIAN, A. J. 2001. Simvastatin induces regression of 
cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic 
rabbit model of human hypertrophic cardiomyopathy. Circulation, 104, 317-324. 
PILLAI, R. S., BHATTACHARYYA, S. N. & FILIPOWICZ, W. 2007. Repression of 
protein synthesis by miRNAs: how many mechanisms? Trends in Cell Biology, 
17, 118-126. 
PRABHAKAR, R., BOIVIN, G. P., GRUPP, I. L., HOIT, B., ARTEAGA, G., SOLARO, R. 
J. & WIECZOREK, D. F. 2001. A Familial Hypertrophic Cardiomyopathy α-
Tropomyosin Mutation Causes Severe Cardiac Hypertrophy and Death in Mice. 
Journal of Molecular and Cellular Cardiology, 33, 1815-1828. 
PRABHAKAR, R., PETRASHEVSKAYA, N., SCHWARTZ, A., ARONOW, B., BOIVIN, 
G. P., MOLKENTIN, J. D. & WIECZOREK, D. F. 2003. A mouse model of 
familial hypertrophic cardiomyopathy caused by a α-tropomyosin mutation. 
Molecular and Cellular Biochemistry, 251, 33-42. 
PREDMORE, J. M., WANG, P., DAVIS, F., BARTOLONE, S., WESTFALL, M. V., 
DYKE, D. B., PAGANI, F., POWELL, S. R. & DAY, S. M. 2010. Ubiquitin 
proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. 
Circulation, 121, 997-1004. 
REDDY, S., ZHAO, M., HU, D.-Q., FAJARDO, G., HU, S., GHOSH, Z., 
RAJAGOPALAN, V., WU, J. C. & BERNSTEIN, D. 2012. Dynamic microRNA 
expression during the transition from right ventricular hypertrophy to failure. 
Physiological genomics, 44, 562-575. 
REISER, P. J., PORTMAN, M. A., NING, X.-H. & MORAVEX, C. S. 2001. Human 
cardiac myosin heavy chain isoforms in fetal and failing adult atria and 
ventricles. American Journal of Physiology. Heart and Circulatory Physiology, 
280, H1814-H1820. 
RICHARD, P., CHARRON, P., CARRIER, L., LEDEUIL, C., CHEAV, T., PICHEREAU, 
C., BENAICHE, A., ISNARD, R., DUBOURG, O., BURBAN, M., GUEFFET, J.-
P., MILLAIRE, A., DESNOS, M., SCHWARTZ, K., HAINQUE, B. & KOMAJDA, 
M. 2003. Hypertrophic Cardiomyopathy: Distribution of Disease Genes, 
  
    203 
Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy. 
Circulation, 107, 2227-2232. 
RICHARD, P., ISNARD, R., CARRIER, L., DUBOURG, O., DONATIEN, Y., MATHIEU, 
B., BONNE, G., GARY, F., CHARRON, P., HAGEGE, A., KOMAJDA, M., 
SCHWARTZ, K. & HAINQUE, B. 1999. Double heterozygosity for mutations in 
the β-myosin heavy chain and in the cardiac myosin binding protein C genes in 
a family with hypertrophic cardiomyopathy. Journal of Medical Genetics, 36, 
542-545. 
RUBY, J. G., JAN, C. H. & BARTEL, D. P. 2007. Intronic microRNA precursors that 
bypass Drosha processing. Nature, 448, 83-86. 
RUST, E. M., ALBAYYA, F. P. & METZGER, J. M. 1999. Identification of a contractile 
deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-
associated mutant troponin T proteins. The Journal of Clinical Investigation, 
103, 1459-1467. 
SANBE, A., JAMES, J., TUZCU, V., NAS, S., MARTIN, L., GULICK, J., OSINSKA, H., 
SAKTHIVEL, S., KLEVITSKY, R., GINSBURG, K. S., BERS, D. M., ZINMAN, 
B., LAKATTA, E. G. & ROBBINS, J. 2005. Transgenic rabbit model for human 
troponin I-based hypertrophic cardiomyopathy. Circulation, 111, 2330-2338. 
SAYED, D., HONG, C., CHEN, I.-Y., LYPOWY, J. & ABDELLATIF, M. 2007. 
MicroRNAs play an essential role in the development of cardiac hypertrophy. 
Circulation Research, 100, 416-424. 
SCHWARZ, D. S., HUTVÁGNER, G., DU, T., XU, Z., ARONIN, N. & ZAMORE, P. D. 
2003. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115, 199-
208. 
SEIDMAN, C. & SEIDMAN, J. G. 1995. Gene mutations that cause familial 
hypertrophic cardiomyopathy. In: HABER, E. (ed.) Molecular cardiovascular 
medicine. New York: Scientific American. 
SEIDMAN, J. G. & SEIDMAN, C. 2001. The Genetic Basis for Cardiomyopathy: from 
Mutation Identification to Mechanistic Paradigms. Cell, 104, 557-567. 
SEMSARIAN, C., AHMAD, I., GIEWAT, M., GEORGAKOPOULOS, D., SCHMITT, J. 
P., MCCONNELL, B. K., REIKEN, S., MENDE, U., MARKS, A. R., KASS, D. A., 
SEIDMAN, C. E. & SEIDMAN, J. G. 2002. The L-type calcium channel inhibitor 
diltiazem prevents cardiomyopathy in a mouse model. The Journal of Clinical 
Investigation, 109, 1013-1020. 
SEMSARIAN, C. & GROUP, C. C. G. D. C. W. 2011. Guidelines for the diagnosis and 
management of hypertrophic cardiomyopathy. Heart, Lung & Circulation, 20, 
688-690. 
  
    204 
SENTHIL, V., CHEN, S. N., TSYBOULEVA, N., HALDER, T., NAGUEH, S. F., 
WILLERSON, J. T., ROBERTS, R. & MARIAN, A. J. 2005. Prevention of 
cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human 
hypertrophic cardiomyopathy. Circulation Research, 97, 285-292. 
SHIBATA, M. C., FLATHER, M. D. & WANG, D. 2001. Systematic review of the impact 
of beta blockers on mortality and hospital admissions in heart failure. European 
Journal of Heart Failure, 3, 351-357. 
SICA, D. A., GEHR, T. W. B. & GHOSH, S. 2005. Clinical pharmacokinetics of 
losartan. Clinical Pharmacokinetics, 44, 797-814. 
SOLOMON, S. D., WOLFF, S., WATKINS, H., RIDKER, P. M., COME, P., MCKENNA, 
W. J., SEIDMAN, C. E. & LEE, R. T. 1993. Left ventricular hypertrophy and 
morphology in familial hypertrophic cardiomyopathy associated with mutations 
of the beta-myosin heavy chain gene. Journal of the American College of 
Cardiology, 22, 498-505. 
SONG, W., DYER, E., STUCKEY, D. J., COPELAND, O. N., LEUNG, M.-C., BAYLISS, 
C., MESSER, A., WILKINSON, R., TREMOLEDA, J. L., SCHNEIDER, M. D., 
HARDING, S. E., REDWOOD, C. S., CLARKE, K., NOWAK, K., MONSERRAT, 
L., WELLS, D. & MARSTON, S. B. 2011. Molecular mechanism of the E99K 
mutation in cardiac actin (ACTC gene) that causes apical hypertrophy in man 
and mouse. The Journal of Biological Chemistry, 286, 27582-27593. 
SPIRITO, P., BELLONE, P., HARRIS, K. M., BERNABO, P., BRUZZI, P. & MARON, B. 
J. 2000. Magnitude of left ventricular hypertrophy and risk of sudden death in 
hypertrophic cardiomyopathy. New England Journal of Medicine, 342, 1778-
1785. 
SPIRITO, P., SEIDMAN, C. E., MCKENNA, W. J. & MARON, B. J. 1997. The 
management of hypertrophic cardiomyopathy. The New England Journal of 
Medicine, 336, 775-785. 
STEIN, M., BOULAKSIL, M., JANSEN, J. A., HEROLD, E., NOORMAN, M., JOLES, J. 
A., VAN VEEN, T. A. B., HOUTMAN, M. J. C., ENGELEN, M. A., HAUER, R. N. 
W., DE BAKKER, J. M. T. & VAN RIJEN, H. V. M. 2010. Reduction of fibrosis-
related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors 
in an aged mouse model. American Journal of Physiology. Heart and 
Circulatory Physiology, 299, H310-H321. 
STEINHELPER, M. E., LANSON, N. A., JR., DRESDNER, K. P., DELCARPIO, J. B., 
WIT, A. L., CLAYCOMB, W. C. & FIELD, L. J. 1990. Proliferation in vivo and in 
culture of differentiated adult atrial cardiomyocytes from transgenic mice. The 
American Journal of Physiology, 259, H1826-1834. 
  
    205 
STULL, L. B., LEPPO, M. K., MARBÁN, E. & JANSSEN, P. M. L. 2002. Physiological 
determinants of contractile force generation and calcium handling in mouse 
myocardium. Journal of Molecular and Cellular Cardiology, 34, 1367-1376. 
SUSSMAN, M. A., LIM, H. W., GUDE, N., TAIGEN, T., OLSON, E. N., ROBBINS, J., 
COLBERT, M. C., GUALBERTO, A., WIEZOREK, D. F. & MOLKENTIN, J. D. 
1998. Prevention of Cardiac Hypertrophy in Mice by Calcineurin Inhibition. 
Science, 281, 1690-1693. 
SZCZESNA-CORDARY, D., GUZMAN, G., ZHAO, J., HERNANDEZ, O., WEI, J. & 
DIAZ-PEREZ, Z. 2005. The E22K mutation of myosin RLC that causes familial 
hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase 
in transgenic mice. Journal of Cell Science, 118, 3675-3683. 
TARDIFF, J. C., FACTOR, S. M., TOMPKINS, B. D., HEWETT, T. E., PALMER, B. M., 
MOORE, R. L., SCHWARTZ, S., ROBBINS, J. & LEINWAND, L. A. 1998. A 
Truncated Cardiac Troponin T Molecule in Transgenic Mice Suggests Multiple 
Cellular Mechanisms for Familial Hypertrophic Cardiomyopathy. The Journal of 
Clinical Investigation, 101, 2800-2011. 
TARDIFF, J. C., HEWETT, T. E., PALMER, B. M., OLSSON, C., FACTOR, S. M., 
MOORE, R. L., ROBBINS, J. & LEINWAND, L. A. 1999. Cardiac troponin T 
mutations result in allele-specific phenotypes in a mouse model for hypertrophic 
cardiomyopathy. The Journal of Clinical Investigation, 104, 469-481. 
TATSUGUCHI, M., SEOK, H. Y., CALLIS, T. E., THOMSON, J. M., CHEN, J.-F., 
NEWMAN, M., ROJAS, M., HAMMOND, S. M. & WANG, D.-Z. 2007. 
Expression of microRNAs is dynamically regulated during cardiomyocytes 
hypertrophy. Journal of Molecular and Cellular Cardiology, 42, 1137-1141. 
TEEKAKIRIKUL, P., EMINAGA, S., TOKA, O., ALCALAI, R., WANG, L., WAKIMOTO, 
H., NAYOR, M., KONNO, T., GORHAM, J. M., WOLF, C. M., KIM, J. B., 
SCHMITT, J. P., MOLKENTIN, J. D., NORRIS, R. A., TAGER, A. M., 
HOFFMAN, S. R., MARKWALD, R. R., SEIDMAN, C. E. & SEIDMAN, J. G. 
2010. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by 
non-myocyte proliferation and requires Tgf-β. The Journal of Clinical 
Investigation, 120, 3520-3529. 
THE DIGITALIS INVESTIGATION GROUP 1997. The effect of digoxin on mortality and 
morbidity in patients with heart failure. The New England Journal of Medicine, 
336, 525-533. 
THEIS, J. L., BOS, J. M., BARTLESON, V. B., WILL, M. L., BINDER, J., VATTA, M., 
TOWBIN, J. A., GERSH, B. J., OMMEN, S. R. & ACKERMAN, M. J. 2006. 
Echocardiographic-determined septal morphology in Z-disc hypertrophic 
  
    206 
cardiomyopathy. Biochemical and Biophysical Research Communications, 351, 
896-902. 
THUM, T., GROZZ, C., FIEDLER, J., FISCHER, T., KISSLER, S., BUSSEN, M., 
GALUPPO, P., JUST, S., ROTTBAUER, W., FRANTZ, S., CASTOLDI, M., 
SOUTSCHEK, J., KOTELIANSKY, V., ROSENWALD, A., BASSON, M. A., 
LICHT, J. D., PENA, J. T. R., ROUHANIFARD, S. H., MUCKENTHALER, M. U., 
TUSCHL, T., MARTIN, G. R., BAUERSACHS, J. & ENGELHARDT, S. 2008. 
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase 
signalling in fibroblasts. Nature, 456, 980-984. 
TIFFEN, J. C., BAILEY, C. G., NG, C., RASKO, J. E. J. & HOLST, J. 2010. Luciferase 
expression and bioluminescence does not affect tumor cell growth in vitro or in 
vivo. Molecular Cancer, 9, 299. 
TORP, M., BRØND, L., HADRUP, N., NIELSEN, J. B., PRÆTORIUS, J., 
CHRISTENSEN, S. & JONASSEN, T. E. N. 2007. Losartan decreases 
vasopressin-mediated cAMP accumulation in the thick ascending limb of the 
loop of Henle in rats with congestive heart failure. Acta Physiologica (Oxford, 
England), 190, 339-350. 
TSOUTSMAN, T., BAGNALL, R. D. & SEMSARIAN, C. 2008a. Impact of multiple gene 
mutations in determining the severity of cardiomyopathy and heart failure. 
Clinical and Experimental Pharmacology and Physiology, 35, 1349-1357. 
TSOUTSMAN, T., CHUNG, J., DOOLAN, A., NGUYEN, L., WILLIAMS, I. A., TU, E., 
LAM, L., BAILEY, C. G., RASKO, J. E., ALLEN, D. G. & SEMSARIAN, C. 2006. 
Molecular insights from a novel cardiac troponin I mouse model of familial 
hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 41, 
623-632. 
TSOUTSMAN, T., KELLY, M., NG, D., TAN, J.-E., TU, E., LAM, L., BOGOYEVITCH, 
M. A., SEIDMAN, C. E., SEIDMAN, J. G. & SEMSARIAN, C. 2008b. Severe 
Heart Failure and Early Mortality in a Double-Mutation Mouse Model of Familial 
Hypertrophic Cardiomyopathy. Circulation, 117, 1820-1831. 
TSOUTSMAN, T., WANG, X., GARCHOW, K., RISER, B., TWIGG, S. & SEMSARIAN, 
C. 2013. CCN2 plays a key role in extracellular matrix gene expression in 
severe hypertrophic cardiomyopathy and heart failure. Journal of Molecular and 
Cellular Cardiology, 62, 164-78. 
UDELSON, J. E., BONOW, R. O., O'GARA, P. T., MARON, B. J., VAN LINGEN, A., 
BACHARACH, S. L. & EPSTEIN, S. E. 1989. Verapamil prevents silent 
myocardial perfusion abnormalities during exercise in asymptomatic patients 
with hypertrophic cardiomyopathy. Circulation, 79, 1052-1060. 
  
    207 
VALENCIA-SANCHEZ, M. A., LIU, J., HANNON, G. J. & PARKER, R. 2006. Control of 
translation and mRNA degradation by miRNAs and siRNAs. Genes & 
Development, 20, 515-524. 
VAN DEN EIJNDE, S. M., VAN DEN HOFF, M. J. B., REUTELINGSPERGER, C. P. 
M., VAN HEERDE, W. L., HENFLING, M. E. R., VERMEIJ-KEERS, C., 
SCHUTTE, B., BORGERS, M. & RAMAEKERS, F. C. S. 2001. Transient 
expression of phosphatidylserine at cell-cell contact areas is required for 
myotube formation. Journal of Cell Science, 114, 3631-3642. 
VAN DRIEST, S. L., OMMEN, S. R., TAJIK, A. J., GERSH, B. J. & ACKERMAN, M. J. 
2005. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clinic 
Proceedings, 80, 463-469. 
VAN DRIEST, S. L., VASILE, V. C., OMMEN, S. R., WILL, M. L., TAJIK, A. J., GERSH, 
B. J. & ACKERMAN, M. J. 2004. Myosin binding protein C mutations and 
compount heterozygosity in hypertrophic cardiomyopathy. Journal of the 
American College of Cardiology, 44, 1903-1910. 
VAN ROOIJ, E., MARSHALL, W. S. & OLSON, E. N. 2008. Toward microRNA-based 
therapeutics for heart disease: the sense in antisense. Circulation Research, 
103, 919-928. 
VAN ROOIJ, E., SUTHERLAND, L. B., LIU, N., WILLIAMS, A. H., MCANALLY, J., 
GERARD, R. D., RICHARDSON, J. A. & OLSON, E. N. 2006. A signature 
pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy 
and  heart failure. Proceedings of the National Academy of Sciences of the 
United States of America, 103, 18255-18260. 
VANDESOMPELE, J., DE PRETER, K., PATTYN, F., POPPE, B., VAN ROY, N., DE 
PAEPE, A. & SPELEMAN, F. 2002. Accurate normalization of real-time 
quantitative RT-PCR data by geometric averaging of multiple internal control 
genes. Genome Biology, 3, RESEARCH0034. 
VARNAVA, A. M., ELLIOTT, P. M., CHRISTINA, B., DAVISON, F., DAVIES, M. J. & 
MCKENNA, W. J. 2001a. Hypertrophic cardiomyopathy: histopathological 
features of sudden death in cardiac troponin T disease. Circulation, 104, 1380-
1384. 
VARNAVA, A. M., ELLIOTT, P. M., MAHON, N., DAVIES, M. J. & MCKENNA, W. J. 
2001b. Relation between myocyte disarray and outcome in hypertrophic 
cardiomyopathy. The American Journal of Cardiology, 88, 275-279. 
VASILE, V. C., WILL, M. L., OMMEN, S. R., EDWARDS, W. D., OLSON, T. M. & 
ACKERMAN, M. J. 2006. Identification of a metavinculin missense mutation, 
  
    208 
R975W, associated with both hypertrophic and dilated cardiomyopathy. 
Molecular Genetics and Metabolism, 87, 169-174. 
VERMEULEN, A., BEHLEN, L., REYNOLDS, A., WOLFSON, A., MARSHALL, W. S., 
KARPILOW, J. & KHVOROVA, A. 2005. The contributions of dsRNA structure 
to Dicer specificity and efficiency. RNA, 11, 674-682. 
VIKSTROM, K. L., FACTOR, S. M. & LEINWAND, L. A. 1996. Mice Expressing Mutant 
Myosin Heavy Chains Are a Model for Familial Hypertrophic Cardiomyopathy. 
Molecular Medicine, 2, 556-567. 
VISCONTI, R. P. & MARKWALD, R. R. 2006. Recruitment of new cells into the 
postnatal heart: potential modification of phenotype by periostin. Annals of the 
New York Academy of Sciences, 1080, 19-33. 
WANG, H., LI, Z., WANG, J., SUN, K., CUI, Q., SONG, L., ZOU, Y., WANG, X., LIU, 
X., HUI, R. & FAN, Y. 2010. Mutations in NEXN, a Z-disc gene, are associated 
with hypertrophic cardiomyopathy. The American Journal of Human Genetics, 
87, 687-693. 
WANG, L., TAO, L. J., PENG, Z. Z. & NING, W. B. 2009a. Losartan inhibits high 
glucose-induced CTGF expression via ERK1/2 MAPK pathways in mouse 
mesangial cells. Chinese Journal of Cellular and Molecular Immunology, 25, 
486-489. 
WANG, X., MCLENNAN, S. V., ALLEN, T. J., TSOUTSMAN, T., SEMSARIAN, C. & 
TWIGG, S. M. 2009b. Adverse effects of high glucose and free fatty acid on 
cardiomyocytes are mediated by connective tissue growth factor. American 
Journal of Physiology - Cell Physiology, 297, C1490-C500. 
WATKINS, H., ROSENZWEIG, A., HWANG, D. S., LEVI, T., MCKENNA, W., 
SEIDMAN, C. E. & SEIDMAN, J. G. 1992. Characteristics and prognostic 
implications of myosin missense mutations in familial hypertrophic 
cardiomyopathy. The New England Journal of Medicine, 326, 1108-1114. 
WATKINS, H., SEIDMAN, C. E., SEIDMAN, J. G., FENG, H. S. & SWEENEY, H. L. 
1996. Expression and functional assessment of a truncated cardiac troponin T 
that causes hypertrophic cardiomyopathy.  Evidence for a dominant negative 
action. The Journal of Clinical Investigation, 98, 2456-2461. 
WATKINS, S. J., BORTHWICK, G. M. & ARTHUR, H. M. 2011. The H9C2 cell line and 
primary neonatal cardiomyocyte cells show similar hypertrophic responses in 
vitro. In Vitro Cellular & Developmental Biology - Animal, 47, 125-131. 
WERNICKE, D., THIEL, C., DUJA-ISAC, C. M., ESSIN, K. V., SPINDLER, M., NUNEZ, 
D. J. R., PLEHM, R., WESSEL, N., HAMMES, A., EDWARDS, R.-J., 
LIPPOLDT, A., ZACHARIAS, U., STRÖMER, H., NEUBAUER, S., DAVIES, M. 
  
    209 
J., MORANO, I. & THIERFELDER, L. 2004. α-Tropomyosin mutations 
Asp175Asn and Glu180Gly affect cardiac function in transgenic rats in different 
ways. American Journal of Physiology - Regulatory, Integrative and 
Comparative Physiology, 287, R685-695. 
WESTERMANN, D., KNOLLMANN, B. C., STEENDIJK, P., RUTSCHOW, S., RIAD, A., 
PAUSCHINGER, M., POTTER, J. D., SCHULTHEISS, H.-P. & TSCHÖPE, C. 
2006. Diltiazem treatment prevents diastolic heart failure in mice with familial 
hypertrophic cardiomyopathy. The European Journal of Heart Failure, 8, 115-
121. 
WESTHOLM, J. O. & LAI, E. C. 2011. Mirtrons: microRNA biogenesis via splicing. 
Biochimie, 93, 1897-1904. 
XIN, H. B., SENBONMATSU, T., CHENG, D. S., WANG, Y. X., COPELLO, J. A., JI, G. 
J., COLLIER, M. L., DENG, K. Y., JEYAKUMAR, L. H., MAGNUSON, M. A., 
INAGAMI, T., KOTLIKOFF, M. I. & FLEISCHER, S. 2002. Oestrogen protects 
FKBP12.6 null mice from cardiac hypertrophy. Nature, 416, 334-338. 
YAMAZAKI, T., SUZUKI, J., SHIMAMOTO, R., TSUJI, T., OHMOTO-SEKINE, Y., 
OHTOMO, K. & NAGAI, R. 2007. A new therapeutic strategy for hypertrophic 
nonobstructive cardiomyopathy in humans. A randomised and prospective 
study with an Angiotensin II receptor blocker. International Heart Journal, 48, 
715-724. 
YANG, F., CHUNG, A. C., HUANG, X. R. & LAN, H. Y. 2009. Angiotensin II induces 
connective tissue growth factor and collagen I expression via transforming 
growth factor-beta-dependent and -independent Smad pathways: the role of 
Smad3. Hypertension, 54, 877-884. 
YI, R., QIN, Y., MACARA, I. G. & CULLEN, B. R. 2003. Exportin-5 mediates the 
nuclear export of pre-microRNAs and short hairpin RNAs. Genes & 
Development, 17, 3011-3016. 
 
 
